WO2022068772A1 - Dérivé de benzimidazole, son procédé de préparation et son utilisation médicale - Google Patents
Dérivé de benzimidazole, son procédé de préparation et son utilisation médicale Download PDFInfo
- Publication number
- WO2022068772A1 WO2022068772A1 PCT/CN2021/120978 CN2021120978W WO2022068772A1 WO 2022068772 A1 WO2022068772 A1 WO 2022068772A1 CN 2021120978 W CN2021120978 W CN 2021120978W WO 2022068772 A1 WO2022068772 A1 WO 2022068772A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methyl
- mmol
- oxetan
- benzo
- ylmethyl
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 75
- 150000003839 salts Chemical class 0.000 claims abstract description 31
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 12
- 239000003814 drug Substances 0.000 claims abstract description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 11
- 201000010099 disease Diseases 0.000 claims abstract description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 7
- -1 cyano, hydroxyl Chemical group 0.000 claims description 174
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 136
- 125000000217 alkyl group Chemical group 0.000 claims description 83
- 229910052757 nitrogen Inorganic materials 0.000 claims description 75
- 125000001424 substituent group Chemical group 0.000 claims description 46
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 30
- 125000001153 fluoro group Chemical group F* 0.000 claims description 29
- 229910052736 halogen Inorganic materials 0.000 claims description 24
- 150000002367 halogens Chemical group 0.000 claims description 24
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 24
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 22
- 125000001072 heteroaryl group Chemical group 0.000 claims description 21
- 229910052760 oxygen Inorganic materials 0.000 claims description 21
- 229910052739 hydrogen Inorganic materials 0.000 claims description 18
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 18
- 125000003545 alkoxy group Chemical group 0.000 claims description 17
- 125000003118 aryl group Chemical group 0.000 claims description 16
- 239000001301 oxygen Substances 0.000 claims description 16
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 15
- 239000001257 hydrogen Substances 0.000 claims description 14
- 229910052731 fluorine Inorganic materials 0.000 claims description 13
- 125000000623 heterocyclic group Chemical group 0.000 claims description 12
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 10
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 10
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 10
- 229910052801 chlorine Inorganic materials 0.000 claims description 9
- 239000000460 chlorine Substances 0.000 claims description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 8
- 239000011737 fluorine Substances 0.000 claims description 8
- 125000001188 haloalkyl group Chemical group 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- 150000003457 sulfones Chemical class 0.000 claims description 8
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims description 7
- 238000006467 substitution reaction Methods 0.000 claims description 7
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims description 6
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 claims description 6
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 claims description 6
- APXRHPDHORGIEB-UHFFFAOYSA-N 1H-pyrazolo[4,3-d]pyrimidine Chemical compound N1=CN=C2C=NNC2=C1 APXRHPDHORGIEB-UHFFFAOYSA-N 0.000 claims description 5
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 125000002947 alkylene group Chemical group 0.000 claims description 5
- 150000001924 cycloalkanes Chemical class 0.000 claims description 5
- 229910052805 deuterium Inorganic materials 0.000 claims description 5
- 125000005842 heteroatom Chemical group 0.000 claims description 5
- QNQCJTHZJJOUGL-UHFFFAOYSA-N pyrimido[5,4-d]triazine Chemical compound N1=NN=CC2=NC=NC=C21 QNQCJTHZJJOUGL-UHFFFAOYSA-N 0.000 claims description 5
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims description 4
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 4
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 claims description 4
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 claims description 4
- CBHTTYDJRXOHHL-UHFFFAOYSA-N 2h-triazolo[4,5-c]pyridazine Chemical compound N1=NC=CC2=C1N=NN2 CBHTTYDJRXOHHL-UHFFFAOYSA-N 0.000 claims description 4
- GIIGHSIIKVOWKZ-UHFFFAOYSA-N 2h-triazolo[4,5-d]pyrimidine Chemical compound N1=CN=CC2=NNN=C21 GIIGHSIIKVOWKZ-UHFFFAOYSA-N 0.000 claims description 4
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 4
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims description 4
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 claims description 4
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
- CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- KDOPAZIWBAHVJB-UHFFFAOYSA-N 5h-pyrrolo[3,2-d]pyrimidine Chemical compound C1=NC=C2NC=CC2=N1 KDOPAZIWBAHVJB-UHFFFAOYSA-N 0.000 claims description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 3
- SJYWOAGLMVOYOD-UHFFFAOYSA-N [1,2]thiazolo[4,5-c]pyridazine Chemical class C1=NN=C2C=NSC2=C1 SJYWOAGLMVOYOD-UHFFFAOYSA-N 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 239000011593 sulfur Substances 0.000 claims description 3
- FNQJDLTXOVEEFB-UHFFFAOYSA-N 1,2,3-benzothiadiazole Chemical compound C1=CC=C2SN=NC2=C1 FNQJDLTXOVEEFB-UHFFFAOYSA-N 0.000 claims description 2
- OWQPOVKKUWUEKE-UHFFFAOYSA-N 1,2,3-benzotriazine Chemical compound N1=NN=CC2=CC=CC=C21 OWQPOVKKUWUEKE-UHFFFAOYSA-N 0.000 claims description 2
- SLLFVLKNXABYGI-UHFFFAOYSA-N 1,2,3-benzoxadiazole Chemical compound C1=CC=C2ON=NC2=C1 SLLFVLKNXABYGI-UHFFFAOYSA-N 0.000 claims description 2
- CSNIZNHTOVFARY-UHFFFAOYSA-N 1,2-benzothiazole Chemical compound C1=CC=C2C=NSC2=C1 CSNIZNHTOVFARY-UHFFFAOYSA-N 0.000 claims description 2
- KTZQTRPPVKQPFO-UHFFFAOYSA-N 1,2-benzoxazole Chemical compound C1=CC=C2C=NOC2=C1 KTZQTRPPVKQPFO-UHFFFAOYSA-N 0.000 claims description 2
- 125000005918 1,2-dimethylbutyl group Chemical group 0.000 claims description 2
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 claims description 2
- 125000006218 1-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 claims description 2
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims description 2
- DDZGQYREBDXECY-UHFFFAOYSA-N 1h-pyrazolo[3,4-b]pyrazine Chemical compound C1=CN=C2C=NNC2=N1 DDZGQYREBDXECY-UHFFFAOYSA-N 0.000 claims description 2
- AMFYRKOUWBAGHV-UHFFFAOYSA-N 1h-pyrazolo[4,3-b]pyridine Chemical compound C1=CN=C2C=NNC2=C1 AMFYRKOUWBAGHV-UHFFFAOYSA-N 0.000 claims description 2
- NMEPLWZDUIIAAC-UHFFFAOYSA-N 1h-pyrazolo[4,3-c]pyridazine Chemical compound C1=NN=C2C=NNC2=C1 NMEPLWZDUIIAAC-UHFFFAOYSA-N 0.000 claims description 2
- XWIYUCRMWCHYJR-UHFFFAOYSA-N 1h-pyrrolo[3,2-b]pyridine Chemical class C1=CC=C2NC=CC2=N1 XWIYUCRMWCHYJR-UHFFFAOYSA-N 0.000 claims description 2
- 125000004778 2,2-difluoroethyl group Chemical group [H]C([H])(*)C([H])(F)F 0.000 claims description 2
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 claims description 2
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 claims description 2
- 125000005916 2-methylpentyl group Chemical group 0.000 claims description 2
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 claims description 2
- CJGGKSPGRJHZNP-UHFFFAOYSA-N 2h-triazolo[4,5-b]pyrazine Chemical compound C1=CN=C2NN=NC2=N1 CJGGKSPGRJHZNP-UHFFFAOYSA-N 0.000 claims description 2
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical compound C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 claims description 2
- LBZYKNAEJRHENJ-UHFFFAOYSA-N 5h-pyrrolo[3,2-c]pyridazine Chemical class N1=CC=C2NC=CC2=N1 LBZYKNAEJRHENJ-UHFFFAOYSA-N 0.000 claims description 2
- 239000005964 Acibenzolar-S-methyl Substances 0.000 claims description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 2
- XUTIDUCSRSNKKP-UHFFFAOYSA-N [1,2]oxazolo[4,5-b]pyridine Chemical compound C1=CN=C2C=NOC2=C1 XUTIDUCSRSNKKP-UHFFFAOYSA-N 0.000 claims description 2
- KJYUKCGUBQRSID-UHFFFAOYSA-N [1,2]oxazolo[4,5-c]pyridazine Chemical class C1=NN=C2C=NOC2=C1 KJYUKCGUBQRSID-UHFFFAOYSA-N 0.000 claims description 2
- XIENVIDSFHMNLY-UHFFFAOYSA-N [1,2]oxazolo[4,5-d]pyrimidine Chemical compound N1=CN=C2C=NOC2=C1 XIENVIDSFHMNLY-UHFFFAOYSA-N 0.000 claims description 2
- HUROIDUMDXPPBG-UHFFFAOYSA-N [1,2]thiazolo[4,5-b]pyrazine Chemical class C1=CN=C2C=NSC2=N1 HUROIDUMDXPPBG-UHFFFAOYSA-N 0.000 claims description 2
- ZTAPFURKEMZRSQ-UHFFFAOYSA-N [1,2]thiazolo[4,5-b]pyridine Chemical compound C1=CN=C2C=NSC2=C1 ZTAPFURKEMZRSQ-UHFFFAOYSA-N 0.000 claims description 2
- OPADCMQOUIZWKV-UHFFFAOYSA-N [1,2]thiazolo[4,5-d]pyrimidine Chemical compound N1=CN=C2C=NSC2=C1 OPADCMQOUIZWKV-UHFFFAOYSA-N 0.000 claims description 2
- HEIZPACCIHXHKV-UHFFFAOYSA-N [1,3]thiazolo[4,5-b]pyrazine Chemical class C1=CN=C2SC=NC2=N1 HEIZPACCIHXHKV-UHFFFAOYSA-N 0.000 claims description 2
- BBAWTPDTGRXPDG-UHFFFAOYSA-N [1,3]thiazolo[4,5-b]pyridine Chemical compound C1=CC=C2SC=NC2=N1 BBAWTPDTGRXPDG-UHFFFAOYSA-N 0.000 claims description 2
- OZDQBAQCPJNKGG-UHFFFAOYSA-N [1,3]thiazolo[4,5-c]pyridazine Chemical class N1=CC=C2SC=NC2=N1 OZDQBAQCPJNKGG-UHFFFAOYSA-N 0.000 claims description 2
- YWBULOYFCXZCGF-UHFFFAOYSA-N [1,3]thiazolo[4,5-d]pyrimidine Chemical compound C1=NC=C2SC=NC2=N1 YWBULOYFCXZCGF-UHFFFAOYSA-N 0.000 claims description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 2
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 claims description 2
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 claims description 2
- 239000012964 benzotriazole Substances 0.000 claims description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- 125000006226 butoxyethyl group Chemical group 0.000 claims description 2
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 claims description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 2
- 125000006232 ethoxy propyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims description 2
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 claims description 2
- YRTCKZIKGWZNCU-UHFFFAOYSA-N furo[3,2-b]pyridine Chemical class C1=CC=C2OC=CC2=N1 YRTCKZIKGWZNCU-UHFFFAOYSA-N 0.000 claims description 2
- KXDJPLSALUSYNT-UHFFFAOYSA-N furo[3,2-c]pyridazine Chemical class N1=CC=C2OC=CC2=N1 KXDJPLSALUSYNT-UHFFFAOYSA-N 0.000 claims description 2
- JUQAECQBUNODQP-UHFFFAOYSA-N furo[3,2-d]pyrimidine Chemical compound C1=NC=C2OC=CC2=N1 JUQAECQBUNODQP-UHFFFAOYSA-N 0.000 claims description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims description 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 2
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 claims description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 claims description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000005244 neohexyl group Chemical group [H]C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- DLHRAOSKUZJSEB-UHFFFAOYSA-N oxadiazolo[4,5-b]pyrazine Chemical class C1=CN=C2ON=NC2=N1 DLHRAOSKUZJSEB-UHFFFAOYSA-N 0.000 claims description 2
- OGIKSURTYJLRMP-UHFFFAOYSA-N oxadiazolo[4,5-b]pyridine Chemical compound C1=CN=C2N=NOC2=C1 OGIKSURTYJLRMP-UHFFFAOYSA-N 0.000 claims description 2
- DFOGZINTVRYAFE-UHFFFAOYSA-N oxadiazolo[4,5-d]pyrimidine Chemical compound C1=NC=C2ON=NC2=N1 DFOGZINTVRYAFE-UHFFFAOYSA-N 0.000 claims description 2
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 claims description 2
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 claims description 2
- 125000006233 propoxy propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])OC([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000006225 propoxyethyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims description 2
- 125000005767 propoxymethyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])[#8]C([H])([H])* 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- OUFHXMSGJIYFPW-UHFFFAOYSA-N pyrazino[2,3-c]pyridazine Chemical compound N1=NC=CC2=NC=CN=C21 OUFHXMSGJIYFPW-UHFFFAOYSA-N 0.000 claims description 2
- NZFZFZPEJHMFQR-UHFFFAOYSA-N pyridazino[4,3-d]triazine Chemical compound N1=NC=C2N=NC=CC2=N1 NZFZFZPEJHMFQR-UHFFFAOYSA-N 0.000 claims description 2
- OHZYAOYVLLHTGW-UHFFFAOYSA-N pyrido[3,2-c]pyridazine Chemical compound C1=CN=NC2=CC=CN=C21 OHZYAOYVLLHTGW-UHFFFAOYSA-N 0.000 claims description 2
- BWESROVQGZSBRX-UHFFFAOYSA-N pyrido[3,2-d]pyrimidine Chemical compound C1=NC=NC2=CC=CN=C21 BWESROVQGZSBRX-UHFFFAOYSA-N 0.000 claims description 2
- HHQDNOXLJMIISM-UHFFFAOYSA-N pyrido[3,2-d]triazine Chemical compound C1=NN=NC2=CC=CN=C21 HHQDNOXLJMIISM-UHFFFAOYSA-N 0.000 claims description 2
- ATVQBGCKUAGPDN-UHFFFAOYSA-N pyrimido[5,4-c]pyridazine Chemical compound C1=NC=C2N=NC=CC2=N1 ATVQBGCKUAGPDN-UHFFFAOYSA-N 0.000 claims description 2
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 claims description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- MLQRCVMGAMNVHO-UHFFFAOYSA-N thiadiazolo[4,5-b]pyrazine Chemical class C1=CN=C2SN=NC2=N1 MLQRCVMGAMNVHO-UHFFFAOYSA-N 0.000 claims description 2
- GNXPUXGOQIHJLJ-UHFFFAOYSA-N thiadiazolo[4,5-b]pyridine Chemical class C1=CN=C2N=NSC2=C1 GNXPUXGOQIHJLJ-UHFFFAOYSA-N 0.000 claims description 2
- SRDPNDROLKFXRH-UHFFFAOYSA-N thiadiazolo[4,5-c]pyridazine Chemical class N1=NC=CC2=C1N=NS2 SRDPNDROLKFXRH-UHFFFAOYSA-N 0.000 claims description 2
- MFWNOJCSZKJNPT-UHFFFAOYSA-N thiadiazolo[4,5-d]pyrimidine Chemical compound C1=NC=C2SN=NC2=N1 MFWNOJCSZKJNPT-UHFFFAOYSA-N 0.000 claims description 2
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- BGSUGJJKALFMSO-UHFFFAOYSA-N 1,3-oxazole;pyridazine Chemical class C1=COC=N1.C1=CC=NN=C1 BGSUGJJKALFMSO-UHFFFAOYSA-N 0.000 claims 1
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 claims 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims 1
- HXTBYLZGLRCHTM-UHFFFAOYSA-N [1,2]oxazolo[4,5-b]pyrazine Chemical class C1=CN=C2C=NOC2=N1 HXTBYLZGLRCHTM-UHFFFAOYSA-N 0.000 claims 1
- UDLYKXSOGKUKHH-UHFFFAOYSA-N [1,3]oxazolo[4,5-d]pyrimidine Chemical compound C1=NC=C2OC=NC2=N1 UDLYKXSOGKUKHH-UHFFFAOYSA-N 0.000 claims 1
- 150000003851 azoles Chemical class 0.000 claims 1
- YGIMRJDORSOGCR-UHFFFAOYSA-N oxadiazolo[4,5-c]pyridazine Chemical class N1=NC=CC2=C1N=NO2 YGIMRJDORSOGCR-UHFFFAOYSA-N 0.000 claims 1
- QNNHQVPFZIFNFK-UHFFFAOYSA-N oxazolo[4,5-b]pyridine Chemical compound C1=CC=C2OC=NC2=N1 QNNHQVPFZIFNFK-UHFFFAOYSA-N 0.000 claims 1
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 abstract description 9
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 abstract description 9
- 229940079593 drug Drugs 0.000 abstract description 7
- 239000000556 agonist Substances 0.000 abstract description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 681
- 238000006243 chemical reaction Methods 0.000 description 511
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 393
- 238000003786 synthesis reaction Methods 0.000 description 336
- 230000015572 biosynthetic process Effects 0.000 description 335
- 239000000243 solution Substances 0.000 description 293
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 292
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 258
- 239000007787 solid Substances 0.000 description 240
- 239000012074 organic phase Substances 0.000 description 197
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 188
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 151
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 137
- 239000000203 mixture Substances 0.000 description 129
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 120
- 238000010898 silica gel chromatography Methods 0.000 description 117
- 239000003480 eluent Substances 0.000 description 113
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 110
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 103
- 230000004224 protection Effects 0.000 description 78
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 76
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 69
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 63
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 62
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 57
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 57
- 239000012043 crude product Substances 0.000 description 57
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 54
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 45
- 238000003756 stirring Methods 0.000 description 45
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 44
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 44
- 229910000024 caesium carbonate Inorganic materials 0.000 description 44
- 238000010791 quenching Methods 0.000 description 44
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 43
- 238000005481 NMR spectroscopy Methods 0.000 description 42
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 41
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 38
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 38
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 35
- 239000000706 filtrate Substances 0.000 description 34
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical group C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 24
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 24
- 238000004440 column chromatography Methods 0.000 description 24
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 23
- 239000003208 petroleum Substances 0.000 description 22
- 229910000027 potassium carbonate Inorganic materials 0.000 description 22
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 21
- 239000010410 layer Substances 0.000 description 19
- 238000000967 suction filtration Methods 0.000 description 19
- 238000004809 thin layer chromatography Methods 0.000 description 19
- 239000003054 catalyst Substances 0.000 description 18
- TUSICEWIXLMXEY-UHFFFAOYSA-N methyl 1h-indazole-6-carboxylate Chemical compound COC(=O)C1=CC=C2C=NNC2=C1 TUSICEWIXLMXEY-UHFFFAOYSA-N 0.000 description 17
- 229910052763 palladium Inorganic materials 0.000 description 17
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 16
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 16
- ZMANZCXQSJIPKH-UHFFFAOYSA-N N,N-Diethylethanamine Substances CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 16
- 239000007983 Tris buffer Substances 0.000 description 16
- 238000004128 high performance liquid chromatography Methods 0.000 description 16
- 229910052744 lithium Inorganic materials 0.000 description 16
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 16
- 238000000746 purification Methods 0.000 description 16
- 239000002904 solvent Substances 0.000 description 16
- 230000007935 neutral effect Effects 0.000 description 15
- 239000012280 lithium aluminium hydride Substances 0.000 description 14
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 13
- MUJIDPITZJWBSW-UHFFFAOYSA-N palladium(2+) Chemical compound [Pd+2] MUJIDPITZJWBSW-UHFFFAOYSA-N 0.000 description 13
- 229920006395 saturated elastomer Polymers 0.000 description 13
- 229940098779 methanesulfonic acid Drugs 0.000 description 12
- 239000003921 oil Substances 0.000 description 12
- 239000012071 phase Substances 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- 239000012046 mixed solvent Substances 0.000 description 11
- 235000002639 sodium chloride Nutrition 0.000 description 11
- 239000012065 filter cake Substances 0.000 description 10
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 10
- 235000017557 sodium bicarbonate Nutrition 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 9
- 235000019270 ammonium chloride Nutrition 0.000 description 9
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical group CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 9
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 8
- 239000013543 active substance Substances 0.000 description 8
- 238000000605 extraction Methods 0.000 description 8
- 238000001914 filtration Methods 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 239000007791 liquid phase Substances 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- LJMDXBFYQJDXHG-UHFFFAOYSA-N CN1N=CC2=CC=C(COC3=NC(Cl)=CC=C3)C=C12 Chemical compound CN1N=CC2=CC=C(COC3=NC(Cl)=CC=C3)C=C12 LJMDXBFYQJDXHG-UHFFFAOYSA-N 0.000 description 7
- FZRCWBZWROHGRT-QHCPKHFHSA-N OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC(C=C3NN=CC3=C3)=C3F)=CC=C1)N2C[C@H]1OCC1)=O Chemical compound OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC(C=C3NN=CC3=C3)=C3F)=CC=C1)N2C[C@H]1OCC1)=O FZRCWBZWROHGRT-QHCPKHFHSA-N 0.000 description 7
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 7
- 239000005457 ice water Substances 0.000 description 7
- ZTOQQKWNYMVOFS-UHFFFAOYSA-N methyl 5-fluoro-1h-indazole-6-carboxylate Chemical compound C1=C(F)C(C(=O)OC)=CC2=C1C=NN2 ZTOQQKWNYMVOFS-UHFFFAOYSA-N 0.000 description 7
- 239000012279 sodium borohydride Substances 0.000 description 7
- 229910000033 sodium borohydride Inorganic materials 0.000 description 7
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 7
- 229910052938 sodium sulfate Inorganic materials 0.000 description 7
- 235000011152 sodium sulphate Nutrition 0.000 description 7
- BGHNWJOTRMAJGU-LBPRGKRZSA-N tert-butyl 2-(chloromethyl)-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylate Chemical compound ClCC1=NC2=C(N1C[C@H]1OCC1)C=C(C=C2)C(=O)OC(C)(C)C BGHNWJOTRMAJGU-LBPRGKRZSA-N 0.000 description 7
- UORVGPXVDQYIDP-UHFFFAOYSA-N trihydridoboron Substances B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 7
- VMZYHYPZUMUAPN-UHFFFAOYSA-N 4,5-diamino-2-fluorobenzoic acid Chemical compound NC1=CC(F)=C(C(O)=O)C=C1N VMZYHYPZUMUAPN-UHFFFAOYSA-N 0.000 description 6
- LUOJJGUZYDDOBW-UHFFFAOYSA-N 4-amino-2-fluoro-5-nitrobenzoic acid Chemical compound NC1=CC(F)=C(C(O)=O)C=C1[N+]([O-])=O LUOJJGUZYDDOBW-UHFFFAOYSA-N 0.000 description 6
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 6
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 description 6
- 229960000583 acetic acid Drugs 0.000 description 6
- 239000012141 concentrate Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- RPHJVNKZUSDUDA-UHFFFAOYSA-N methyl 1-methylindazole-6-carboxylate Chemical compound COC(=O)C1=CC=C2C=NN(C)C2=C1 RPHJVNKZUSDUDA-UHFFFAOYSA-N 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- FFFCEVQHPCPZFO-FQEVSTJZSA-N tert-butyl 2-[[4-(6-chloropyridin-2-yl)piperidin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylate Chemical compound CC(C)(C)OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(Cl)=CC=C1)N2C[C@H]1OCC1)=O FFFCEVQHPCPZFO-FQEVSTJZSA-N 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- BVPUKTSBKDFGBN-UHFFFAOYSA-N (1-methylindazol-6-yl)methanol Chemical compound C1=C(CO)C=C2N(C)N=CC2=C1 BVPUKTSBKDFGBN-UHFFFAOYSA-N 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 5
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 5
- JFBZPFYRPYOZCQ-UHFFFAOYSA-N [Li].[Al] Chemical compound [Li].[Al] JFBZPFYRPYOZCQ-UHFFFAOYSA-N 0.000 description 5
- 125000004429 atom Chemical group 0.000 description 5
- 125000003963 dichloro group Chemical group Cl* 0.000 description 5
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 5
- 239000011259 mixed solution Substances 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 239000012312 sodium hydride Substances 0.000 description 5
- 229910000104 sodium hydride Inorganic materials 0.000 description 5
- YAWLZFBIZMMVLI-UHFFFAOYSA-N tert-butyl 4-(6-chloropyridin-2-yl)piperidine-1-carboxylate Chemical compound ClC1=CC=CC(=N1)C1CCN(CC1)C(=O)OC(C)(C)C YAWLZFBIZMMVLI-UHFFFAOYSA-N 0.000 description 5
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Substances CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 5
- ASOJENREUJHTMD-UHFFFAOYSA-N (1-methylindazol-5-yl)methanol Chemical compound OCC1=CC=C2N(C)N=CC2=C1 ASOJENREUJHTMD-UHFFFAOYSA-N 0.000 description 4
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 4
- YZUPZGFPHUVJKC-UHFFFAOYSA-N 1-bromo-2-methoxyethane Chemical compound COCCBr YZUPZGFPHUVJKC-UHFFFAOYSA-N 0.000 description 4
- BXSCQAOOACXBMC-DEOSSOPVSA-N CC1=NC(C=C(COC2=CC=CC(C3CCN(CC4=NC(C=CC(C(O)=O)=C5)=C5N4C[C@H]4OCC4)CC3)=N2)C=C2)=C2S1 Chemical compound CC1=NC(C=C(COC2=CC=CC(C3CCN(CC4=NC(C=CC(C(O)=O)=C5)=C5N4C[C@H]4OCC4)CC3)=N2)C=C2)=C2S1 BXSCQAOOACXBMC-DEOSSOPVSA-N 0.000 description 4
- GGWCGUWGPCKBEX-HZJYTTRNSA-N CCCCC/C=C\C/C=C\CCC(C(CCCC(O)=O)[N+]([O-])=O)Cl Chemical compound CCCCC/C=C\C/C=C\CCC(C(CCCC(O)=O)[N+]([O-])=O)Cl GGWCGUWGPCKBEX-HZJYTTRNSA-N 0.000 description 4
- OTWCYAJSTJPDDN-SANMLTNESA-N CCN1N=CC2=CC(COC3=CC=CC(C4CCN(CC5=NC(C=CC(C(O)=O)=C6)=C6N5C[C@H]5OCC5)CC4)=N3)=CC=C12 Chemical compound CCN1N=CC2=CC(COC3=CC=CC(C4CCN(CC5=NC(C=CC(C(O)=O)=C6)=C6N5C[C@H]5OCC5)CC4)=N3)=CC=C12 OTWCYAJSTJPDDN-SANMLTNESA-N 0.000 description 4
- LZFKSFXNGDXGRA-UHFFFAOYSA-N CN(C1=C2)N=CC1=CC(F)=C2C(OC)=O Chemical compound CN(C1=C2)N=CC1=CC(F)=C2C(OC)=O LZFKSFXNGDXGRA-UHFFFAOYSA-N 0.000 description 4
- KCUSMXRWCKDRRE-UHFFFAOYSA-N COCCN1N=CC2=CC=C(CO)C=C12 Chemical compound COCCN1N=CC2=CC=C(CO)C=C12 KCUSMXRWCKDRRE-UHFFFAOYSA-N 0.000 description 4
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 4
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 239000005909 Kieselgur Substances 0.000 description 4
- PIUARZOQTXYVGL-UHFFFAOYSA-N OCC1=CC=C(C=NN2C(F)F)C2=C1 Chemical compound OCC1=CC=C(C=NN2C(F)F)C2=C1 PIUARZOQTXYVGL-UHFFFAOYSA-N 0.000 description 4
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 4
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 229910000085 borane Inorganic materials 0.000 description 4
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 150000002431 hydrogen Chemical group 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- VYAKGJFJEKSHRC-UHFFFAOYSA-N methyl 1-acetyl-5-fluoroindazole-6-carboxylate Chemical compound C1=C(F)C(C(=O)OC)=CC2=C1C=NN2C(C)=O VYAKGJFJEKSHRC-UHFFFAOYSA-N 0.000 description 4
- FYYXDQCSRGOVDG-UHFFFAOYSA-N methyl 2-propan-2-ylindazole-6-carboxylate Chemical compound C1=C(C(=O)OC)C=CC2=CN(C(C)C)N=C21 FYYXDQCSRGOVDG-UHFFFAOYSA-N 0.000 description 4
- UNQOAPFVWPFNKR-UHFFFAOYSA-N methyl 3-bromo-1-methylindazole-6-carboxylate Chemical compound COC(=O)C1=CC=C2C(Br)=NN(C)C2=C1 UNQOAPFVWPFNKR-UHFFFAOYSA-N 0.000 description 4
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 description 4
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- XHWQICHKIOOKPN-UHFFFAOYSA-N (1,3-dimethylindazol-6-yl)methanol Chemical compound OCC1=CC=C2C(C)=NN(C)C2=C1 XHWQICHKIOOKPN-UHFFFAOYSA-N 0.000 description 3
- FNWIOHZJMSLWCF-UHFFFAOYSA-N (1-methylbenzimidazol-5-yl)methanol Chemical compound OCC1=CC=C2N(C)C=NC2=C1 FNWIOHZJMSLWCF-UHFFFAOYSA-N 0.000 description 3
- HRDMALIGWIPQLM-UHFFFAOYSA-N (1-methylindol-4-yl)methanol Chemical compound C1=CC=C2N(C)C=CC2=C1CO HRDMALIGWIPQLM-UHFFFAOYSA-N 0.000 description 3
- BWATVBMLJUIXDT-UHFFFAOYSA-N (2-ethyl-1,3-benzoxazol-6-yl)methanol Chemical compound C1=C(CO)C=C2OC(CC)=NC2=C1 BWATVBMLJUIXDT-UHFFFAOYSA-N 0.000 description 3
- BHCZAVCHQMOXAB-UHFFFAOYSA-N (2-methyl-1,3-benzothiazol-5-yl)methanol Chemical compound OCC1=CC=C2SC(C)=NC2=C1 BHCZAVCHQMOXAB-UHFFFAOYSA-N 0.000 description 3
- QZYREQWDFMCGNO-UHFFFAOYSA-N (2-methylindazol-5-yl)methanol Chemical compound C1=C(CO)C=CC2=NN(C)C=C21 QZYREQWDFMCGNO-UHFFFAOYSA-N 0.000 description 3
- ICROYDHYTAEOHS-UHFFFAOYSA-N (2-methylindazol-6-yl)methanol Chemical compound C1=CC(CO)=CC2=NN(C)C=C21 ICROYDHYTAEOHS-UHFFFAOYSA-N 0.000 description 3
- GTDWETNQAOSZPF-UHFFFAOYSA-N (6-chloroquinolin-3-yl)methanol Chemical compound OCc1cnc2ccc(Cl)cc2c1 GTDWETNQAOSZPF-UHFFFAOYSA-N 0.000 description 3
- XHVKBSRBADVXRM-UHFFFAOYSA-N (6-chloroquinolin-8-yl)methanol Chemical compound C1=CN=C2C(CO)=CC(Cl)=CC2=C1 XHVKBSRBADVXRM-UHFFFAOYSA-N 0.000 description 3
- FRRWCNJCQZBESF-UHFFFAOYSA-N (7-fluoroquinolin-6-yl)methanol Chemical compound C1=CN=C2C=C(F)C(CO)=CC2=C1 FRRWCNJCQZBESF-UHFFFAOYSA-N 0.000 description 3
- KZKRRZFCAYOXQE-UHFFFAOYSA-N 1$l^{2}-azinane Chemical group C1CC[N]CC1 KZKRRZFCAYOXQE-UHFFFAOYSA-N 0.000 description 3
- GFTNSZIYQMJJMD-UHFFFAOYSA-N 1-methylindole-4-carbaldehyde Chemical compound C1=CC=C2N(C)C=CC2=C1C=O GFTNSZIYQMJJMD-UHFFFAOYSA-N 0.000 description 3
- MVRNAPZMQQYTIN-UHFFFAOYSA-N 2,3,4,5-tetrafluoropyridine Chemical compound FC1=CN=C(F)C(F)=C1F MVRNAPZMQQYTIN-UHFFFAOYSA-N 0.000 description 3
- MNVKJEDUWUEZEQ-UHFFFAOYSA-N 2,3-difluoro-4-nitrobenzoic acid Chemical compound OC(=O)C1=CC=C([N+]([O-])=O)C(F)=C1F MNVKJEDUWUEZEQ-UHFFFAOYSA-N 0.000 description 3
- HWEOLANUQJPQKR-UHFFFAOYSA-N 2-fluoro-5-hydroxy-4-nitrobenzoic acid Chemical compound OC(=O)c1cc(O)c(cc1F)[N+]([O-])=O HWEOLANUQJPQKR-UHFFFAOYSA-N 0.000 description 3
- IAEVMQJCFZLDNR-UHFFFAOYSA-N 3-iodo-1-methylindazole-6-carbaldehyde Chemical compound IC1=NN(C2=CC(=CC=C12)C=O)C IAEVMQJCFZLDNR-UHFFFAOYSA-N 0.000 description 3
- MFUZJLPIGYIBSM-UHFFFAOYSA-N 4-(bromomethyl)naphthalene-1-carbonitrile Chemical compound C1=CC=C2C(CBr)=CC=C(C#N)C2=C1 MFUZJLPIGYIBSM-UHFFFAOYSA-N 0.000 description 3
- PZKDOSHWQBLVJW-UHFFFAOYSA-N 4-(hydroxymethyl)naphthalene-1-carbonitrile Chemical compound C1=CC=C2C(CO)=CC=C(C#N)C2=C1 PZKDOSHWQBLVJW-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- YFQWHTAXALUFGB-UHFFFAOYSA-N C(C1=C2N=CC=CC2=CC=C1)OC1=CC=CC(C2CCNCC2)=N1 Chemical compound C(C1=C2N=CC=CC2=CC=C1)OC1=CC=CC(C2CCNCC2)=N1 YFQWHTAXALUFGB-UHFFFAOYSA-N 0.000 description 3
- LQLAXNNCIFELDE-NDEPHWFRSA-N CC(C)(C)OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(NCC3=CC=C4NC=CC4=C3)=CC=C1)N2C[C@H]1OCC1)=O Chemical compound CC(C)(C)OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(NCC3=CC=C4NC=CC4=C3)=CC=C1)N2C[C@H]1OCC1)=O LQLAXNNCIFELDE-NDEPHWFRSA-N 0.000 description 3
- UHRHUAWGJNYYED-MHZLTWQESA-N CC(C)(C)OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC(C=C3)=CC4=C3N=C(C)S4)=CC=C1)N2C[C@H]1OCC1)=O Chemical compound CC(C)(C)OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC(C=C3)=CC4=C3N=C(C)S4)=CC=C1)N2C[C@H]1OCC1)=O UHRHUAWGJNYYED-MHZLTWQESA-N 0.000 description 3
- SEKYPXXJMFHQAJ-LJAQVGFWSA-N CC(C)(C)OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=CC=C(C=NN4CC#N)C4=C3)=CC=C1)N2C[C@H]1OCC1)=O Chemical compound CC(C)(C)OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=CC=C(C=NN4CC#N)C4=C3)=CC=C1)N2C[C@H]1OCC1)=O SEKYPXXJMFHQAJ-LJAQVGFWSA-N 0.000 description 3
- POSPPELATSAMBC-LJAQVGFWSA-N CC(C)(C)OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=CN=CC4=CC=CC=C34)=CC=C1)N2C[C@H]1OCC1)=O Chemical compound CC(C)(C)OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=CN=CC4=CC=CC=C34)=CC=C1)N2C[C@H]1OCC1)=O POSPPELATSAMBC-LJAQVGFWSA-N 0.000 description 3
- UQQIBCRZGTUFBB-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1C1=NC(OCC2=CC=C3N=CC=CC3=C2)=CC=C1)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1C1=NC(OCC2=CC=C3N=CC=CC3=C2)=CC=C1)=O UQQIBCRZGTUFBB-UHFFFAOYSA-N 0.000 description 3
- JMQXMOLTILVNQZ-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCN1C1=NC(OCC2=CC=C(C=NN3C)C3=C2)=CC=C1)=O Chemical compound CC(C)(C)OC(N(CC1)CCN1C1=NC(OCC2=CC=C(C=NN3C)C3=C2)=CC=C1)=O JMQXMOLTILVNQZ-UHFFFAOYSA-N 0.000 description 3
- NCUXVMPUHLDXDZ-UHFFFAOYSA-N CC(C)(CN(C1=C2)N=CC1=CC=C2C(OC)=O)O Chemical compound CC(C)(CN(C1=C2)N=CC1=CC=C2C(OC)=O)O NCUXVMPUHLDXDZ-UHFFFAOYSA-N 0.000 description 3
- YRJXDCGWFLFZIW-MHZLTWQESA-N CC(C)N1N=CC2=CC=C(COC3=CC=CC(C4CCN(CC5=NC(C=CC(C(O)=O)=C6)=C6N5C[C@H]5OCC5)CC4)=N3)C=C12 Chemical compound CC(C)N1N=CC2=CC=C(COC3=CC=CC(C4CCN(CC5=NC(C=CC(C(O)=O)=C6)=C6N5C[C@H]5OCC5)CC4)=N3)C=C12 YRJXDCGWFLFZIW-MHZLTWQESA-N 0.000 description 3
- VGHIGFLQQJFREJ-UHFFFAOYSA-N CC1(CN(C2=C3)N=CC2=CC=C3C(OC)=O)COC1 Chemical compound CC1(CN(C2=C3)N=CC2=CC=C3C(OC)=O)COC1 VGHIGFLQQJFREJ-UHFFFAOYSA-N 0.000 description 3
- WDIDVBYLKAENNL-UHFFFAOYSA-N CCN1N=C(C=C(C=C2)C(OC)=O)C2=C1 Chemical compound CCN1N=C(C=C(C=C2)C(OC)=O)C2=C1 WDIDVBYLKAENNL-UHFFFAOYSA-N 0.000 description 3
- BXHAEVOFNLKBJU-UHFFFAOYSA-N CN(C1=CC(C(OC)=O)=CC=C11)N=C1Cl Chemical compound CN(C1=CC(C(OC)=O)=CC=C11)N=C1Cl BXHAEVOFNLKBJU-UHFFFAOYSA-N 0.000 description 3
- YWLCKNYSRSPYRH-UHFFFAOYSA-N CN(C1=CC(C(OC)=O)=CC=C11)N=C1F Chemical compound CN(C1=CC(C(OC)=O)=CC=C11)N=C1F YWLCKNYSRSPYRH-UHFFFAOYSA-N 0.000 description 3
- SACMBZUGZBPOTG-UHFFFAOYSA-N CN(C1=CC(CO)=CC=C11)N=C1I Chemical compound CN(C1=CC(CO)=CC=C11)N=C1I SACMBZUGZBPOTG-UHFFFAOYSA-N 0.000 description 3
- DMBQRVKBHWNJEN-UHFFFAOYSA-N CN1N=C(C=C(CO)C(F)=C2)C2=C1 Chemical compound CN1N=C(C=C(CO)C(F)=C2)C2=C1 DMBQRVKBHWNJEN-UHFFFAOYSA-N 0.000 description 3
- VPINIZMSGNQYJD-UHFFFAOYSA-N CN1N=CC2=CC(COC(C=C(C=C3)Br)=C3F)=CC=C12 Chemical compound CN1N=CC2=CC(COC(C=C(C=C3)Br)=C3F)=CC=C12 VPINIZMSGNQYJD-UHFFFAOYSA-N 0.000 description 3
- ZGOSHLBONSAORU-NQCNTLBGSA-N CN1N=CC2=CC(COC(N=C(C(F)=C3)N(CC4)CCC4(C4)C4C4=NC(C=CC(C(O)=O)=C5)=C5N4C[C@H]4OCC4)=C3F)=CC=C12 Chemical compound CN1N=CC2=CC(COC(N=C(C(F)=C3)N(CC4)CCC4(C4)C4C4=NC(C=CC(C(O)=O)=C5)=C5N4C[C@H]4OCC4)=C3F)=CC=C12 ZGOSHLBONSAORU-NQCNTLBGSA-N 0.000 description 3
- OBBJZSCJSGCQIU-UXMRNZNESA-N CN1N=CC2=CC(COC(N=C(C(F)=C3)N(CC4)CCC4(C4)C4C4=NC(C=CC(C(OC)=O)=C5)=C5N4C[C@H]4OCC4)=C3F)=CC=C12 Chemical compound CN1N=CC2=CC(COC(N=C(C(F)=C3)N(CC4)CCC4(C4)C4C4=NC(C=CC(C(OC)=O)=C5)=C5N4C[C@H]4OCC4)=C3F)=CC=C12 OBBJZSCJSGCQIU-UXMRNZNESA-N 0.000 description 3
- PEPGVBBCDVWECO-VWLOTQADSA-N CN1N=CC2=CC(COC3=CC=CC(C4CCN(CC5=NC(C=CC(C(O)=O)=C6)=C6N5C[C@H]5OCC5)CC4)=N3)=CC=C12 Chemical compound CN1N=CC2=CC(COC3=CC=CC(C4CCN(CC5=NC(C=CC(C(O)=O)=C6)=C6N5C[C@H]5OCC5)CC4)=N3)=CC=C12 PEPGVBBCDVWECO-VWLOTQADSA-N 0.000 description 3
- ZYCQDROTLNCWBA-UHFFFAOYSA-N CN1N=CC2=CC=C(COC3=NC(C4CCNCC4)=CC=C3)C=C12 Chemical compound CN1N=CC2=CC=C(COC3=NC(C4CCNCC4)=CC=C3)C=C12 ZYCQDROTLNCWBA-UHFFFAOYSA-N 0.000 description 3
- OANIZSQPDFCHBB-UHFFFAOYSA-N COC(=O)c1ccc2c(C)nn(C)c2c1 Chemical compound COC(=O)c1ccc2c(C)nn(C)c2c1 OANIZSQPDFCHBB-UHFFFAOYSA-N 0.000 description 3
- MJGDJNIMXNSJIB-UHFFFAOYSA-N COC(C(C=C(C(NC(C1CC1)=O)=C1)O)=C1F)=O Chemical compound COC(C(C=C(C(NC(C1CC1)=O)=C1)O)=C1F)=O MJGDJNIMXNSJIB-UHFFFAOYSA-N 0.000 description 3
- JCBMEKKFHUWEDF-UHFFFAOYSA-N COC(C(C=C1N(C2COC2)N=CC1=C1)=C1F)=O Chemical compound COC(C(C=C1N(C2COC2)N=CC1=C1)=C1F)=O JCBMEKKFHUWEDF-UHFFFAOYSA-N 0.000 description 3
- FNTWKEITRXYMNG-UHFFFAOYSA-N COC(C1=CC2=NN(CC(F)F)C=C2C=C1)=O Chemical compound COC(C1=CC2=NN(CC(F)F)C=C2C=C1)=O FNTWKEITRXYMNG-UHFFFAOYSA-N 0.000 description 3
- LDFMAFBEHSGPGO-UHFFFAOYSA-N COC(C1=CC=C(C=NN2C3CCOCC3)C2=C1)=O Chemical compound COC(C1=CC=C(C=NN2C3CCOCC3)C2=C1)=O LDFMAFBEHSGPGO-UHFFFAOYSA-N 0.000 description 3
- WPMYCZOLJSHRED-UHFFFAOYSA-N COC(C1=CC=C(C=NN2C3COC3)C2=C1)=O Chemical compound COC(C1=CC=C(C=NN2C3COC3)C2=C1)=O WPMYCZOLJSHRED-UHFFFAOYSA-N 0.000 description 3
- YOMBLBLDLLXPOL-UHFFFAOYSA-N COC(C1=CC=C(C=NN2CC(F)(F)F)C2=C1)=O Chemical compound COC(C1=CC=C(C=NN2CC(F)(F)F)C2=C1)=O YOMBLBLDLLXPOL-UHFFFAOYSA-N 0.000 description 3
- OWZMOORRVGYXPF-UHFFFAOYSA-N COC(C1=CC=C(C=NN2CC(F)F)C2=C1)=O Chemical compound COC(C1=CC=C(C=NN2CC(F)F)C2=C1)=O OWZMOORRVGYXPF-UHFFFAOYSA-N 0.000 description 3
- DYDHGXYBRAUJPN-UHFFFAOYSA-N COC(C1=CC=C(C=NN2CC3CC3)C2=C1)=O Chemical compound COC(C1=CC=C(C=NN2CC3CC3)C2=C1)=O DYDHGXYBRAUJPN-UHFFFAOYSA-N 0.000 description 3
- ILTJVWTXLFUXAD-UHFFFAOYSA-N COC(C1=CC=C(C=NN2CC3COC3)C2=C1)=O Chemical compound COC(C1=CC=C(C=NN2CC3COC3)C2=C1)=O ILTJVWTXLFUXAD-UHFFFAOYSA-N 0.000 description 3
- XBZXQQNJQRRSQU-UHFFFAOYSA-N COC(C1=CC=C(C=NN2CCF)C2=C1)=O Chemical compound COC(C1=CC=C(C=NN2CCF)C2=C1)=O XBZXQQNJQRRSQU-UHFFFAOYSA-N 0.000 description 3
- SKLWDOKKAFLALK-UHFFFAOYSA-N COCCN(C1=C2)N=CC1=CC(F)=C2C(OC)=O Chemical compound COCCN(C1=C2)N=CC1=CC(F)=C2C(OC)=O SKLWDOKKAFLALK-UHFFFAOYSA-N 0.000 description 3
- JMVJEZOTVBIOEE-UHFFFAOYSA-N COCCN(C1=C2)N=CC1=CC=C2C(OC)=O Chemical compound COCCN(C1=C2)N=CC1=CC=C2C(OC)=O JMVJEZOTVBIOEE-UHFFFAOYSA-N 0.000 description 3
- ZBJNLPHMHCXECC-UHFFFAOYSA-N COCCN1N=C(C=C(C(OC)=O)C(F)=C2)C2=C1 Chemical compound COCCN1N=C(C=C(C(OC)=O)C(F)=C2)C2=C1 ZBJNLPHMHCXECC-UHFFFAOYSA-N 0.000 description 3
- BFYFIWFRCFTJFA-UHFFFAOYSA-N COCCN1N=C(C=C(C=C2)C(OC)=O)C2=C1 Chemical compound COCCN1N=C(C=C(C=C2)C(OC)=O)C2=C1 BFYFIWFRCFTJFA-UHFFFAOYSA-N 0.000 description 3
- PKIJMRDBDRSHHM-UHFFFAOYSA-N COCCN1N=C(C=C(CO)C(F)=C2)C2=C1 Chemical compound COCCN1N=C(C=C(CO)C(F)=C2)C2=C1 PKIJMRDBDRSHHM-UHFFFAOYSA-N 0.000 description 3
- ZLIKYJAQACIWOA-UHFFFAOYSA-N COCCN1N=CC2=CC(F)=C(CO)C=C12 Chemical compound COCCN1N=CC2=CC(F)=C(CO)C=C12 ZLIKYJAQACIWOA-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- WBLICZJWXJUBMB-UHFFFAOYSA-N N#CCN1N=CC2=CC=C(CO)C=C12 Chemical compound N#CCN1N=CC2=CC=C(CO)C=C12 WBLICZJWXJUBMB-UHFFFAOYSA-N 0.000 description 3
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 3
- OZOUZLMNEYURDL-VWLOTQADSA-N OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(NCC3=CC=C4NC=CC4=C3)=CC=C1)N2C[C@H]1OCC1)=O Chemical compound OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(NCC3=CC=C4NC=CC4=C3)=CC=C1)N2C[C@H]1OCC1)=O OZOUZLMNEYURDL-VWLOTQADSA-N 0.000 description 3
- OTWOXFVDLZMFEJ-SANMLTNESA-N OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=C(C=NC=C4)C4=CC=C3)=CC=C1)N2C[C@H]1OCC1)=O Chemical compound OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=C(C=NC=C4)C4=CC=C3)=CC=C1)N2C[C@H]1OCC1)=O OTWOXFVDLZMFEJ-SANMLTNESA-N 0.000 description 3
- PBIDWTVBDFQWJR-UHFFFAOYSA-N OCC1=CC2=CN=CN2C=C1 Chemical compound OCC1=CC2=CN=CN2C=C1 PBIDWTVBDFQWJR-UHFFFAOYSA-N 0.000 description 3
- WLBQNOSVHXHRGL-UHFFFAOYSA-N OCC1=CC2=NN(CC(F)F)C=C2C=C1 Chemical compound OCC1=CC2=NN(CC(F)F)C=C2C=C1 WLBQNOSVHXHRGL-UHFFFAOYSA-N 0.000 description 3
- CTMALUSITVTRQA-UHFFFAOYSA-N OCC1=CC=C(C=NN2CC(F)(F)F)C2=C1 Chemical compound OCC1=CC=C(C=NN2CC(F)(F)F)C2=C1 CTMALUSITVTRQA-UHFFFAOYSA-N 0.000 description 3
- ZZAJTZFSJYTSPR-UHFFFAOYSA-N OCC1=CC=C(C=NN2CC(F)F)C2=C1 Chemical compound OCC1=CC=C(C=NN2CC(F)F)C2=C1 ZZAJTZFSJYTSPR-UHFFFAOYSA-N 0.000 description 3
- IILWMDHVHYAFND-UHFFFAOYSA-N OCC1=CC=C(C=NN2CCF)C2=C1 Chemical compound OCC1=CC=C(C=NN2CCF)C2=C1 IILWMDHVHYAFND-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- OCABPFFFLQAPOE-UHFFFAOYSA-N [1-[(3-methyloxetan-3-yl)methyl]indazol-6-yl]methanol Chemical compound N1=CC2=CC=C(CO)C=C2N1CC1(C)COC1 OCABPFFFLQAPOE-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 3
- 238000001212 derivatisation Methods 0.000 description 3
- VFAYOJXREITCQO-UHFFFAOYSA-N ethyl 7-fluoroquinoline-6-carboxylate Chemical compound C1=CN=C2C=C(F)C(C(=O)OCC)=CC2=C1 VFAYOJXREITCQO-UHFFFAOYSA-N 0.000 description 3
- BIKKPOLJEWZNOX-UHFFFAOYSA-N imidazo[1,5-a]pyridin-6-ylmethanol Chemical compound C1=C(CO)C=CC2=CN=CN21 BIKKPOLJEWZNOX-UHFFFAOYSA-N 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000003914 insulin secretion Effects 0.000 description 3
- QWTIYWBQFLATTN-UHFFFAOYSA-N isoquinolin-4-ylmethanol Chemical compound C1=CC=C2C(CO)=CN=CC2=C1 QWTIYWBQFLATTN-UHFFFAOYSA-N 0.000 description 3
- HSPKIXPRSRGOQK-UHFFFAOYSA-N isoquinolin-5-ylmethanol Chemical compound N1=CC=C2C(CO)=CC=CC2=C1 HSPKIXPRSRGOQK-UHFFFAOYSA-N 0.000 description 3
- XIRLIZNMBKEUDD-UHFFFAOYSA-N isoquinolin-6-ylmethanol Chemical compound C1=NC=CC2=CC(CO)=CC=C21 XIRLIZNMBKEUDD-UHFFFAOYSA-N 0.000 description 3
- VLONTUPZTAEOIH-UHFFFAOYSA-N isoquinolin-7-ylmethanol Chemical compound C1=CN=CC2=CC(CO)=CC=C21 VLONTUPZTAEOIH-UHFFFAOYSA-N 0.000 description 3
- UDNDYRZGZAWJHB-UHFFFAOYSA-N isoquinolin-8-ylmethanol Chemical compound C1=NC=C2C(CO)=CC=CC2=C1 UDNDYRZGZAWJHB-UHFFFAOYSA-N 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- UVWUEXQSBNBKPU-UHFFFAOYSA-N methyl 1-ethylindazole-6-carboxylate Chemical compound C1=C(C(=O)OC)C=C2N(CC)N=CC2=C1 UVWUEXQSBNBKPU-UHFFFAOYSA-N 0.000 description 3
- HBYFGEOBNHODCG-UHFFFAOYSA-N methyl 1-methylbenzimidazole-5-carboxylate Chemical compound COC(=O)C1=CC=C2N(C)C=NC2=C1 HBYFGEOBNHODCG-UHFFFAOYSA-N 0.000 description 3
- DEEFDHHJEASOQV-UHFFFAOYSA-N methyl 1-propan-2-ylindazole-6-carboxylate Chemical compound COC(=O)C1=CC=C2C=NN(C(C)C)C2=C1 DEEFDHHJEASOQV-UHFFFAOYSA-N 0.000 description 3
- XGJNKHWBBSJFGB-UHFFFAOYSA-N methyl 2,3-difluoro-4-nitrobenzoate Chemical compound COC(=O)c1ccc(c(F)c1F)[N+]([O-])=O XGJNKHWBBSJFGB-UHFFFAOYSA-N 0.000 description 3
- ZXTHAWXDCNDYFT-UHFFFAOYSA-N methyl 2-ethyl-1,3-benzoxazole-6-carboxylate Chemical compound CCc1nc2ccc(cc2o1)C(=O)OC ZXTHAWXDCNDYFT-UHFFFAOYSA-N 0.000 description 3
- AMEWYDYFUOESMG-UHFFFAOYSA-N methyl 2-fluoro-5-hydroxy-4-nitrobenzoate Chemical compound COC(=O)c1cc(O)c(cc1F)[N+]([O-])=O AMEWYDYFUOESMG-UHFFFAOYSA-N 0.000 description 3
- CIGMBXJEQUHKPR-UHFFFAOYSA-N methyl 2-methyl-1,3-benzoxazole-6-carboxylate Chemical compound COC(=O)C1=CC=C2N=C(C)OC2=C1 CIGMBXJEQUHKPR-UHFFFAOYSA-N 0.000 description 3
- ISBRVRYHPZCEKB-UHFFFAOYSA-N methyl 3-(difluoromethyl)-1-methylindazole-6-carboxylate Chemical compound FC(C1=NN(C2=CC(=CC=C12)C(=O)OC)C)F ISBRVRYHPZCEKB-UHFFFAOYSA-N 0.000 description 3
- DIRJAODPZUSMIH-UHFFFAOYSA-N methyl 3-cyclopropyl-1-methylindazole-6-carboxylate Chemical compound C1(CC1)C1=NN(C2=CC(=CC=C12)C(=O)OC)C DIRJAODPZUSMIH-UHFFFAOYSA-N 0.000 description 3
- KSHFQRQFDNSQMH-UHFFFAOYSA-N methyl 3-formyl-1-methylindazole-6-carboxylate Chemical compound COC(=O)C1=CC=C2C(C=O)=NN(C)C2=C1 KSHFQRQFDNSQMH-UHFFFAOYSA-N 0.000 description 3
- RIMFBLUHPCMPNV-UHFFFAOYSA-N methyl 4-amino-2-fluoro-5-hydroxybenzoate Chemical compound COC(=O)c1cc(O)c(N)cc1F RIMFBLUHPCMPNV-UHFFFAOYSA-N 0.000 description 3
- UVPWZEOLHRROQK-UHFFFAOYSA-N methyl isoquinoline-6-carboxylate Chemical compound C1=NC=CC2=CC(C(=O)OC)=CC=C21 UVPWZEOLHRROQK-UHFFFAOYSA-N 0.000 description 3
- IBSCADYIYSQTJC-UHFFFAOYSA-N methyl isoquinoline-7-carboxylate Chemical compound C1=CN=CC2=CC(C(=O)OC)=CC=C21 IBSCADYIYSQTJC-UHFFFAOYSA-N 0.000 description 3
- KBZRUHZYILYXFD-UHFFFAOYSA-N methyl pyrazolo[1,5-a]pyridine-4-carboxylate Chemical compound COC(=O)C1=CC=CN2N=CC=C12 KBZRUHZYILYXFD-UHFFFAOYSA-N 0.000 description 3
- ABTMMGGHSGNLNY-UHFFFAOYSA-N methyl pyrazolo[1,5-a]pyridine-5-carboxylate Chemical compound C1=C(C(=O)OC)C=CN2N=CC=C21 ABTMMGGHSGNLNY-UHFFFAOYSA-N 0.000 description 3
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 238000002953 preparative HPLC Methods 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- JZDRYPJLENDYQU-UHFFFAOYSA-N pyrazolo[1,5-a]pyridin-5-ylmethanol Chemical compound C1=C(CO)C=CN2N=CC=C21 JZDRYPJLENDYQU-UHFFFAOYSA-N 0.000 description 3
- FLGKQMOTLCGOQH-UHFFFAOYSA-N quinolin-3-ylmethanol Chemical compound C1=CC=CC2=CC(CO)=CN=C21 FLGKQMOTLCGOQH-UHFFFAOYSA-N 0.000 description 3
- ZKPMQVSVRVORAH-UHFFFAOYSA-N quinolin-5-ylmethanol Chemical compound C1=CC=C2C(CO)=CC=CC2=N1 ZKPMQVSVRVORAH-UHFFFAOYSA-N 0.000 description 3
- RDBBFCMDRBOXIG-UHFFFAOYSA-N quinolin-7-ylmethanol Chemical compound C1=CC=NC2=CC(CO)=CC=C21 RDBBFCMDRBOXIG-UHFFFAOYSA-N 0.000 description 3
- BGLZVNYGUGILJU-UHFFFAOYSA-N quinolin-8-ylmethanol Chemical compound C1=CN=C2C(CO)=CC=CC2=C1 BGLZVNYGUGILJU-UHFFFAOYSA-N 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- UJLHZADPYFJZIT-UHFFFAOYSA-N (1-ethylindazol-6-yl)methanol Chemical compound C1=C(CO)C=C2N(CC)N=CC2=C1 UJLHZADPYFJZIT-UHFFFAOYSA-N 0.000 description 2
- VZKUKEKIMSDQPK-UHFFFAOYSA-N (1-propan-2-ylindazol-6-yl)methanol Chemical compound C1=C(CO)C=C2N(C(C)C)N=CC2=C1 VZKUKEKIMSDQPK-UHFFFAOYSA-N 0.000 description 2
- RKTQADDCDLDOFS-UHFFFAOYSA-N (2-ethylindazol-6-yl)methanol Chemical compound C1=CC(CO)=CC2=NN(CC)C=C21 RKTQADDCDLDOFS-UHFFFAOYSA-N 0.000 description 2
- SFCHIWNAOMJWLM-UHFFFAOYSA-N (2-methyl-1,3-benzoxazol-6-yl)methanol Chemical compound C1=C(CO)C=C2OC(C)=NC2=C1 SFCHIWNAOMJWLM-UHFFFAOYSA-N 0.000 description 2
- AWZAHRIAIVONDP-UHFFFAOYSA-N (2-propan-2-ylindazol-6-yl)methanol Chemical compound C1=CC(CO)=CC2=NN(C(C)C)C=C21 AWZAHRIAIVONDP-UHFFFAOYSA-N 0.000 description 2
- CTLZHAOUNJXHMU-UHFFFAOYSA-N (3-chloro-1-methylindazol-6-yl)methanol Chemical compound C1=C(CO)C=C2N(C)N=C(Cl)C2=C1 CTLZHAOUNJXHMU-UHFFFAOYSA-N 0.000 description 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 2
- VMFCTZUYOILUMY-UHFFFAOYSA-N 1,1-difluoro-2-iodoethane Chemical compound FC(F)CI VMFCTZUYOILUMY-UHFFFAOYSA-N 0.000 description 2
- RFFLAFLAYFXFSW-UHFFFAOYSA-N 1,2-dichlorobenzene Chemical compound ClC1=CC=CC=C1Cl RFFLAFLAYFXFSW-UHFFFAOYSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- WZCQPVLAXQMTJO-UHFFFAOYSA-N 1h-indazol-6-ylmethanol Chemical compound OCC1=CC=C2C=NNC2=C1 WZCQPVLAXQMTJO-UHFFFAOYSA-N 0.000 description 2
- MDFSGDMPHMKKGB-UHFFFAOYSA-N 2,4-difluoro-5-nitrobenzoic acid Chemical compound OC(=O)C1=CC([N+]([O-])=O)=C(F)C=C1F MDFSGDMPHMKKGB-UHFFFAOYSA-N 0.000 description 2
- FILKGCRCWDMBKA-UHFFFAOYSA-N 2,6-dichloropyridine Chemical compound ClC1=CC=CC(Cl)=N1 FILKGCRCWDMBKA-UHFFFAOYSA-N 0.000 description 2
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
- KBEIFKMKVCDETC-UHFFFAOYSA-N 3-iodooxetane Chemical compound IC1COC1 KBEIFKMKVCDETC-UHFFFAOYSA-N 0.000 description 2
- YPTHSYKJDRMAJY-UHFFFAOYSA-N 5-bromo-2-fluorophenol Chemical compound OC1=CC(Br)=CC=C1F YPTHSYKJDRMAJY-UHFFFAOYSA-N 0.000 description 2
- PRENRLXOGJUJAG-UHFFFAOYSA-N 6-(bromomethyl)-1-methylindazole Chemical compound C1=C(CBr)C=C2N(C)N=CC2=C1 PRENRLXOGJUJAG-UHFFFAOYSA-N 0.000 description 2
- LWVYELNVZVWUHG-UHFFFAOYSA-N 7-fluoroquinoxaline-6-carboxylic acid Chemical compound C1=CN=C2C=C(F)C(C(=O)O)=CC2=N1 LWVYELNVZVWUHG-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- CWRCIPBSRZSYTO-NDEPHWFRSA-N CC(C)(C)OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC(C=C(C=CC=N3)C3=C3)=C3F)=CC=C1)N2C[C@H]1OCC1)=O Chemical compound CC(C)(C)OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC(C=C(C=CC=N3)C3=C3)=C3F)=CC=C1)N2C[C@H]1OCC1)=O CWRCIPBSRZSYTO-NDEPHWFRSA-N 0.000 description 2
- INUBCVCBUDANBN-MHZLTWQESA-N CC(C)(C)OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC(C=C3)=CC4=C3SC(C)=N4)=CC=C1)N2C[C@H]1OCC1)=O Chemical compound CC(C)(C)OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC(C=C3)=CC4=C3SC(C)=N4)=CC=C1)N2C[C@H]1OCC1)=O INUBCVCBUDANBN-MHZLTWQESA-N 0.000 description 2
- MLXVBGNJRQVFOD-LJAQVGFWSA-N CC(C)(C)OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC(C=C3N(C4COC4)N=CC3=C3)=C3F)=CC=C1)N2C[C@H]1OCC1)=O Chemical compound CC(C)(C)OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC(C=C3N(C4COC4)N=CC3=C3)=C3F)=CC=C1)N2C[C@H]1OCC1)=O MLXVBGNJRQVFOD-LJAQVGFWSA-N 0.000 description 2
- KWPHIIQNYJPEGT-NDEPHWFRSA-N CC(C)(C)OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=CC4=NN(CC(F)F)C=C4C=C3)=CC=C1)N2C[C@H]1OCC1)=O Chemical compound CC(C)(C)OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=CC4=NN(CC(F)F)C=C4C=C3)=CC=C1)N2C[C@H]1OCC1)=O KWPHIIQNYJPEGT-NDEPHWFRSA-N 0.000 description 2
- REJDITLULHPKDL-NDEPHWFRSA-N CC(C)(C)OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=CC=C(C=NN4CC(F)F)C4=C3)=CC=C1)N2C[C@H]1OCC1)=O Chemical compound CC(C)(C)OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=CC=C(C=NN4CC(F)F)C4=C3)=CC=C1)N2C[C@H]1OCC1)=O REJDITLULHPKDL-NDEPHWFRSA-N 0.000 description 2
- YQEDJDBHAKCXDU-HKBQPEDESA-N CC(C)(C)OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=CC=C(C=NN4CC5COC5)C4=C3)=CC=C1)N2C[C@H]1OCC1)=O Chemical compound CC(C)(C)OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=CC=C(C=NN4CC5COC5)C4=C3)=CC=C1)N2C[C@H]1OCC1)=O YQEDJDBHAKCXDU-HKBQPEDESA-N 0.000 description 2
- GQEJWIDIAVLRIC-LJAQVGFWSA-N CC(C)(C)OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=NC4=CC=CC=C4C=C3)=CC=C1)N2C[C@H]1OCC1)=O Chemical compound CC(C)(C)OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=NC4=CC=CC=C4C=C3)=CC=C1)N2C[C@H]1OCC1)=O GQEJWIDIAVLRIC-LJAQVGFWSA-N 0.000 description 2
- CNPXGQOZMMHBGZ-ZENAZSQFSA-N CC(C)(C)OC(N(CC1)CCC1(C1)C1C(NC(C=CC(C(OC)=O)=C1)=C1NC[C@H]1OCC1)=O)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1(C1)C1C(NC(C=CC(C(OC)=O)=C1)=C1NC[C@H]1OCC1)=O)=O CNPXGQOZMMHBGZ-ZENAZSQFSA-N 0.000 description 2
- VEONFFDYXRKSRP-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1C(C=C1)=CC(O)=C1F)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1C(C=C1)=CC(O)=C1F)=O VEONFFDYXRKSRP-UHFFFAOYSA-N 0.000 description 2
- OLQLBQVMUCYPOB-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1C1=NC(OCC2=CC=C(C=NN3C)C3=C2)=CC=C1)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1C1=NC(OCC2=CC=C(C=NN3C)C3=C2)=CC=C1)=O OLQLBQVMUCYPOB-UHFFFAOYSA-N 0.000 description 2
- URPSMTONTDWZHM-UHFFFAOYSA-N CC(C)(CN1N=CC2=CC=C(CO)C=C12)O Chemical compound CC(C)(CN1N=CC2=CC=C(CO)C=C12)O URPSMTONTDWZHM-UHFFFAOYSA-N 0.000 description 2
- MTCGTKWNBYKAAE-PMERELPUSA-N CC(C)N1N=C(C=C(COC2=CC=CC(C3CCN(CC4=NC(C=CC(C(OC(C)(C)C)=O)=C5)=C5N4C[C@H]4OCC4)CC3)=N2)C=C2)C2=C1 Chemical compound CC(C)N1N=C(C=C(COC2=CC=CC(C3CCN(CC4=NC(C=CC(C(OC(C)(C)C)=O)=C5)=C5N4C[C@H]4OCC4)CC3)=N2)C=C2)C2=C1 MTCGTKWNBYKAAE-PMERELPUSA-N 0.000 description 2
- DLGGNJSBXDWZPA-VIFPVBQESA-N CC(C)OC(C(C=C1)=NC(NC[C@H]2OCC2)=C1[N+]([O-])=O)=O Chemical compound CC(C)OC(C(C=C1)=NC(NC[C@H]2OCC2)=C1[N+]([O-])=O)=O DLGGNJSBXDWZPA-VIFPVBQESA-N 0.000 description 2
- STHLDTBJGPJSPU-UHFFFAOYSA-N CC(C=NC1=C2)=NC1=CC(C(O)=O)=C2F Chemical compound CC(C=NC1=C2)=NC1=CC(C(O)=O)=C2F STHLDTBJGPJSPU-UHFFFAOYSA-N 0.000 description 2
- XNVBLBBJJWZMES-DEOSSOPVSA-N CC1=NC(C=CC(COC2=CC=CC(C3CCN(CC4=NC(C=CC(C(O)=O)=C5)=C5N4C[C@H]4OCC4)CC3)=N2)=C2)=C2S1 Chemical compound CC1=NC(C=CC(COC2=CC=CC(C3CCN(CC4=NC(C=CC(C(O)=O)=C5)=C5N4C[C@H]4OCC4)CC3)=N2)=C2)=C2S1 XNVBLBBJJWZMES-DEOSSOPVSA-N 0.000 description 2
- OREPLXBZHGVFIY-VWLOTQADSA-N CC1=NN(C)C2=CC(COC3=CC=CC(C4CCN(CC5=NC(C=CC(C(O)=O)=C6)=C6N5C[C@H]5OCC5)CC4)=N3)=CC=C12 Chemical compound CC1=NN(C)C2=CC(COC3=CC=CC(C4CCN(CC5=NC(C=CC(C(O)=O)=C6)=C6N5C[C@H]5OCC5)CC4)=N3)=CC=C12 OREPLXBZHGVFIY-VWLOTQADSA-N 0.000 description 2
- ZDGXBWFUYYSPQP-MHZLTWQESA-N CCC1=NC(C=CC(COC2=CC=CC(C3CCN(CC4=NC(C=CC(C(OC(C)(C)C)=O)=C5)=C5N4C[C@H]4OCC4)CC3)=N2)=C2)=C2O1 Chemical compound CCC1=NC(C=CC(COC2=CC=CC(C3CCN(CC4=NC(C=CC(C(OC(C)(C)C)=O)=C5)=C5N4C[C@H]4OCC4)CC3)=N2)=C2)=C2O1 ZDGXBWFUYYSPQP-MHZLTWQESA-N 0.000 description 2
- PCLTWLNXDMSDAO-MURFETPASA-N CCCCC/C=C\C/C=C\CCC(C(CCCC(OC(C)C)=O)[N+]([O-])=O)Cl Chemical compound CCCCC/C=C\C/C=C\CCC(C(CCCC(OC(C)C)=O)[N+]([O-])=O)Cl PCLTWLNXDMSDAO-MURFETPASA-N 0.000 description 2
- GJFFEVWJIOWGQK-LJAQVGFWSA-N CCN1N=CC2=CC(COC3=CC=CC(C4CCN(CC5=NC(C=CC(C(OC(C)(C)C)=O)=C6)=C6N5C[C@H]5OCC5)CC4)=N3)=CC=C12 Chemical compound CCN1N=CC2=CC(COC3=CC=CC(C4CCN(CC5=NC(C=CC(C(OC(C)(C)C)=O)=C6)=C6N5C[C@H]5OCC5)CC4)=N3)=CC=C12 GJFFEVWJIOWGQK-LJAQVGFWSA-N 0.000 description 2
- HHDMPOZEFDELMX-UHFFFAOYSA-N CN(C1=CC(C=O)=CC=C11)N=C1C#N Chemical compound CN(C1=CC(C=O)=CC=C11)N=C1C#N HHDMPOZEFDELMX-UHFFFAOYSA-N 0.000 description 2
- MXVFKMSXBURGRN-UHFFFAOYSA-N CN(C1=CC(CO)=CC=C11)N=C1F Chemical compound CN(C1=CC(CO)=CC=C11)N=C1F MXVFKMSXBURGRN-UHFFFAOYSA-N 0.000 description 2
- ZFCFARMSAHDVHP-UHFFFAOYSA-N CN1N=C(C2CC2)C2=CC=C(CO)C=C12 Chemical compound CN1N=C(C2CC2)C2=CC=C(CO)C=C12 ZFCFARMSAHDVHP-UHFFFAOYSA-N 0.000 description 2
- ZPBXLKSQOVTUSQ-UHFFFAOYSA-N CN1N=C(C=C(C(OC)=O)C(F)=C2)C2=C1 Chemical compound CN1N=C(C=C(C(OC)=O)C(F)=C2)C2=C1 ZPBXLKSQOVTUSQ-UHFFFAOYSA-N 0.000 description 2
- WOPIXWBEPVXSPU-UXMRNZNESA-N CN1N=C(C=C(COC(N=C(C(F)=C2)N(CC3)CCC3(C3)C3C3=NC(C=CC(C(OC)=O)=C4)=C4N3C[C@H]3OCC3)=C2F)C=C2)C2=C1 Chemical compound CN1N=C(C=C(COC(N=C(C(F)=C2)N(CC3)CCC3(C3)C3C3=NC(C=CC(C(OC)=O)=C4)=C4N3C[C@H]3OCC3)=C2F)C=C2)C2=C1 WOPIXWBEPVXSPU-UXMRNZNESA-N 0.000 description 2
- SLVWPHKVHNAZOR-DEOSSOPVSA-N CN1N=C(C=C(COC2=CC=CC(C3CCN(CC4=NC(C=CC(C(O)=O)=C5)=C5N4C[C@H]4OCC4)CC3)=N2)C(F)=C2)C2=C1 Chemical compound CN1N=C(C=C(COC2=CC=CC(C3CCN(CC4=NC(C=CC(C(O)=O)=C5)=C5N4C[C@H]4OCC4)CC3)=N2)C(F)=C2)C2=C1 SLVWPHKVHNAZOR-DEOSSOPVSA-N 0.000 description 2
- GIAHHSVVKREHJU-UHFFFAOYSA-N CN1N=CC2=CC(COC3=NC(Cl)=NC=C3F)=CC=C12 Chemical compound CN1N=CC2=CC(COC3=NC(Cl)=NC=C3F)=CC=C12 GIAHHSVVKREHJU-UHFFFAOYSA-N 0.000 description 2
- QMLKJMNELMOJQB-NQCNTLBGSA-N CN1N=CC2=CC(COC3=NC(N(CC4)CCC4(C4)C4C4=NC(C=CC(C(O)=O)=C5)=C5N4C[C@H]4OCC4)=NC=C3F)=CC=C12 Chemical compound CN1N=CC2=CC(COC3=NC(N(CC4)CCC4(C4)C4C4=NC(C=CC(C(O)=O)=C5)=C5N4C[C@H]4OCC4)=NC=C3F)=CC=C12 QMLKJMNELMOJQB-NQCNTLBGSA-N 0.000 description 2
- HALLCVSDAJDORK-UHFFFAOYSA-N CN1N=CC2=CC(F)=C(CO)C=C12 Chemical compound CN1N=CC2=CC(F)=C(CO)C=C12 HALLCVSDAJDORK-UHFFFAOYSA-N 0.000 description 2
- KJPTVLDPGOSCIU-UHFFFAOYSA-N CN1N=CC2=CC=C(COC3=NC(N4CCNCC4)=CC=C3)C=C12 Chemical compound CN1N=CC2=CC=C(COC3=NC(N4CCNCC4)=CC=C3)C=C12 KJPTVLDPGOSCIU-UHFFFAOYSA-N 0.000 description 2
- ICHRVZJBGZSSOA-UHFFFAOYSA-N COC(C(C(F)=C1)=CC2=C1N=C(C1CC1)O2)=O Chemical compound COC(C(C(F)=C1)=CC2=C1N=C(C1CC1)O2)=O ICHRVZJBGZSSOA-UHFFFAOYSA-N 0.000 description 2
- SOVHDTLFOIPBJA-MLCCFXAWSA-N COC(C(C=C1)=CC2=C1N=C(C(C1)C11CCNCC1)N2C[C@H]1OCC1)=O Chemical compound COC(C(C=C1)=CC2=C1N=C(C(C1)C11CCNCC1)N2C[C@H]1OCC1)=O SOVHDTLFOIPBJA-MLCCFXAWSA-N 0.000 description 2
- FFNNHGHZRZICPR-UHFFFAOYSA-N COC(C1=CC=C(C=NN2C(F)F)C2=C1)=O Chemical compound COC(C1=CC=C(C=NN2C(F)F)C2=C1)=O FFNNHGHZRZICPR-UHFFFAOYSA-N 0.000 description 2
- MBRNHTLAESUGBA-UHFFFAOYSA-N COCCN1N=C(C=C(CO)C=C2)C2=C1 Chemical compound COCCN1N=C(C=C(CO)C=C2)C2=C1 MBRNHTLAESUGBA-UHFFFAOYSA-N 0.000 description 2
- RENHKTRAXOROCV-AWEZNQCLSA-N C[C@@H](C1)NCCN1C1=CC=CC(OCC2=CC=C(C=NN3C)C3=C2)=N1 Chemical compound C[C@@H](C1)NCCN1C1=CC=CC(OCC2=CC=C(C=NN3C)C3=C2)=N1 RENHKTRAXOROCV-AWEZNQCLSA-N 0.000 description 2
- UJAGAWRUMZKEES-KKFHFHRHSA-N C[C@@H](CC(CC1)C2=NC(OCC3=CC=C(C=NN4C)C4=C3)=CC=C2)N1C(OC(C)(C)C)=O Chemical compound C[C@@H](CC(CC1)C2=NC(OCC3=CC=C(C=NN4C)C4=C3)=CC=C2)N1C(OC(C)(C)C)=O UJAGAWRUMZKEES-KKFHFHRHSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- ZDIZQPWNOCBDIR-SANMLTNESA-N N#CCN1N=CC2=CC=C(COC3=CC=CC(C4CCN(CC5=NC(C=CC(C(O)=O)=C6)=C6N5C[C@H]5OCC5)CC4)=N3)C=C12 Chemical compound N#CCN1N=CC2=CC=C(COC3=CC=CC(C4CCN(CC5=NC(C=CC(C(O)=O)=C6)=C6N5C[C@H]5OCC5)CC4)=N3)C=C12 ZDIZQPWNOCBDIR-SANMLTNESA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- ATHHXGZTWNVVOU-UHFFFAOYSA-N N-methylformamide Chemical compound CNC=O ATHHXGZTWNVVOU-UHFFFAOYSA-N 0.000 description 2
- QDMXFUSIJCMEIX-SANMLTNESA-N OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(NCC3=CC=C4N=CC=CC4=C3)=CC=C1)N2C[C@H]1OCC1)=O Chemical compound OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(NCC3=CC=C4N=CC=CC4=C3)=CC=C1)N2C[C@H]1OCC1)=O QDMXFUSIJCMEIX-SANMLTNESA-N 0.000 description 2
- GACLUUIVIBVIOF-SANMLTNESA-N OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=CC4=CC(Cl)=CC=C4N=C3)=CC=C1)N2C[C@H]1OCC1)=O Chemical compound OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=CC4=CC(Cl)=CC=C4N=C3)=CC=C1)N2C[C@H]1OCC1)=O GACLUUIVIBVIOF-SANMLTNESA-N 0.000 description 2
- RUYNBDNDXVGBJG-SANMLTNESA-N OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=CC=C(C=CC=N4)C4=C3)=CC=C1)N2C[C@H]1OCC1)=O Chemical compound OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=CC=C(C=CC=N4)C4=C3)=CC=C1)N2C[C@H]1OCC1)=O RUYNBDNDXVGBJG-SANMLTNESA-N 0.000 description 2
- AACGXYDXWMTTHC-DEOSSOPVSA-N OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=CC=C4N=CC=NC4=C3)=CC=C1)N2C[C@H]1OCC1)=O Chemical compound OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=CC=C4N=CC=NC4=C3)=CC=C1)N2C[C@H]1OCC1)=O AACGXYDXWMTTHC-DEOSSOPVSA-N 0.000 description 2
- IUTCEDDFKQUPPU-SANMLTNESA-N OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=CN=CC4=CC=CC=C34)=CC=C1)N2C[C@H]1OCC1)=O Chemical compound OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=CN=CC4=CC=CC=C34)=CC=C1)N2C[C@H]1OCC1)=O IUTCEDDFKQUPPU-SANMLTNESA-N 0.000 description 2
- AADJDIQUQXDEMA-SANMLTNESA-N OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=NC4=CC=CC=C4C=C3)=CC=C1)N2C[C@H]1OCC1)=O Chemical compound OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=NC4=CC=CC=C4C=C3)=CC=C1)N2C[C@H]1OCC1)=O AADJDIQUQXDEMA-SANMLTNESA-N 0.000 description 2
- JXOFLPRYDOWIHL-UHFFFAOYSA-N OCC(C(F)=C1)=CC2=C1N=C(C1CC1)O2 Chemical compound OCC(C(F)=C1)=CC2=C1N=C(C1CC1)O2 JXOFLPRYDOWIHL-UHFFFAOYSA-N 0.000 description 2
- FIEZWHIEVYAWDI-UHFFFAOYSA-N OCC(C=C1N(C2COC2)N=CC1=C1)=C1F Chemical compound OCC(C=C1N(C2COC2)N=CC1=C1)=C1F FIEZWHIEVYAWDI-UHFFFAOYSA-N 0.000 description 2
- XMVBLIZSVHFYLT-UHFFFAOYSA-N OCC(C=C1NN=CC1=C1)=C1F Chemical compound OCC(C=C1NN=CC1=C1)=C1F XMVBLIZSVHFYLT-UHFFFAOYSA-N 0.000 description 2
- XYUHUMZPDFDWLO-UHFFFAOYSA-N OCC1=CC=C(C=NN2C3CCOCC3)C2=C1 Chemical compound OCC1=CC=C(C=NN2C3CCOCC3)C2=C1 XYUHUMZPDFDWLO-UHFFFAOYSA-N 0.000 description 2
- JUJYZPQYSGARAR-UHFFFAOYSA-N OCC1=CC=C(C=NN2C3COC3)C2=C1 Chemical compound OCC1=CC=C(C=NN2C3COC3)C2=C1 JUJYZPQYSGARAR-UHFFFAOYSA-N 0.000 description 2
- VVMFZQDKDVLLCZ-UHFFFAOYSA-N OCC1=CC=C(C=NN2CC3COC3)C2=C1 Chemical compound OCC1=CC=C(C=NN2CC3COC3)C2=C1 VVMFZQDKDVLLCZ-UHFFFAOYSA-N 0.000 description 2
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- YWVCWYGPMZLXGU-UHFFFAOYSA-N [1-(cyclopropylmethyl)indazol-6-yl]methanol Chemical compound C12=CC(CO)=CC=C2C=NN1CC1CC1 YWVCWYGPMZLXGU-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- YKIOKAURTKXMSB-UHFFFAOYSA-N adams's catalyst Chemical compound O=[Pt]=O YKIOKAURTKXMSB-UHFFFAOYSA-N 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- UHKPOGGUWJGGID-UHFFFAOYSA-N carbonic acid;cesium Chemical compound [Cs].OC(O)=O UHKPOGGUWJGGID-UHFFFAOYSA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- UKNZIQFPZSCIPW-UHFFFAOYSA-N dicyclohexyl-[2-[2,4,6-tri(propan-2-yl)phenyl]phenyl]phosphane methanesulfonic acid Chemical group CS(O)(=O)=O.CC(C)c1cc(C(C)C)c(c(c1)C(C)C)-c1ccccc1P(C1CCCCC1)C1CCCCC1 UKNZIQFPZSCIPW-UHFFFAOYSA-N 0.000 description 2
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 2
- GPAYUJZHTULNBE-UHFFFAOYSA-N diphenylphosphine Chemical compound C=1C=CC=CC=1PC1=CC=CC=C1 GPAYUJZHTULNBE-UHFFFAOYSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 2
- PSXRWZBTVAZNSF-UHFFFAOYSA-N hydron;quinoline;chloride Chemical compound Cl.N1=CC=CC2=CC=CC=C21 PSXRWZBTVAZNSF-UHFFFAOYSA-N 0.000 description 2
- IEOADZOTWIMSMC-UHFFFAOYSA-N imidazo[1,2-a]pyridin-6-ylmethanol Chemical compound C1=C(CO)C=CC2=NC=CN21 IEOADZOTWIMSMC-UHFFFAOYSA-N 0.000 description 2
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 2
- 230000000155 isotopic effect Effects 0.000 description 2
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 2
- SLQIJFSQRNXACV-JTQLQIEISA-N methyl 2-(chloromethyl)-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylate Chemical compound ClCC1=NC2=C(N1C[C@H]1OCC1)C=C(C=C2)C(=O)OC SLQIJFSQRNXACV-JTQLQIEISA-N 0.000 description 2
- CEYHKCZODRRMMV-VIFPVBQESA-N methyl 4-amino-3-[[(2S)-oxetan-2-yl]methylamino]benzoate Chemical compound NC1=C(C=C(C(=O)OC)C=C1)NC[C@H]1OCC1 CEYHKCZODRRMMV-VIFPVBQESA-N 0.000 description 2
- HTYWVEUBCLGQES-VIFPVBQESA-N methyl 4-nitro-3-[[(2S)-oxetan-2-yl]methylamino]benzoate Chemical compound [N+](=O)([O-])C1=C(C=C(C(=O)OC)C=C1)NC[C@H]1OCC1 HTYWVEUBCLGQES-VIFPVBQESA-N 0.000 description 2
- AARVSKZCFCFPQC-UHFFFAOYSA-N methyl 6-chloroquinoline-8-carboxylate Chemical compound C1=CN=C2C(C(=O)OC)=CC(Cl)=CC2=C1 AARVSKZCFCFPQC-UHFFFAOYSA-N 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- ZWLPBLYKEWSWPD-UHFFFAOYSA-N o-toluic acid Chemical compound CC1=CC=CC=C1C(O)=O ZWLPBLYKEWSWPD-UHFFFAOYSA-N 0.000 description 2
- 239000003444 phase transfer catalyst Substances 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- DZHGXBCKXKTZOX-UHFFFAOYSA-N pyrazolo[1,5-a]pyridin-4-ylmethanol Chemical compound OCC1=CC=CN2N=CC=C12 DZHGXBCKXKTZOX-UHFFFAOYSA-N 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- KXYNLLGPBDUAHW-UHFFFAOYSA-N quinolin-4-ylmethanol Chemical compound C1=CC=C2C(CO)=CC=NC2=C1 KXYNLLGPBDUAHW-UHFFFAOYSA-N 0.000 description 2
- OVZQVGZERAFSPI-UHFFFAOYSA-N quinoline-8-carbaldehyde Chemical compound C1=CN=C2C(C=O)=CC=CC2=C1 OVZQVGZERAFSPI-UHFFFAOYSA-N 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 2
- 150000004756 silanes Chemical class 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- VNFWTIYUKDMAOP-UHFFFAOYSA-N sphos Chemical compound COC1=CC=CC(OC)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 VNFWTIYUKDMAOP-UHFFFAOYSA-N 0.000 description 2
- 229960002317 succinimide Drugs 0.000 description 2
- ITVZXUFYFLFDIH-JTQLQIEISA-N tert-butyl (2S)-4-(2-chloropyrimidin-4-yl)-2-methylpiperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)[C@@H](C)CN1C1=CC=NC(Cl)=N1 ITVZXUFYFLFDIH-JTQLQIEISA-N 0.000 description 2
- DATRVIMZZZVHMP-QMMMGPOBSA-N tert-butyl (2s)-2-methylpiperazine-1-carboxylate Chemical compound C[C@H]1CNCCN1C(=O)OC(C)(C)C DATRVIMZZZVHMP-QMMMGPOBSA-N 0.000 description 2
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- DLUSENJBIUDZMA-UHFFFAOYSA-N (1-ethylindazol-5-yl)methanol Chemical compound OCC1=CC=C2N(CC)N=CC2=C1 DLUSENJBIUDZMA-UHFFFAOYSA-N 0.000 description 1
- KMABUKKLVPBEIB-UHFFFAOYSA-N (2-methyl-1,3-benzothiazol-6-yl)methanol Chemical compound C1=C(CO)C=C2SC(C)=NC2=C1 KMABUKKLVPBEIB-UHFFFAOYSA-N 0.000 description 1
- ZVBPKWNJXRJGOR-UHFFFAOYSA-N (2-methyl-1,3-benzoxazol-5-yl)methanol Chemical compound OCC1=CC=C2OC(C)=NC2=C1 ZVBPKWNJXRJGOR-UHFFFAOYSA-N 0.000 description 1
- HLFYJILNIBADGG-UHFFFAOYSA-N (2-methylquinolin-6-yl)methanol Chemical compound C1=C(CO)C=CC2=NC(C)=CC=C21 HLFYJILNIBADGG-UHFFFAOYSA-N 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N 1,1'-Carbonyldiimidazole Substances C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- RKOUFQLNMRAACI-UHFFFAOYSA-N 1,1,1-trifluoro-2-iodoethane Chemical compound FC(F)(F)CI RKOUFQLNMRAACI-UHFFFAOYSA-N 0.000 description 1
- ZGMNAIODRDOMEK-UHFFFAOYSA-N 1,1,1-trimethoxypropane Chemical compound CCC(OC)(OC)OC ZGMNAIODRDOMEK-UHFFFAOYSA-N 0.000 description 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- FZTLLUYFWAOGGB-UHFFFAOYSA-N 1,4-dioxane dioxane Chemical compound C1COCCO1.C1COCCO1 FZTLLUYFWAOGGB-UHFFFAOYSA-N 0.000 description 1
- TUQRSERENKSCFM-UHFFFAOYSA-N 1-(2,2,2-trifluoroethyl)indazole Chemical compound C1=CC=C2N(CC(F)(F)F)N=CC2=C1 TUQRSERENKSCFM-UHFFFAOYSA-N 0.000 description 1
- GAGLHGFBPUCZPJ-UHFFFAOYSA-N 1-(oxan-4-yl)indole Chemical compound C1COCCC1N1C2=CC=CC=C2C=C1 GAGLHGFBPUCZPJ-UHFFFAOYSA-N 0.000 description 1
- DNUTZBZXLPWRJG-UHFFFAOYSA-N 1-Piperidine carboxylic acid Chemical compound OC(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-N 0.000 description 1
- MICMHFIQSAMEJG-UHFFFAOYSA-N 1-bromopyrrolidine-2,5-dione Chemical compound BrN1C(=O)CCC1=O.BrN1C(=O)CCC1=O MICMHFIQSAMEJG-UHFFFAOYSA-N 0.000 description 1
- LVYJIIRJQDEGBR-UHFFFAOYSA-N 1-fluoro-2-iodoethane Chemical compound FCCI LVYJIIRJQDEGBR-UHFFFAOYSA-N 0.000 description 1
- DFPYXQYWILNVAU-UHFFFAOYSA-N 1-hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1.C1=CC=C2N(O)N=NC2=C1 DFPYXQYWILNVAU-UHFFFAOYSA-N 0.000 description 1
- ZZRGDSMZKOGYPC-UHFFFAOYSA-N 1-phenyl-2-propylbenzene Chemical group CCCC1=CC=CC=C1C1=CC=CC=C1 ZZRGDSMZKOGYPC-UHFFFAOYSA-N 0.000 description 1
- UAYYSAPJTRVEQA-UHFFFAOYSA-N 1h-indol-5-ylmethanamine Chemical compound NCC1=CC=C2NC=CC2=C1 UAYYSAPJTRVEQA-UHFFFAOYSA-N 0.000 description 1
- SHPHYIMDOLOPIB-UHFFFAOYSA-N 2,3-dibenzylidene-1H-indene Chemical compound C(C1=CC=CC=C1)=C1C(C2=CC=CC=C2C1)=CC1=CC=CC=C1 SHPHYIMDOLOPIB-UHFFFAOYSA-N 0.000 description 1
- DQKUCXAFYAIKFJ-UHFFFAOYSA-N 2,3-difluoro-1-methyl-4-nitrobenzene Chemical compound CC1=CC=C([N+]([O-])=O)C(F)=C1F DQKUCXAFYAIKFJ-UHFFFAOYSA-N 0.000 description 1
- KEQTWHPMSVAFDA-UHFFFAOYSA-N 2,3-dihydro-1h-pyrazole Chemical compound C1NNC=C1 KEQTWHPMSVAFDA-UHFFFAOYSA-N 0.000 description 1
- WHPFEQUEHBULBW-UHFFFAOYSA-N 2,4-dichloro-5-fluoropyrimidine Chemical compound FC1=CN=C(Cl)N=C1Cl WHPFEQUEHBULBW-UHFFFAOYSA-N 0.000 description 1
- BTTNYQZNBZNDOR-UHFFFAOYSA-N 2,4-dichloropyrimidine Chemical compound ClC1=CC=NC(Cl)=N1 BTTNYQZNBZNDOR-UHFFFAOYSA-N 0.000 description 1
- GPTNSBLYGCZJQV-UHFFFAOYSA-N 2,5-difluoro-4-nitrobenzoic acid Chemical compound OC(=O)C1=CC(F)=C([N+]([O-])=O)C=C1F GPTNSBLYGCZJQV-UHFFFAOYSA-N 0.000 description 1
- HYBAKUMPISVZQP-DEOSSOPVSA-N 2-[[4-[6-[(4-cyano-2-fluorophenyl)methoxy]pyridin-2-yl]piperidin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid Chemical compound C(#N)C1=CC(=C(COC2=CC=CC(=N2)C2CCN(CC2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)O)C=C1)F HYBAKUMPISVZQP-DEOSSOPVSA-N 0.000 description 1
- REXUYBKPWIPONM-UHFFFAOYSA-N 2-bromoacetonitrile Chemical compound BrCC#N REXUYBKPWIPONM-UHFFFAOYSA-N 0.000 description 1
- UIEVSGOVFXWCIK-UHFFFAOYSA-N 2-chloro-6-methyl-3-nitropyridine Chemical compound CC1=CC=C([N+]([O-])=O)C(Cl)=N1 UIEVSGOVFXWCIK-UHFFFAOYSA-N 0.000 description 1
- TVUFPZOJUJGDDD-UHFFFAOYSA-N 2-methyl-1,3-benzothiazole-5-carboxylic acid Chemical compound OC(=O)C1=CC=C2SC(C)=NC2=C1 TVUFPZOJUJGDDD-UHFFFAOYSA-N 0.000 description 1
- GFYDDTFAVDJJAI-UHFFFAOYSA-N 2-methyl-1,3-benzoxazole-6-carboxylic acid Chemical compound C1=C(C(O)=O)C=C2OC(C)=NC2=C1 GFYDDTFAVDJJAI-UHFFFAOYSA-N 0.000 description 1
- MSYTXODFYXIIRE-UHFFFAOYSA-N 2-methyl-3-oxoprop-2-enal Chemical compound O=CC(C)=C=O MSYTXODFYXIIRE-UHFFFAOYSA-N 0.000 description 1
- TWBPWBPGNQWFSJ-UHFFFAOYSA-N 2-phenylaniline Chemical group NC1=CC=CC=C1C1=CC=CC=C1 TWBPWBPGNQWFSJ-UHFFFAOYSA-N 0.000 description 1
- RMHQDKYZXJVCME-UHFFFAOYSA-N 2-pyridin-4-ylpyridine Chemical compound N1=CC=CC=C1C1=CC=NC=C1 RMHQDKYZXJVCME-UHFFFAOYSA-N 0.000 description 1
- JHUUPUMBZGWODW-UHFFFAOYSA-N 3,6-dihydro-1,2-dioxine Chemical compound C1OOCC=C1 JHUUPUMBZGWODW-UHFFFAOYSA-N 0.000 description 1
- MGBZKWOJRYGRTO-UHFFFAOYSA-N 3-(bromomethyl)-3-methyloxetane Chemical compound BrCC1(C)COC1 MGBZKWOJRYGRTO-UHFFFAOYSA-N 0.000 description 1
- IEDRUQXJIWTVIL-UHFFFAOYSA-N 3-(bromomethyl)oxetane Chemical compound BrCC1COC1 IEDRUQXJIWTVIL-UHFFFAOYSA-N 0.000 description 1
- NBSSLTLKZGDWRU-UHFFFAOYSA-N 3-fluoro-4-methylquinoline Chemical compound C1=CC=C2C(C)=C(F)C=NC2=C1 NBSSLTLKZGDWRU-UHFFFAOYSA-N 0.000 description 1
- QHERSCUZBKDVOC-UHFFFAOYSA-N 4-amino-2-fluorobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C(F)=C1 QHERSCUZBKDVOC-UHFFFAOYSA-N 0.000 description 1
- GNEAOPSGHASSBV-QMMMGPOBSA-N 4-amino-3-[[(2S)-oxetan-2-yl]methylamino]benzoic acid Chemical compound Nc1ccc(cc1NC[C@@H]1CCO1)C(O)=O GNEAOPSGHASSBV-QMMMGPOBSA-N 0.000 description 1
- IVBVKTPDEWDNRW-UHFFFAOYSA-N 4-bromooxane Chemical compound BrC1CCOCC1 IVBVKTPDEWDNRW-UHFFFAOYSA-N 0.000 description 1
- XDIWTJZAYBYKHM-UHFFFAOYSA-N 4-methylnaphthalene-1-carbonitrile Chemical compound C1=CC=C2C(C)=CC=C(C#N)C2=C1 XDIWTJZAYBYKHM-UHFFFAOYSA-N 0.000 description 1
- HANMWNJJOSJZHD-UHFFFAOYSA-N 4-methylquinolin-3-amine Chemical compound C1=CC=C2C(C)=C(N)C=NC2=C1 HANMWNJJOSJZHD-UHFFFAOYSA-N 0.000 description 1
- WZWLDIHQAIEQPV-UHFFFAOYSA-N 5-fluoro-2-methylindazole Chemical compound C1=C(F)C=CC2=NN(C)C=C21 WZWLDIHQAIEQPV-UHFFFAOYSA-N 0.000 description 1
- HFTVJMFWJUFBNO-UHFFFAOYSA-N 5h-pyrrolo[2,3-b]pyrazine Chemical compound C1=CN=C2NC=CC2=N1 HFTVJMFWJUFBNO-UHFFFAOYSA-N 0.000 description 1
- ZVMOSXHYOPBSRN-UHFFFAOYSA-N 6-[(2-methylpropan-2-yl)oxycarbonyl]-6-azaspiro[2.5]octane-2-carboxylic acid Chemical compound C1CN(C(=O)OC(C)(C)C)CCC11C(C(O)=O)C1 ZVMOSXHYOPBSRN-UHFFFAOYSA-N 0.000 description 1
- UYQIRJWFRMCAID-UHFFFAOYSA-N 6-chloroquinoline-3-carboxylic acid Chemical compound C1=CC(Cl)=CC2=CC(C(=O)O)=CN=C21 UYQIRJWFRMCAID-UHFFFAOYSA-N 0.000 description 1
- GGHKFVNCVUIGRP-UHFFFAOYSA-N 6-chloroquinoline-8-carboxylic acid Chemical compound C1=CN=C2C(C(=O)O)=CC(Cl)=CC2=C1 GGHKFVNCVUIGRP-UHFFFAOYSA-N 0.000 description 1
- ZYZNMACIXVIOGU-UHFFFAOYSA-N 6-methyl-1-(oxan-4-yl)indazole Chemical compound Cc1ccc2cnn(C3CCOCC3)c2c1 ZYZNMACIXVIOGU-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229910001148 Al-Li alloy Inorganic materials 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- VHIBOFWCGOAFJE-UHFFFAOYSA-N C1=CC=C[C-]1P(C1=CC=CC=C1)C1=CC=CC=C1.C1=CC=C[C-]1P(C1=CC=CC=C1)C1=CC=CC=C1.Cl.Cl.[Fe+2] Chemical compound C1=CC=C[C-]1P(C1=CC=CC=C1)C1=CC=CC=C1.C1=CC=C[C-]1P(C1=CC=CC=C1)C1=CC=CC=C1.Cl.Cl.[Fe+2] VHIBOFWCGOAFJE-UHFFFAOYSA-N 0.000 description 1
- AABJRCYFMBFHHM-UHFFFAOYSA-N C1CN(C)CCC1C1=CC=CC(Cl)=N1 Chemical compound C1CN(C)CCC1C1=CC=CC(Cl)=N1 AABJRCYFMBFHHM-UHFFFAOYSA-N 0.000 description 1
- YDJHQACYCCOYAP-MHZLTWQESA-N CC(C)(C)OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC(C=C3)=CC4=C3N(C)C=N4)=CC=C1)N2C[C@H]1OCC1)=O Chemical compound CC(C)(C)OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC(C=C3)=CC4=C3N(C)C=N4)=CC=C1)N2C[C@H]1OCC1)=O YDJHQACYCCOYAP-MHZLTWQESA-N 0.000 description 1
- XRSCSAMCBVXFKJ-MHZLTWQESA-N CC(C)(C)OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC(C=C3)=CC4=C3N=C(C)O4)=CC=C1)N2C[C@H]1OCC1)=O Chemical compound CC(C)(C)OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC(C=C3)=CC4=C3N=C(C)O4)=CC=C1)N2C[C@H]1OCC1)=O XRSCSAMCBVXFKJ-MHZLTWQESA-N 0.000 description 1
- JNOCSSDEHWPPBD-NDEPHWFRSA-N CC(C)(C)OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC(C=C3)=CN4C3=CN=C4)=CC=C1)N2C[C@H]1OCC1)=O Chemical compound CC(C)(C)OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC(C=C3)=CN4C3=CN=C4)=CC=C1)N2C[C@H]1OCC1)=O JNOCSSDEHWPPBD-NDEPHWFRSA-N 0.000 description 1
- UALPSAHWTIIYNU-MHZLTWQESA-N CC(C)(C)OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC(C=C3)=CN4C3=NC=C4)=CC=C1)N2C[C@H]1OCC1)=O Chemical compound CC(C)(C)OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC(C=C3)=CN4C3=NC=C4)=CC=C1)N2C[C@H]1OCC1)=O UALPSAHWTIIYNU-MHZLTWQESA-N 0.000 description 1
- FRUWYQNUQMFCFA-LJAQVGFWSA-N CC(C)(C)OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC(C=C3N(CCOC)N=CC3=C3)=C3F)=CC=C1)N2C[C@H]1OCC1)=O Chemical compound CC(C)(C)OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC(C=C3N(CCOC)N=CC3=C3)=C3F)=CC=C1)N2C[C@H]1OCC1)=O FRUWYQNUQMFCFA-LJAQVGFWSA-N 0.000 description 1
- ORMXYAQVXVIPMO-LJAQVGFWSA-N CC(C)(C)OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=C4N=CC=CC4=CC(Cl)=C3)=CC=C1)N2C[C@H]1OCC1)=O Chemical compound CC(C)(C)OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=C4N=CC=CC4=CC(Cl)=C3)=CC=C1)N2C[C@H]1OCC1)=O ORMXYAQVXVIPMO-LJAQVGFWSA-N 0.000 description 1
- RVELMANVKFOFQJ-LJAQVGFWSA-N CC(C)(C)OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=C4N=CC=CC4=CC=C3)=CC=C1)N2C[C@H]1OCC1)=O Chemical compound CC(C)(C)OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=C4N=CC=CC4=CC=C3)=CC=C1)N2C[C@H]1OCC1)=O RVELMANVKFOFQJ-LJAQVGFWSA-N 0.000 description 1
- LKELHEUIXDCNNH-LJAQVGFWSA-N CC(C)(C)OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=CC4=CC(Cl)=CC=C4N=C3)=CC=C1)N2C[C@H]1OCC1)=O Chemical compound CC(C)(C)OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=CC4=CC(Cl)=CC=C4N=C3)=CC=C1)N2C[C@H]1OCC1)=O LKELHEUIXDCNNH-LJAQVGFWSA-N 0.000 description 1
- TUJHSSMWCNGVBD-LJAQVGFWSA-N CC(C)(C)OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=CC4=CC=CC=C4N=C3)=CC=C1)N2C[C@H]1OCC1)=O Chemical compound CC(C)(C)OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=CC4=CC=CC=C4N=C3)=CC=C1)N2C[C@H]1OCC1)=O TUJHSSMWCNGVBD-LJAQVGFWSA-N 0.000 description 1
- FKGNOUVWPJMQFS-LJAQVGFWSA-N CC(C)(C)OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=CC4=NN(CCOC)C=C4C=C3F)=CC=C1)N2C[C@H]1OCC1)=O Chemical compound CC(C)(C)OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=CC4=NN(CCOC)C=C4C=C3F)=CC=C1)N2C[C@H]1OCC1)=O FKGNOUVWPJMQFS-LJAQVGFWSA-N 0.000 description 1
- QKFATADHTSSNKE-LJAQVGFWSA-N CC(C)(C)OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=CC=C(C=CC=N4)C4=C3)=CC=C1)N2C[C@H]1OCC1)=O Chemical compound CC(C)(C)OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=CC=C(C=CC=N4)C4=C3)=CC=C1)N2C[C@H]1OCC1)=O QKFATADHTSSNKE-LJAQVGFWSA-N 0.000 description 1
- HWUPDJMWPDZWEZ-PMERELPUSA-N CC(C)(C)OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=CC=C(C=CN=C4)C4=C3)=CC=C1)N2C[C@H]1OCC1)=O Chemical compound CC(C)(C)OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=CC=C(C=CN=C4)C4=C3)=CC=C1)N2C[C@H]1OCC1)=O HWUPDJMWPDZWEZ-PMERELPUSA-N 0.000 description 1
- MWZWNCNUHSAMPD-NDEPHWFRSA-N CC(C)(C)OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=CC=C(C=NN4CC(F)(F)F)C4=C3)=CC=C1)N2C[C@H]1OCC1)=O Chemical compound CC(C)(C)OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=CC=C(C=NN4CC(F)(F)F)C4=C3)=CC=C1)N2C[C@H]1OCC1)=O MWZWNCNUHSAMPD-NDEPHWFRSA-N 0.000 description 1
- CHXUCKGVWXINGK-HKBQPEDESA-N CC(C)(C)OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=CC=C(C=NN4CC5(C)COC5)C4=C3)=CC=C1)N2C[C@H]1OCC1)=O Chemical compound CC(C)(C)OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=CC=C(C=NN4CC5(C)COC5)C4=C3)=CC=C1)N2C[C@H]1OCC1)=O CHXUCKGVWXINGK-HKBQPEDESA-N 0.000 description 1
- NWDZCAHEZRZOIH-HKBQPEDESA-N CC(C)(C)OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=CC=C(C=NN4CC5CC5)C4=C3)=CC=C1)N2C[C@H]1OCC1)=O Chemical compound CC(C)(C)OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=CC=C(C=NN4CC5CC5)C4=C3)=CC=C1)N2C[C@H]1OCC1)=O NWDZCAHEZRZOIH-HKBQPEDESA-N 0.000 description 1
- LXCYUHJQMFQVMZ-SANMLTNESA-N CC(C)(C)OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=CC=C4C(F)=NN(C)C4=C3)=CC=C1)N2C[C@H]1OCC1)=O Chemical compound CC(C)(C)OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=CC=C4C(F)=NN(C)C4=C3)=CC=C1)N2C[C@H]1OCC1)=O LXCYUHJQMFQVMZ-SANMLTNESA-N 0.000 description 1
- MNTZAAYHCAEPMA-NDEPHWFRSA-N CC(C)(C)OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=CC=NC4=CC=CC=C34)=CC=C1)N2C[C@H]1OCC1)=O Chemical compound CC(C)(C)OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=CC=NC4=CC=CC=C34)=CC=C1)N2C[C@H]1OCC1)=O MNTZAAYHCAEPMA-NDEPHWFRSA-N 0.000 description 1
- NYKJSXNLRCQJMQ-NDEPHWFRSA-N CC(C)(C)OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=NC=CC4=CC=CC=C34)=CC=C1)N2C[C@H]1OCC1)=O Chemical compound CC(C)(C)OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=NC=CC4=CC=CC=C34)=CC=C1)N2C[C@H]1OCC1)=O NYKJSXNLRCQJMQ-NDEPHWFRSA-N 0.000 description 1
- JBMJDRXKCSTFTC-MHZLTWQESA-N CC(C)N1N=C(C=C(COC2=CC=CC(C3CCN(CC4=NC(C=CC(C(O)=O)=C5)=C5N4C[C@H]4OCC4)CC3)=N2)C=C2)C2=C1 Chemical compound CC(C)N1N=C(C=C(COC2=CC=CC(C3CCN(CC4=NC(C=CC(C(O)=O)=C5)=C5N4C[C@H]4OCC4)CC3)=N2)C=C2)C2=C1 JBMJDRXKCSTFTC-MHZLTWQESA-N 0.000 description 1
- WFBHOBBJWXPGQT-UHFFFAOYSA-N CC(N1N=CC2=CC(F)=C(CO)C=C12)=O Chemical compound CC(N1N=CC2=CC(F)=C(CO)C=C12)=O WFBHOBBJWXPGQT-UHFFFAOYSA-N 0.000 description 1
- JWGPLIOKEOBVML-NDEPHWFRSA-N CC1(CN2N=CC3=CC=C(COC4=CC=CC(C5CCN(CC6=NC(C=CC(C(O)=O)=C7)=C7N6C[C@H]6OCC6)CC5)=N4)C=C23)COC1 Chemical compound CC1(CN2N=CC3=CC=C(COC4=CC=CC(C5CCN(CC6=NC(C=CC(C(O)=O)=C7)=C7N6C[C@H]6OCC6)CC5)=N4)C=C23)COC1 JWGPLIOKEOBVML-NDEPHWFRSA-N 0.000 description 1
- BELJSRRIINBIKT-QHCPKHFHSA-N CC1=NC(C=C(C(COC2=CC=CC(C3CCN(CC4=NC(C=CC(C(O)=O)=C5)=C5N4C[C@H]4OCC4)CC3)=N2)=C2)F)=C2O1 Chemical compound CC1=NC(C=C(C(COC2=CC=CC(C3CCN(CC4=NC(C=CC(C(O)=O)=C5)=C5N4C[C@H]4OCC4)CC3)=N2)=C2)F)=C2O1 BELJSRRIINBIKT-QHCPKHFHSA-N 0.000 description 1
- BAQKEUBXICODGX-MHZLTWQESA-N CC1=NC2=CC=C(COC3=CC=CC(C4CCN(CC5=NC(C=CC(C(O)=O)=C6)=C6N5C[C@H]5OCC5)CC4)=N3)C=C2C=C1 Chemical compound CC1=NC2=CC=C(COC3=CC=CC(C4CCN(CC5=NC(C=CC(C(O)=O)=C6)=C6N5C[C@H]5OCC5)CC4)=N3)C=C2C=C1 BAQKEUBXICODGX-MHZLTWQESA-N 0.000 description 1
- LOLDTAHGZYUPTQ-SANMLTNESA-N CCN1N=C(C=C(COC2=CC=CC(C3CCN(CC4=NC(C=CC(C(O)=O)=C5)=C5N4C[C@H]4OCC4)CC3)=N2)C=C2)C2=C1 Chemical compound CCN1N=C(C=C(COC2=CC=CC(C3CCN(CC4=NC(C=CC(C(O)=O)=C5)=C5N4C[C@H]4OCC4)CC3)=N2)C=C2)C2=C1 LOLDTAHGZYUPTQ-SANMLTNESA-N 0.000 description 1
- AQVSPJQFVLCYCV-LJAQVGFWSA-N CCN1N=C(C=C(COC2=CC=CC(C3CCN(CC4=NC(C=CC(C(OC(C)(C)C)=O)=C5)=C5N4C[C@H]4OCC4)CC3)=N2)C=C2)C2=C1 Chemical compound CCN1N=C(C=C(COC2=CC=CC(C3CCN(CC4=NC(C=CC(C(OC(C)(C)C)=O)=C5)=C5N4C[C@H]4OCC4)CC3)=N2)C=C2)C2=C1 AQVSPJQFVLCYCV-LJAQVGFWSA-N 0.000 description 1
- HKMQVPBITWYCNQ-LJAQVGFWSA-N CCN1N=CC2=CC=C(COC3=CC=CC(C4CCN(CC5=NC(C=CC(C(OC(C)(C)C)=O)=C6)=C6N5C[C@H]5OCC5)CC4)=N3)C=C12 Chemical compound CCN1N=CC2=CC=C(COC3=CC=CC(C4CCN(CC5=NC(C=CC(C(OC(C)(C)C)=O)=C6)=C6N5C[C@H]5OCC5)CC4)=N3)C=C12 HKMQVPBITWYCNQ-LJAQVGFWSA-N 0.000 description 1
- VGJQOQDUSATOHW-QHCPKHFHSA-N CN(C1=CC(COC2=CC=CC(C3CCN(CC4=NC(C=CC(C(O)=O)=C5)=C5N4C[C@H]4OCC4)CC3)=N2)=CC=C11)N=C1F Chemical compound CN(C1=CC(COC2=CC=CC(C3CCN(CC4=NC(C=CC(C(O)=O)=C5)=C5N4C[C@H]4OCC4)CC3)=N2)=CC=C11)N=C1F VGJQOQDUSATOHW-QHCPKHFHSA-N 0.000 description 1
- PXXCUVGDOANPAA-DEOSSOPVSA-N CN1C(C=CC(COC2=CC=CC(C3CCN(CC4=NC(C=CC(C(O)=O)=C5)=C5N4C[C@H]4OCC4)CC3)=N2)=C2)=C2N=C1 Chemical compound CN1C(C=CC(COC2=CC=CC(C3CCN(CC4=NC(C=CC(C(O)=O)=C5)=C5N4C[C@H]4OCC4)CC3)=N2)=C2)=C2N=C1 PXXCUVGDOANPAA-DEOSSOPVSA-N 0.000 description 1
- YLFFFUSLYPWNLM-UHFFFAOYSA-N CN1N=C(C(F)F)C2=CC=C(CO)C=C12 Chemical compound CN1N=C(C(F)F)C2=CC=C(CO)C=C12 YLFFFUSLYPWNLM-UHFFFAOYSA-N 0.000 description 1
- UBGRFGYQKGIKEP-SANMLTNESA-N CN1N=C(C2CC2)C2=CC=C(COC3=CC=CC(C4CCN(CC5=NC(C=CC(C(O)=O)=C6)=C6N5C[C@H]5OCC5)CC4)=N3)C=C12 Chemical compound CN1N=C(C2CC2)C2=CC=C(COC3=CC=CC(C4CCN(CC5=NC(C=CC(C(O)=O)=C6)=C6N5C[C@H]5OCC5)CC4)=N3)C=C12 UBGRFGYQKGIKEP-SANMLTNESA-N 0.000 description 1
- GCRXAKKLRUMFQO-NQCNTLBGSA-N CN1N=C(C=C(COC(N=C(C(F)=C2)N(CC3)CCC3(C3)C3C3=NC(C=CC(C(O)=O)=C4)=C4N3C[C@H]3OCC3)=C2F)C=C2)C2=C1 Chemical compound CN1N=C(C=C(COC(N=C(C(F)=C2)N(CC3)CCC3(C3)C3C3=NC(C=CC(C(O)=O)=C4)=C4N3C[C@H]3OCC3)=C2F)C=C2)C2=C1 GCRXAKKLRUMFQO-NQCNTLBGSA-N 0.000 description 1
- LQHZYTNYQPQZRB-NQCNTLBGSA-N CN1N=C(C=CC(COC(N=C(C(F)=C2)N(CC3)CCC3(C3)C3C3=NC(C=CC(C(O)=O)=C4)=C4N3C[C@H]3OCC3)=C2F)=C2)C2=C1 Chemical compound CN1N=C(C=CC(COC(N=C(C(F)=C2)N(CC3)CCC3(C3)C3C3=NC(C=CC(C(O)=O)=C4)=C4N3C[C@H]3OCC3)=C2F)=C2)C2=C1 LQHZYTNYQPQZRB-NQCNTLBGSA-N 0.000 description 1
- LTZNIHMVEHGALJ-SANMLTNESA-N CN1N=CC2=CC(COC(C=C(C3CCN(CC4=NC(C=CC(C(O)=O)=C5)=C5N4C[C@H]4OCC4)CC3)C=C3)=C3F)=CC=C12 Chemical compound CN1N=CC2=CC(COC(C=C(C3CCN(CC4=NC(C=CC(C(O)=O)=C5)=C5N4C[C@H]4OCC4)CC3)C=C3)=C3F)=CC=C12 LTZNIHMVEHGALJ-SANMLTNESA-N 0.000 description 1
- LNQOVARLUPQFCE-UHFFFAOYSA-N CN1N=CC2=CC(COC(C=C(C=C3)C4=CCNCC4)=C3F)=CC=C12 Chemical compound CN1N=CC2=CC(COC(C=C(C=C3)C4=CCNCC4)=C3F)=CC=C12 LNQOVARLUPQFCE-UHFFFAOYSA-N 0.000 description 1
- JOSPJOMMJQCTKK-UXMRNZNESA-N CN1N=CC2=CC(COC3=NC(N(CC4)CCC4(C4)C4C4=NC(C=CC(C(OC)=O)=C5)=C5N4C[C@H]4OCC4)=NC=C3F)=CC=C12 Chemical compound CN1N=CC2=CC(COC3=NC(N(CC4)CCC4(C4)C4C4=NC(C=CC(C(OC)=O)=C5)=C5N4C[C@H]4OCC4)=NC=C3F)=CC=C12 JOSPJOMMJQCTKK-UXMRNZNESA-N 0.000 description 1
- RTUVOUSNFBPMNB-DEOSSOPVSA-N CN1N=CC2=CC(F)=C(COC3=CC=CC(C4CCN(CC5=NC(C=CC(C(O)=O)=C6)=C6N5C[C@H]5OCC5)CC4)=N3)C=C12 Chemical compound CN1N=CC2=CC(F)=C(COC3=CC=CC(C4CCN(CC5=NC(C=CC(C(O)=O)=C6)=C6N5C[C@H]5OCC5)CC4)=N3)C=C12 RTUVOUSNFBPMNB-DEOSSOPVSA-N 0.000 description 1
- GDLVJXFPGRIUNL-SANMLTNESA-N CN1N=CC2=CC=C(COC(C=C(C3CCN(CC4=NC(C=CC(C(O)=O)=C5)=C5N4C[C@H]4OCC4)CC3)C=C3)=C3F)C=C12 Chemical compound CN1N=CC2=CC=C(COC(C=C(C3CCN(CC4=NC(C=CC(C(O)=O)=C5)=C5N4C[C@H]4OCC4)CC3)C=C3)=C3F)C=C12 GDLVJXFPGRIUNL-SANMLTNESA-N 0.000 description 1
- KLFBZNZRIXJSNR-NQCNTLBGSA-N CN1N=CC2=CC=C(COC(N=C(C(F)=C3)N(CC4)CCC4(C4)C4C4=NC(C=CC(C(O)=O)=C5)=C5N4C[C@H]4OCC4)=C3F)C=C12 Chemical compound CN1N=CC2=CC=C(COC(N=C(C(F)=C3)N(CC4)CCC4(C4)C4C4=NC(C=CC(C(O)=O)=C5)=C5N4C[C@H]4OCC4)=C3F)C=C12 KLFBZNZRIXJSNR-NQCNTLBGSA-N 0.000 description 1
- MRXFWLKIJVQXGT-VWLOTQADSA-N CN1N=CC2=CC=C(COC3=CC=CC(C4CCN(CC5=NC(C=CC(C(O)=O)=C6)=C6N5C[C@H]5OCC5)CC4)=N3)C=C12 Chemical compound CN1N=CC2=CC=C(COC3=CC=CC(C4CCN(CC5=NC(C=CC(C(O)=O)=C6)=C6N5C[C@H]5OCC5)CC4)=N3)C=C12 MRXFWLKIJVQXGT-VWLOTQADSA-N 0.000 description 1
- CWIVFAIIDVVRHQ-SANMLTNESA-N CN1N=CC2=CC=C(COC3=CC=CC(C4CCN(CC5=NC(C=CC(C(OC)=O)=C6)=C6N5C[C@H]5OCC5)CC4)=N3)C=C12 Chemical compound CN1N=CC2=CC=C(COC3=CC=CC(C4CCN(CC5=NC(C=CC(C(OC)=O)=C6)=C6N5C[C@H]5OCC5)CC4)=N3)C=C12 CWIVFAIIDVVRHQ-SANMLTNESA-N 0.000 description 1
- BDVVMIZXXBRLRW-DEOSSOPVSA-N CN1N=CC2=CC=C(COC3=CC=CC(N4CCN(CC5=NC(C=CC(C(O)=O)=C6)=C6N5C[C@H]5OCC5)CC4)=N3)C=C12 Chemical compound CN1N=CC2=CC=C(COC3=CC=CC(N4CCN(CC5=NC(C=CC(C(O)=O)=C6)=C6N5C[C@H]5OCC5)CC4)=N3)C=C12 BDVVMIZXXBRLRW-DEOSSOPVSA-N 0.000 description 1
- ICZMYUZJKCGHRX-UHFFFAOYSA-N CN1NC2=CC(COC(C(F)=C3)=NC(F)=C3F)=CC=C2C1 Chemical compound CN1NC2=CC(COC(C(F)=C3)=NC(F)=C3F)=CC=C2C1 ICZMYUZJKCGHRX-UHFFFAOYSA-N 0.000 description 1
- BDGCJSONIGYNEY-SANMLTNESA-N COCCN1N=C(C=C(COC2=CC=CC(C3CCN(CC4=NC(C=CC(C(O)=O)=C5)=C5N4C[C@H]4OCC4)CC3)=N2)C(F)=C2)C2=C1 Chemical compound COCCN1N=C(C=C(COC2=CC=CC(C3CCN(CC4=NC(C=CC(C(O)=O)=C5)=C5N4C[C@H]4OCC4)CC3)=N2)C(F)=C2)C2=C1 BDGCJSONIGYNEY-SANMLTNESA-N 0.000 description 1
- SVNBNCGTRXNPQM-SANMLTNESA-N COCCN1N=CC2=CC(F)=C(COC3=CC=CC(C4CCN(CC5=NC(C=CC(C(O)=O)=C6)=C6N5C[C@H]5OCC5)CC4)=N3)C=C12 Chemical compound COCCN1N=CC2=CC(F)=C(COC3=CC=CC(C4CCN(CC5=NC(C=CC(C(O)=O)=C6)=C6N5C[C@H]5OCC5)CC4)=N3)C=C12 SVNBNCGTRXNPQM-SANMLTNESA-N 0.000 description 1
- ZFNJASYDJLRSHI-KRWDZBQOSA-N C[C@@H](CC(C1=NC(OCC2=CC=C(C=NN3C)C3=C2)=CC=C1)=CC1)N1C(OC(C)(C)C)=O Chemical compound C[C@@H](CC(C1=NC(OCC2=CC=C(C=NN3C)C3=C2)=CC=C1)=CC1)N1C(OC(C)(C)C)=O ZFNJASYDJLRSHI-KRWDZBQOSA-N 0.000 description 1
- OLJCNNCKLSXCOI-KRWDZBQOSA-N C[C@@H](CN(CC1)C2=NC(OCC3=CC=C(C=NN4C)C4=C3)=CC=C2)N1C(OC(C)(C)C)=O Chemical compound C[C@@H](CN(CC1)C2=NC(OCC3=CC=C(C=NN4C)C4=C3)=CC=C2)N1C(OC(C)(C)C)=O OLJCNNCKLSXCOI-KRWDZBQOSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 1
- 108010011459 Exenatide Proteins 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 206010023379 Ketoacidosis Diseases 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- 108010019598 Liraglutide Proteins 0.000 description 1
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-Chlorosuccinimide Substances ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- OWBDPEAYOXNXGZ-QHCPKHFHSA-N OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC(C3=CC=CC=C3N=C3)=C3F)=CC=C1)N2C[C@H]1OCC1)=O Chemical compound OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC(C3=CC=CC=C3N=C3)=C3F)=CC=C1)N2C[C@H]1OCC1)=O OWBDPEAYOXNXGZ-QHCPKHFHSA-N 0.000 description 1
- JRUOKTJSDZSJNJ-VWLOTQADSA-N OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC(C=C(C=CC=N3)C3=C3)=C3F)=CC=C1)N2C[C@H]1OCC1)=O Chemical compound OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC(C=C(C=CC=N3)C3=C3)=C3F)=CC=C1)N2C[C@H]1OCC1)=O JRUOKTJSDZSJNJ-VWLOTQADSA-N 0.000 description 1
- UJLJNYKBHQHAEX-VWLOTQADSA-N OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC(C=C3)=CN4C3=CN=C4)=CC=C1)N2C[C@H]1OCC1)=O Chemical compound OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC(C=C3)=CN4C3=CN=C4)=CC=C1)N2C[C@H]1OCC1)=O UJLJNYKBHQHAEX-VWLOTQADSA-N 0.000 description 1
- XMXQRAXRMXWDHD-DEOSSOPVSA-N OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC(C=C3)=CN4C3=NC=C4)=CC=C1)N2C[C@H]1OCC1)=O Chemical compound OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC(C=C3)=CN4C3=NC=C4)=CC=C1)N2C[C@H]1OCC1)=O XMXQRAXRMXWDHD-DEOSSOPVSA-N 0.000 description 1
- ITBHKAPRRVNUQV-SANMLTNESA-N OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC(C=C3N(C4COC4)N=CC3=C3)=C3F)=CC=C1)N2C[C@H]1OCC1)=O Chemical compound OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC(C=C3N(C4COC4)N=CC3=C3)=C3F)=CC=C1)N2C[C@H]1OCC1)=O ITBHKAPRRVNUQV-SANMLTNESA-N 0.000 description 1
- BYRAGCULJVQFKZ-QHCPKHFHSA-N OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC(C=C3N=CC=NC3=C3)=C3F)=CC=C1)N2C[C@H]1OCC1)=O Chemical compound OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC(C=C3N=CC=NC3=C3)=C3F)=CC=C1)N2C[C@H]1OCC1)=O BYRAGCULJVQFKZ-QHCPKHFHSA-N 0.000 description 1
- BDCHJYMOJZPLKI-SANMLTNESA-N OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=C(C=CN=C4)C4=CC=C3)=CC=C1)N2C[C@H]1OCC1)=O Chemical compound OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=C(C=CN=C4)C4=CC=C3)=CC=C1)N2C[C@H]1OCC1)=O BDCHJYMOJZPLKI-SANMLTNESA-N 0.000 description 1
- WASDOCHFKVKSOW-SANMLTNESA-N OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=C4N=CC=CC4=CC=C3)=CC=C1)N2C[C@H]1OCC1)=O Chemical compound OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=C4N=CC=CC4=CC=C3)=CC=C1)N2C[C@H]1OCC1)=O WASDOCHFKVKSOW-SANMLTNESA-N 0.000 description 1
- DKMQCLFZJIXVBZ-SANMLTNESA-N OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=CC4=CC=CC=C4N=C3)=CC=C1)N2C[C@H]1OCC1)=O Chemical compound OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=CC4=CC=CC=C4N=C3)=CC=C1)N2C[C@H]1OCC1)=O DKMQCLFZJIXVBZ-SANMLTNESA-N 0.000 description 1
- ZKYAOARNKBIMKJ-VWLOTQADSA-N OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=CC4=CC=NN4C=C3)=CC=C1)N2C[C@H]1OCC1)=O Chemical compound OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=CC4=CC=NN4C=C3)=CC=C1)N2C[C@H]1OCC1)=O ZKYAOARNKBIMKJ-VWLOTQADSA-N 0.000 description 1
- OAQOBGSVXXRHIO-VWLOTQADSA-N OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=CC4=CN=CN4C=C3)=CC=C1)N2C[C@H]1OCC1)=O Chemical compound OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=CC4=CN=CN4C=C3)=CC=C1)N2C[C@H]1OCC1)=O OAQOBGSVXXRHIO-VWLOTQADSA-N 0.000 description 1
- DSWJZTKKUABTCT-VWLOTQADSA-N OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=CC4=NN(CC(F)F)C=C4C=C3)=CC=C1)N2C[C@H]1OCC1)=O Chemical compound OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=CC4=NN(CC(F)F)C=C4C=C3)=CC=C1)N2C[C@H]1OCC1)=O DSWJZTKKUABTCT-VWLOTQADSA-N 0.000 description 1
- MZYSTMJRSREJJX-MHZLTWQESA-N OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=CC=C(C=CN=C4)C4=C3)=CC=C1)N2C[C@H]1OCC1)=O Chemical compound OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=CC=C(C=CN=C4)C4=C3)=CC=C1)N2C[C@H]1OCC1)=O MZYSTMJRSREJJX-MHZLTWQESA-N 0.000 description 1
- GWZVSSIJAJEHSP-MHZLTWQESA-N OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=CC=C(C=NC=C4)C4=C3)=CC=C1)N2C[C@H]1OCC1)=O Chemical compound OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=CC=C(C=NC=C4)C4=C3)=CC=C1)N2C[C@H]1OCC1)=O GWZVSSIJAJEHSP-MHZLTWQESA-N 0.000 description 1
- MEFWBQXHQVNNMD-DEOSSOPVSA-N OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=CC=C(C=NN4C(F)F)C4=C3)=CC=C1)N2C[C@H]1OCC1)=O Chemical compound OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=CC=C(C=NN4C(F)F)C4=C3)=CC=C1)N2C[C@H]1OCC1)=O MEFWBQXHQVNNMD-DEOSSOPVSA-N 0.000 description 1
- QZUDGKCBJRTCOH-MHZLTWQESA-N OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=CC=C(C=NN4C5COC5)C4=C3)=CC=C1)N2C[C@H]1OCC1)=O Chemical compound OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=CC=C(C=NN4C5COC5)C4=C3)=CC=C1)N2C[C@H]1OCC1)=O QZUDGKCBJRTCOH-MHZLTWQESA-N 0.000 description 1
- DQDZKTXSVISDHV-VWLOTQADSA-N OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=CC=C(C=NN4CC(F)F)C4=C3)=CC=C1)N2C[C@H]1OCC1)=O Chemical compound OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=CC=C(C=NN4CC(F)F)C4=C3)=CC=C1)N2C[C@H]1OCC1)=O DQDZKTXSVISDHV-VWLOTQADSA-N 0.000 description 1
- ZGXPYLYCQKADPZ-NDEPHWFRSA-N OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=CC=C(C=NN4CC5CC5)C4=C3)=CC=C1)N2C[C@H]1OCC1)=O Chemical compound OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=CC=C(C=NN4CC5CC5)C4=C3)=CC=C1)N2C[C@H]1OCC1)=O ZGXPYLYCQKADPZ-NDEPHWFRSA-N 0.000 description 1
- GYDUMALNKNWCBZ-NDEPHWFRSA-N OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=CC=C(C=NN4CC5COC5)C4=C3)=CC=C1)N2C[C@H]1OCC1)=O Chemical compound OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=CC=C(C=NN4CC5COC5)C4=C3)=CC=C1)N2C[C@H]1OCC1)=O GYDUMALNKNWCBZ-NDEPHWFRSA-N 0.000 description 1
- QFBIMFQAPKVWEA-SANMLTNESA-N OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=CC=C4N=CC=CC4=C3)=CC=C1)N2C[C@H]1OCC1)=O Chemical compound OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=CC=C4N=CC=CC4=C3)=CC=C1)N2C[C@H]1OCC1)=O QFBIMFQAPKVWEA-SANMLTNESA-N 0.000 description 1
- CBCHJTMZWOODDS-DEOSSOPVSA-N OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=CC=CN4N=CC=C34)=CC=C1)N2C[C@H]1OCC1)=O Chemical compound OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=CC=CN4N=CC=C34)=CC=C1)N2C[C@H]1OCC1)=O CBCHJTMZWOODDS-DEOSSOPVSA-N 0.000 description 1
- ZPDGOENWODWCIA-VWLOTQADSA-N OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=CC=NC4=CC=CC=C34)=CC=C1)N2C[C@H]1OCC1)=O Chemical compound OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=CC=NC4=CC=CC=C34)=CC=C1)N2C[C@H]1OCC1)=O ZPDGOENWODWCIA-VWLOTQADSA-N 0.000 description 1
- WKICVNQCKRRLNB-VWLOTQADSA-N OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=NC=CC4=CC=CC=C34)=CC=C1)N2C[C@H]1OCC1)=O Chemical compound OC(C(C=C1)=CC2=C1N=C(CN(CC1)CCC1C1=NC(OCC3=NC=CC4=CC=CC=C34)=CC=C1)N2C[C@H]1OCC1)=O WKICVNQCKRRLNB-VWLOTQADSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229910002666 PdCl2 Inorganic materials 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- DLSWIYLPEUIQAV-UHFFFAOYSA-N Semaglutide Chemical compound CCC(C)C(NC(=O)C(Cc1ccccc1)NC(=O)C(CCC(O)=O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(NC(=O)CCCCCCCCCCCCCCCCC(O)=O)C(O)=O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(N)=O)NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(C)(C)NC(=O)C(N)Cc1cnc[nH]1)C(C)O)C(C)O)C(C)C)C(=O)NC(C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CCCNC(N)=N)C(=O)NCC(O)=O DLSWIYLPEUIQAV-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical class [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical class [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- QDEFNAHLCTUWAH-BYPYZUCNSA-N [(2s)-oxetan-2-yl]methanamine Chemical compound NC[C@@H]1CCO1 QDEFNAHLCTUWAH-BYPYZUCNSA-N 0.000 description 1
- PUZFXDRHCPIYCB-UHFFFAOYSA-N [1,3]oxazolo[4,5-b]pyrazine Chemical class C1=CN=C2OC=NC2=N1 PUZFXDRHCPIYCB-UHFFFAOYSA-N 0.000 description 1
- PNDPGZBMCMUPRI-XXSWNUTMSA-N [125I][125I] Chemical compound [125I][125I] PNDPGZBMCMUPRI-XXSWNUTMSA-N 0.000 description 1
- FCVHBUFELUXTLR-UHFFFAOYSA-N [Li].[AlH3] Chemical class [Li].[AlH3] FCVHBUFELUXTLR-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- YBCVMFKXIKNREZ-UHFFFAOYSA-N acoh acetic acid Chemical compound CC(O)=O.CC(O)=O YBCVMFKXIKNREZ-UHFFFAOYSA-N 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940058303 antinematodal benzimidazole derivative Drugs 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000037429 base substitution Effects 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 1
- 150000001556 benzimidazoles Chemical class 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 125000006267 biphenyl group Chemical group 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- AEILLAXRDHDKDY-UHFFFAOYSA-N bromomethylcyclopropane Chemical compound BrCC1CC1 AEILLAXRDHDKDY-UHFFFAOYSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 229940089960 chloroacetate Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229940117975 chromium trioxide Drugs 0.000 description 1
- WGLPBDUCMAPZCE-UHFFFAOYSA-N chromium trioxide Inorganic materials O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 1
- GAMDZJFZMJECOS-UHFFFAOYSA-N chromium(6+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Cr+6] GAMDZJFZMJECOS-UHFFFAOYSA-N 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- FOEGXSBIOJIQDV-UHFFFAOYSA-N cyclopropane;hydrochloride Chemical compound Cl.C1CC1 FOEGXSBIOJIQDV-UHFFFAOYSA-N 0.000 description 1
- WLVKDFJTYKELLQ-UHFFFAOYSA-N cyclopropylboronic acid Chemical compound OB(O)C1CC1 WLVKDFJTYKELLQ-UHFFFAOYSA-N 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- JMRYOSQOYJBDOI-UHFFFAOYSA-N dilithium;di(propan-2-yl)azanide Chemical compound [Li+].CC(C)[N-]C(C)C.CC(C)N([Li])C(C)C JMRYOSQOYJBDOI-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- CZZYITDELCSZES-UHFFFAOYSA-N diphenylmethane Chemical class C=1C=CC=CC=1CC1=CC=CC=C1 CZZYITDELCSZES-UHFFFAOYSA-N 0.000 description 1
- WJJMNDUMQPNECX-UHFFFAOYSA-N dipicolinic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=N1 WJJMNDUMQPNECX-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- IRSJDVYTJUCXRV-UHFFFAOYSA-N ethyl 2-bromo-2,2-difluoroacetate Chemical compound CCOC(=O)C(F)(F)Br IRSJDVYTJUCXRV-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 229960001519 exenatide Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 235000019256 formaldehyde Nutrition 0.000 description 1
- XEZPQQXHOCEWLB-UHFFFAOYSA-N furo[2,3-b]pyrazine Chemical compound C1=CN=C2OC=CC2=N1 XEZPQQXHOCEWLB-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 229940015043 glyoxal Drugs 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- DCPMPXBYPZGNDC-UHFFFAOYSA-N hydron;methanediimine;chloride Chemical compound Cl.N=C=N DCPMPXBYPZGNDC-UHFFFAOYSA-N 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- JYVLKIIQYXAJSZ-UHFFFAOYSA-N imidazo[1,2-a]pyridin-7-ylmethanol Chemical compound C1=C(CO)C=CN2C=CN=C21 JYVLKIIQYXAJSZ-UHFFFAOYSA-N 0.000 description 1
- GMBMIWBXIHLWDP-UHFFFAOYSA-N imidazo[1,5-a]pyridine-7-carboxylic acid Chemical compound C1=C(C(=O)O)C=CN2C=NC=C21 GMBMIWBXIHLWDP-UHFFFAOYSA-N 0.000 description 1
- MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 description 1
- 239000000859 incretin Substances 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- JFDDFGLNZWNJTK-UHFFFAOYSA-N indole-4-carbaldehyde Chemical compound O=CC1=CC=CC2=C1C=CN2 JFDDFGLNZWNJTK-UHFFFAOYSA-N 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 229940044173 iodine-125 Drugs 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- OWFXIOWLTKNBAP-UHFFFAOYSA-N isoamyl nitrite Chemical compound CC(C)CCON=O OWFXIOWLTKNBAP-UHFFFAOYSA-N 0.000 description 1
- FMKOJHQHASLBPH-UHFFFAOYSA-N isopropyl iodide Chemical compound CC(C)I FMKOJHQHASLBPH-UHFFFAOYSA-N 0.000 description 1
- HQABEHZXAJHCLV-UHFFFAOYSA-N isoquinolin-1-ylmethanol Chemical compound C1=CC=C2C(CO)=NC=CC2=C1 HQABEHZXAJHCLV-UHFFFAOYSA-N 0.000 description 1
- CMGQQHGOFWZGJH-UHFFFAOYSA-N isoquinolin-3-ylmethanol Chemical compound C1=CC=C2C=NC(CO)=CC2=C1 CMGQQHGOFWZGJH-UHFFFAOYSA-N 0.000 description 1
- RNQQJLYJLDQGGL-UHFFFAOYSA-N isoquinoline-4-carbaldehyde Chemical compound C1=CC=C2C(C=O)=CN=CC2=C1 RNQQJLYJLDQGGL-UHFFFAOYSA-N 0.000 description 1
- ILRSABOCKMOFGW-UHFFFAOYSA-N isoquinoline-5-carbaldehyde Chemical compound N1=CC=C2C(C=O)=CC=CC2=C1 ILRSABOCKMOFGW-UHFFFAOYSA-N 0.000 description 1
- ADAHADRJWVCICR-UHFFFAOYSA-N isoquinoline-6-carboxylic acid Chemical compound C1=NC=CC2=CC(C(=O)O)=CC=C21 ADAHADRJWVCICR-UHFFFAOYSA-N 0.000 description 1
- QUFUUBBLCOBJPH-UHFFFAOYSA-N isoquinoline-7-carboxylic acid Chemical compound C1=CN=CC2=CC(C(=O)O)=CC=C21 QUFUUBBLCOBJPH-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 229960002701 liraglutide Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- OCQQWLLEQNSXDU-ZETCQYMHSA-N methyl 2-fluoro-4-nitro-3-[[(2S)-oxetan-2-yl]methylamino]benzoate Chemical compound C1(N(=O)=O)=C(NC[C@H]2OCC2)C(F)=C(C(=O)OC)C=C1 OCQQWLLEQNSXDU-ZETCQYMHSA-N 0.000 description 1
- DPDPLMPLBWKMSG-UHFFFAOYSA-N methyl 2-methylindazole-6-carboxylate Chemical compound C1=C(C(=O)OC)C=CC2=CN(C)N=C21 DPDPLMPLBWKMSG-UHFFFAOYSA-N 0.000 description 1
- NXMJEXMODINMIJ-UHFFFAOYSA-N methyl 3-bromo-2h-indazole-6-carboxylate Chemical compound COC(=O)C1=CC=C2C(Br)=NNC2=C1 NXMJEXMODINMIJ-UHFFFAOYSA-N 0.000 description 1
- FKMZNQQOPCCUTD-UHFFFAOYSA-N methyl 3-fluoro-4-nitrobenzoate Chemical compound COC(=O)C1=CC=C([N+]([O-])=O)C(F)=C1 FKMZNQQOPCCUTD-UHFFFAOYSA-N 0.000 description 1
- SQVPAFJTHBHULZ-UHFFFAOYSA-N methyl 3-methylbenzimidazole-5-carboxylate Chemical compound COC(=O)C1=CC=C2N=CN(C)C2=C1 SQVPAFJTHBHULZ-UHFFFAOYSA-N 0.000 description 1
- WJHHIVYNOVTVGY-UHFFFAOYSA-N methyl 3h-benzimidazole-5-carboxylate Chemical compound COC(=O)C1=CC=C2N=CNC2=C1 WJHHIVYNOVTVGY-UHFFFAOYSA-N 0.000 description 1
- OCZXDVNSNDITBS-UHFFFAOYSA-N methyl 4-amino-3-hydroxybenzoate Chemical compound COC(=O)C1=CC=C(N)C(O)=C1 OCZXDVNSNDITBS-UHFFFAOYSA-N 0.000 description 1
- JEGPFOWHUQYGMT-UHFFFAOYSA-N methyl 5-amino-2-fluoro-4-methylbenzoate Chemical compound COC(=O)C1=CC(N)=C(C)C=C1F JEGPFOWHUQYGMT-UHFFFAOYSA-N 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 229940050176 methyl chloride Drugs 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- MUBQQJSSJDOSKH-UHFFFAOYSA-N methyl imidazo[1,5-a]pyridine-6-carboxylate Chemical compound C1=C(C(=O)OC)C=CC2=CN=CN21 MUBQQJSSJDOSKH-UHFFFAOYSA-N 0.000 description 1
- ZTZCGCCFJZVRTO-UHFFFAOYSA-N methyl quinoline-7-carboxylate Chemical compound C1=CC=NC2=CC(C(=O)OC)=CC=C21 ZTZCGCCFJZVRTO-UHFFFAOYSA-N 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 1
- WOOWBQQQJXZGIE-UHFFFAOYSA-N n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound CCN(C(C)C)C(C)C.CCN(C(C)C)C(C)C WOOWBQQQJXZGIE-UHFFFAOYSA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- 150000004866 oxadiazoles Chemical class 0.000 description 1
- 125000006299 oxetan-3-yl group Chemical group [H]C1([H])OC([H])([H])C1([H])* 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- ZOUWOGOTHLRRLS-UHFFFAOYSA-N palladium;phosphane Chemical compound P.[Pd] ZOUWOGOTHLRRLS-UHFFFAOYSA-N 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000003408 phase transfer catalysis Methods 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- RPGWZZNNEUHDAQ-UHFFFAOYSA-N phenylphosphine Chemical compound PC1=CC=CC=C1 RPGWZZNNEUHDAQ-UHFFFAOYSA-N 0.000 description 1
- FVZVCSNXTFCBQU-UHFFFAOYSA-N phosphanyl Chemical group [PH2] FVZVCSNXTFCBQU-UHFFFAOYSA-N 0.000 description 1
- 125000004437 phosphorous atom Chemical group 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 description 1
- 229920000137 polyphosphoric acid Polymers 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 1
- ARYJURLFRJCKLP-UHFFFAOYSA-N pyrazino[2,3-d]triazine Chemical compound N1=NN=CC2=NC=CN=C21 ARYJURLFRJCKLP-UHFFFAOYSA-N 0.000 description 1
- MTPOAZCBBRPRQQ-UHFFFAOYSA-N pyrazolo[1,5-a]pyridine-4-carboxylic acid Chemical compound OC(=O)C1=CC=CN2N=CC=C12 MTPOAZCBBRPRQQ-UHFFFAOYSA-N 0.000 description 1
- PKBWKZMOZIZGJB-UHFFFAOYSA-N pyrazolo[1,5-a]pyridine-5-carboxylic acid Chemical compound C1=C(C(=O)O)C=CN2N=CC=C21 PKBWKZMOZIZGJB-UHFFFAOYSA-N 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- HREHOXSRYOZKNT-UHFFFAOYSA-N quinolin-2-ylmethanol Chemical compound C1=CC=CC2=NC(CO)=CC=C21 HREHOXSRYOZKNT-UHFFFAOYSA-N 0.000 description 1
- RZIPENSSTUBRAA-UHFFFAOYSA-N quinolin-6-ylmethanamine Chemical compound N1=CC=CC2=CC(CN)=CC=C21 RZIPENSSTUBRAA-UHFFFAOYSA-N 0.000 description 1
- YQEJIIUSNDZIGO-UHFFFAOYSA-N quinolin-6-ylmethanol Chemical compound N1=CC=CC2=CC(CO)=CC=C21 YQEJIIUSNDZIGO-UHFFFAOYSA-N 0.000 description 1
- BNEVFKZLYCGDFG-UHFFFAOYSA-N quinoline-5-carbaldehyde Chemical compound C1=CC=C2C(C=O)=CC=CC2=N1 BNEVFKZLYCGDFG-UHFFFAOYSA-N 0.000 description 1
- PNAADFVYDHLFHT-UHFFFAOYSA-N quinoxalin-6-ylmethanol Chemical compound N1=CC=NC2=CC(CO)=CC=C21 PNAADFVYDHLFHT-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 108010060325 semaglutide Proteins 0.000 description 1
- 229950011186 semaglutide Drugs 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- RSIJVJUOQBWMIM-UHFFFAOYSA-L sodium sulfate decahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].[O-]S([O-])(=O)=O RSIJVJUOQBWMIM-UHFFFAOYSA-L 0.000 description 1
- LJRGBERXYNQPJI-UHFFFAOYSA-M sodium;3-nitrobenzenesulfonate Chemical compound [Na+].[O-][N+](=O)C1=CC=CC(S([O-])(=O)=O)=C1 LJRGBERXYNQPJI-UHFFFAOYSA-M 0.000 description 1
- SYXYWTXQFUUWLP-UHFFFAOYSA-N sodium;butan-1-olate Chemical compound [Na+].CCCC[O-] SYXYWTXQFUUWLP-UHFFFAOYSA-N 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- YPYJUPOKIAKWHW-LBPRGKRZSA-N tert-butyl (6S)-6-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-2H-pyridine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)[C@@H](C)C=C1B1OC(C)(C)C(C)(C)O1 YPYJUPOKIAKWHW-LBPRGKRZSA-N 0.000 description 1
- XTDXZSGSIMLARD-UHFFFAOYSA-N tert-butyl 2h-pyridine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC=CC=C1 XTDXZSGSIMLARD-UHFFFAOYSA-N 0.000 description 1
- VVDCRJGWILREQH-UHFFFAOYSA-N tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-2h-pyridine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCC(B2OC(C)(C)C(C)(C)O2)=C1 VVDCRJGWILREQH-UHFFFAOYSA-N 0.000 description 1
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 1
- 150000005621 tetraalkylammonium salts Chemical class 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- FIQMHBFVRAXMOP-UHFFFAOYSA-N triphenylphosphane oxide Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=O)C1=CC=CC=C1 FIQMHBFVRAXMOP-UHFFFAOYSA-N 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Definitions
- the invention belongs to the technical field of chemical medicine, and provides a series of agonists of glucagon-like peptide-1 receptor (GLP-1R).
- GLP-1R glucagon-like peptide-1 receptor
- the present invention also relates to pharmaceutical compositions containing these compounds and the use of the compounds in medicines for treating diseases such as diabetes.
- Diabetes affects millions of people worldwide and is considered one of the major threats to human mortality in the 21st century. Over time, uncontrolled diabetes can damage body systems, including the heart, blood vessels, eyes, kidneys and nerves. Worldwide, the socioeconomic burden of diabetes is high.
- Type I diabetes is characterized by insulin deficiency, mainly caused by autoimmune-mediated destruction of islet beta cells
- type II diabetes is characterized by abnormal insulin secretion and consequent insulin resistance.
- To prevent ketoacidosis patients with type 1 diabetes must take exogenous insulin to survive.
- type II diabetics are not as dependent on exogenous insulin as type I diabetics, they may require exogenous insulin to control blood sugar levels.
- GLP-1 Glucagon-like peptide-1
- GLP-1R GLP-1 receptor
- GLP-1R GLP-1 receptor
- GLP-1 receptor agonist is a new type of hypoglycemic drug, which can not only effectively control blood sugar level without causing hypoglycemia, but also increase satiety, delay gastric emptying, suppress appetite and reduce fat. Accumulation, etc., effectively reduce body weight and achieve the purpose of weight loss.
- GLP-1 receptor agonist-based polypeptide drugs liraglutide, exenatide, semaglutide, etc. have been applied to obese type II diabetic patients and simple obesity or overweight patients, all showing Significantly reduce body weight, but often accompanied by nausea, vomiting and other gastrointestinal adverse reactions.
- Oral non-peptide drugs have always been tried by research institutions for the treatment of type II diabetes and weight loss.
- the glucagon-like peptide-1 receptor small molecule drugs are limited. 's discovery.
- the present invention aims to discover new non-polypeptide GLP-1 receptor agonists, especially new compounds with good biological properties that can be safely applied to the human body, and the present invention also provides for prevention and/or The tools needed to treat GLP-1 related diseases, especially diabetes related diseases.
- the invention provides a series of benzimidazole derivatives, their preparation method and their application in medicine.
- the present invention provides compounds of formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts thereof, wherein all variables are as defined herein.
- GLP-1 R glucagon-like peptide 1 receptor
- the present invention realizes through the following technical solutions:
- A is selected from 8-10-membered fused aromatic rings
- R 1 is selected from hydrogen, halogen, cyano, alkyl, alkoxy, haloalkyl, haloalkoxy, alkoxyalkyl, cycloalkyl, heterocycloalkyl, alkyl substituted with 1 or more R 7 , aryl and heteroaryl substituted with one or more R 8 ;
- n 0, 1, 2 or 3;
- W is O or NH
- R 2 is selected from hydrogen, halogen, cyano
- R 3 is selected from fluorine, hydroxyl, cyano, C 1-3 alkyl, OC 1-3 alkyl, C 3-4 cycloalkyl, or 2 R 3 are cyclized together to form C 3-4 spirocycloalkyl, Wherein C 1-3 alkyl and OC 1-3 alkyl, cycloalkyl or spirocycloalkyl can be substituted by 0 to 3 fluorine atoms or 0 to 1 hydroxyl group when the valence allows;
- q 0, 1, 2;
- XL is selected from N- CH2 , CHCH2 , or cyclopropyl
- Y is CH or NH
- R 4 is -C 1-3 alkyl, -C 0-3 alkylene-C 3-6 cycloalkyl, -C 0-3 alkylene-R 5 or -C 1-3 alkylene-R 6 , wherein the alkyl group can be independently selected from 0 to 3 substituents of 0 to 3 F atoms through 0 to 3 substituents or through 0 to 1 selected from -C 0-1 alkylene-CN, Substituents of -C 0-1 alkylene-OR O and -N(R N ) 2 , wherein the alkylene and cycloalkyl groups can be independently selected from 0 to 2 when the valence allows Substituent from 0 to 2 F atoms or substituted with 0 to 1 selected from -C 0-1 alkylene-CN, -C 0-1 alkylene-OR O and -N(R N ) 2 base substitution;
- R 5 is a 4- to 6-membered heterocycloalkyl group, wherein the heterocycloalkyl group may be substituted, as valence permits, with 0 to 2 substituents independently selected from the following:
- R 6 is a 5- to 6-membered heteroaryl group, wherein the heteroaryl group may be substituted, as valence permits, with 0 to 2 substituents independently selected from the following:
- alkyl group may be substituted, as valency allows, with 0 to 3 substituents independently selected from the following:
- Each R O is independently H or -C 1-3 alkyl, wherein C 1-3 alkyl may be substituted with 0 to 3 F atoms;
- each R N is independently H or -C 1-3 alkyl
- Z 1 , Z 2 and Z 3 are each independently -CR Z or N, and each R Z is independently H, F, Cl or -CH 3 ;
- R 7 is selected from halogen, cyano, hydroxyl, cycloalkyl, heterocycloalkyl, sulfone;
- R 8 is selected from halogen, cyano, alkyl, haloalkyl, alkoxy, haloalkoxy, alkoxyalkyl, cycloalkyl, heterocycloalkyl, sulfone.
- A is selected from 8-10-membered fused aromatic rings
- R 1 is selected from hydrogen, halogen, cyano, alkyl, alkoxy, haloalkyl, haloalkoxy, alkoxyalkyl, cycloalkyl, heterocycloalkyl, alkyl substituted with 1 or more R 7 , aryl and heteroaryl substituted with one or more R 8 ;
- n 0, 1, 2 or 3;
- W is O or NH
- R 3 is selected from fluorine, hydroxyl, cyano, C 1-3 alkyl, OC 1-3 alkyl, C 3-4 cycloalkyl, or 2 R 3 are cyclized together to form C 3-4 spirocycloalkyl, Wherein C 1-3 alkyl and OC 1-3 alkyl, cycloalkyl or spirocycloalkyl can be substituted by 0 to 3 fluorine atoms or 0 to 1 hydroxyl group when the valence allows;
- q 0, 1, 2;
- XL is selected from N- CH2 , CHCH2 , or cyclopropyl
- Y is CH or N
- R 4 is -C 1-3 alkyl, -C 0-3 alkylene-C 3-6 cycloalkyl, -C 0-3 alkylene-R 5 or -C 1-3 alkylene-R 6 , wherein the alkyl group can be independently selected from 0 to 3 substituents of 0 to 3 F atoms through 0 to 3 substituents or through 0 to 1 selected from -C 0-1 alkylene-CN, Substituent substitution of -C 0-1 alkylene-OR O or -N(R N ) 2 , and the alkylene and cycloalkyl groups described therein may be independently replaced by 0 to 2 when the valence allows Substituents selected from 0 to 2 F atoms or through 0 to 1 selected from -C 0-1 alkylene-CN, -C 0-1 alkylene-OR O or -N(R N ) 2 Substituent substitution;
- R 5 is a 4- to 6-membered heterocycloalkyl group, wherein the heterocycloalkyl group may be substituted, as valence permits, with 0 to 2 substituents independently selected from the following:
- R 6 is a 5- to 6-membered heteroaryl group, wherein the heteroaryl group may be substituted, as valence permits, with 0 to 2 substituents independently selected from the following:
- alkyl group may be substituted, as valency allows, with 0 to 3 substituents independently selected from the following:
- Each R O is independently H or -C 1-3 alkyl, wherein C 1-3 alkyl may be substituted with 0 to 3 F atoms;
- each R N is independently H or -C 1-3 alkyl
- Z 1 , Z 2 and Z 3 are each independently -CR Z or N, and each R Z is independently H, F, Cl or -CH 3 ;
- R 7 is selected from halogen, cyano, hydroxyl, cycloalkyl, heterocycloalkyl, sulfone;
- R 8 is selected from halogen, cyano, alkyl, haloalkyl, alkoxy, haloalkoxy, alkoxyalkyl, cycloalkyl, heterocycloalkyl, sulfone.
- the alkyl group refers to a branched, unbranched and cyclic saturated hydrocarbon chain containing a specified number of carbon atoms, preferably an alkyl group selected from C 1-6 , the C 1 -6
- the alkyl group is selected from methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, sec-pentyl, 1-ethylpropyl , 2-methylbutyl, tert-amyl, 1,2-dimethylpropyl, isopentyl, neopentyl, n-hexyl, isohexyl, sec-hexyl, tert-hexyl, neohexyl, 2-methylpentyl base, 1,2-dimethylbutyl, 1-ethylbutyl.
- the alkoxy group refers to an alkyl ether radical, preferably from a C 1-6 alkoxy group, and the C 1-6 alkoxy group is selected from methoxy, ethyl Oxy, propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, n-pentoxy, sec-pentoxy, 1-ethylpropoxy, 2-methylbutoxy, tert-amyloxy, 1,2-dimethylpropoxy, isopentyloxy, neopentyloxy, n-hexyloxy, isohexyloxy, sec-hexyloxy, tert-hexyloxy group, neohexyloxy, 2-methylpentyloxy, 1,2-dimethylbutoxy, 1-ethylbutoxy.
- the alkoxyalkyl group means that one or more hydrogen atoms of the alkyl group are substituted by an alkoxy group, preferably an alkyl group selected from C 1-4 alkoxy C 1-4 , and further selected from Methoxymethyl, Methoxyethyl, Methoxypropyl, Methoxybutyl, Ethoxymethyl, Ethoxyethyl, Ethoxypropyl, Ethoxybutyl, Propoxymethyl, Propoxyethyl, Propoxypropyl, propoxybutyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, etc.
- the halogen is selected from fluorine, chlorine, bromine and iodine
- haloalkyl means that one or more hydrogen atoms of an alkyl group are replaced by halogen
- haloalkoxy means that one or more hydrogen atoms of an alkoxy group are replaced by halogen
- hydroxyalkyl means that more than one hydrogen atom of an alkyl group is replaced by a hydroxyl group
- heterocycloalkyl means that more than one hydrogen atom of an alkyl group is replaced by a heterocyclic ring
- cycloalkanemethylene means that one or more hydrogen atoms of an alkyl group are replaced by a heterocyclic ring. Cycloalkane substitution.
- the fused aromatic ring is selected from naphthalene or a fused aromatic heterocyclic ring
- the fused aromatic heterocyclic ring refers to an aromatic ring or a heteroaromatic ring and a heteroaromatic ring fused
- the heteroaromatic ring is fused.
- the heteroatom on the aromatic ring is selected from nitrogen, oxygen and sulfur, and the heteroatom is one or more.
- the fused aromatic heterocycle is selected from indazole, quinoline, isoquinoline, quinoxaline, indole, isoindole, cinnoline, quinazoline, phthalazine, purine, Naphthyridine, pteridine, benzofuran, benzothiophene, benzoxazole, benzothiazole, benzisoxazole, benzisothiazole, benzoxadiazole, benzothiadiazole, benzotriazole , benzotriazine, benzimidazole, pyrazinopyrazole, pyrazinopyrimidine, pyrazinopyridazine, pyrazinotriazine, pyrimidopyrazole, pyrimidazole, pyrimidotriazole, pyrimidotriazine azine, pyrimidopyridazine, pyridazine, pyrida
- the naphthyridine is selected from The pyridoimidazole is selected from The pyrazinimidazole is selected from The pyrazinotriazole is selected from The pyrimidopyrazole is selected from The pyrimimidazole is selected from The pyrimidotriazole is selected from The pyridazinimidazole is selected from The pyridazinotriazole is selected from The triazineimidazole is selected from The pyridopyridazine is selected from The pyridopyrazole is selected from The pyridopyrimidine is selected from The pyridotriazine is selected from The pyrimidotriazine is selected from
- the heterocycle of the heterocycloalkyl is selected from 4- to 10-membered heterocycles, and the 4- to 10-membered heterocycles are selected from
- the aryl group is selected from phenyl; the heteroaryl group is selected from the 5- to 12-membered heteroaryl group, and the 5- to 12-membered heteroaryl group is selected from
- the "alkylene group” means that the alkyl group can be independently substituted by 0 to 2 substituents when the valence allows.
- the "heterocycle” refers to a saturated or unsaturated heterocycle containing one or more heteroatoms (nitrogen, oxygen, sulfur);
- the "aromatic ring” is a Refers to a benzene ring;
- the "heteroaromatic ring” refers to a heterocyclic ring with a closed conjugated system of 4n+2 ⁇ electrons, such as furan, thiophene, tetrahydropyrrole, dihydropyrazole, imidazole, thiazole, isotope Thiazole, thiadiazole, oxazole, oxadiazole, isoxazole, piperidine, piperazine, pyridazine, pyrazine, triazine, pyrimidine, morpholine or pyridine, etc.; the multiple refers to two, three one, or four.
- the cycloalkane is selected from C 3-6 cycloalkane, and the C 3-6 cycloalkane is selected from cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
- the A is selected from
- the compound or its stereoisomer, tautomer and pharmaceutically acceptable salt wherein: the A is selected from
- R 1 is selected from hydrogen, cyano, methyl, ethyl, isopropyl, cyclopropyl, methoxy, methoxyethyl, difluoromethyl, trifluoromethyl, oxetan-3-yl , fluorine, chlorine, 2,2-difluoroethyl, 2-fluoroethyl, trifluoroethyl, cyanomethyl, cyclopropylmethyl, 2-methoxy-2-oxoethyl, oxygen Hetidine-3-ylmethyl,
- R 2 is hydrogen
- R 3 is methyl
- R 4 is oxetan-2-ylmethyl
- XL is selected from N- CH2 , CHCH2 , or cyclopropyl
- W is O
- Y is CH or N
- Z 1 is CH or N
- Z 2 is CH, CF or N
- Z 3 is CH, CF or N.
- the compound or a pharmaceutically acceptable salt thereof is selected from the following compounds:
- the pharmaceutically acceptable salt refers to the preparation of a compound with a pharmaceutically acceptable acid or base.
- more than one hydrogen atom of the compound is substituted with the isotope deuterium.
- Another object of the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising the aforementioned compound of formula (I), or a stereoisomer, tautomer, pharmaceutically acceptable salt and more than one pharmaceutically acceptable compound thereof a.
- Another object of the present invention is to provide the compound of formula (I), or its stereoisomers, tautomers, pharmaceutically acceptable salts, in the preparation of pharmaceutical use for the preparation of treatment of GLP-1 related diseases , in particular, relates to the pharmaceutical use of diabetes-related diseases.
- pharmaceutically acceptable salt refers to a salt of a compound of the present invention, prepared from a compound of the present invention having a specified substituent and a pharmaceutically acceptable acid or base.
- the compounds provided herein also exist in prodrug forms.
- Prodrugs of the compounds described herein are readily chemically altered under physiological conditions to convert to the compounds of the present invention.
- prodrugs can be converted to the compounds of the present invention by chemical or biochemical methods in an in vivo environment.
- the compounds of the present invention may exist in specific geometric or stereoisomeric forms.
- the present invention contemplates all such compounds, including cis and trans isomers, (-)- and (+)-enantiomers, (R)- and (S)-enantiomers, diastereomers isomers, (D)-isomers, (L)-isomers, and racemic and other mixtures thereof, such as enantiomerically or diastereomerically enriched mixtures, all of which belong to within the scope of the present invention.
- Additional asymmetric carbon atoms may be present in substituents such as alkyl. All such isomers, as well as mixtures thereof, are included within the scope of the present invention.
- Optically active (R)- and (S)-isomers can be prepared by chiral synthesis or chiral reagents or other conventional techniques. If one enantiomer of a compound of the present invention is desired, it can be prepared by asymmetric synthesis or derivatization with a chiral auxiliary, wherein the resulting mixture of diastereomers is separated and the auxiliary group is cleaved to provide pure desired enantiomer.
- a diastereomeric salt is formed with an appropriate optically active acid or base, followed by conventional methods known in the art
- the diastereoisomers were resolved and the pure enantiomers recovered.
- separation of enantiomers and diastereomers is usually accomplished by the use of chromatography employing a chiral stationary phase, optionally in combination with chemical derivatization (eg, from amines to amino groups) formate).
- the atoms of the molecules of the compounds of the present invention are isotopes, and the isotope derivatization can usually prolong the half-life, reduce the clearance rate, stabilize the metabolism and improve the activity in vivo. Also, an embodiment is included in which at least one atom is replaced by an atom having the same atomic number (number of protons) and a different mass number (sum of protons and neutrons).
- isotopes included in the compounds of the present invention include hydrogen atom, carbon atom, nitrogen atom, oxygen atom, phosphorus atom, sulfur atom, fluorine atom, chlorine atom, which respectively include 2 H, 3 H, 13 C, 14 C, 15 N, 17 O, 18 O, 31 P, 32 P, 35 S, 18 F, 36 Cl.
- radioisotopes that emit radiation as they decay such as 3 H or 14 C, are useful in the topological examination of pharmaceutical formulations or compounds in vivo. Stable isotopes neither decay or change with their amount nor are they radioactive, so they are safe to use.
- the isotopes can be converted according to general methods by substituting the reagents used in the synthesis with reagents containing the corresponding isotopes.
- the compounds of the present invention may contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute the compound.
- compounds can be labeled with radioisotopes, such as deuterium ( 2 H), iodine-125 ( 125 I) or C-14 ( 14 C). All transformations of the isotopic composition of the compounds of the present invention, whether radioactive or not, are included within the scope of the present invention.
- one or more hydrogen atoms of the compounds of the present invention are substituted by the isotope deuterium ( 2 H).
- the compounds of the present invention After deuteration, the compounds of the present invention have the effects of prolonging half-life, reducing clearance rate, stabilizing metabolism and improving in vivo activity.
- the preparation methods of the isotopic derivatives generally include: a phase transfer catalysis method.
- a preferred deuteration method employs a phase transfer catalyst (eg, tetraalkylammonium salts, NBu4HSO4 ) .
- the methylene protons of diphenylmethane compounds are exchanged using a phase transfer catalyst, resulting in higher ratios than with deuterated silanes (eg, triethyldeuterated silane) or with Lewis acids such as trichloro in the presence of an acid (eg, methanesulfonic acid) Aluminium is reduced with sodium deuteroborate to introduce higher deuterium.
- pharmaceutically acceptable carrier refers to any formulation carrier or medium capable of delivering an effective amount of the active substance of the present invention, without interfering with the biological activity of the active substance, and without toxic side effects to the host or patient
- representative carriers include water, oil , vegetables and minerals, cream bases, lotion bases, ointment bases, etc. These bases include suspending agents, tackifiers, penetration enhancers, and the like.
- Their formulations are well known to those skilled in the cosmetic or topical pharmaceutical field. For additional information on carriers, reference can be made to Remington: The Science and Practice of Pharmacy, 21st Ed., Lippincott, Williams & Wilkins (2005), the contents of which are incorporated herein by reference.
- excipient generally refers to the carrier, diluent and/or medium required to formulate an effective pharmaceutical composition.
- an "effective amount” or “therapeutically effective amount” with respect to a drug or pharmacologically active agent refers to a nontoxic but sufficient amount of the drug or agent to achieve the desired effect.
- an "effective amount” of one active substance in a composition refers to the amount required to achieve the desired effect when used in combination with another active substance in the composition.
- the determination of the effective amount varies from person to person, depends on the age and general condition of the recipient, and also depends on the specific active substance, and the appropriate effective amount in individual cases can be determined by those skilled in the art based on routine experiments.
- active ingredient refers to a chemical entity that is effective in treating the target disorder, disease or condition.
- the compounds of the present invention can be prepared by a variety of synthetic methods well known to those skilled in the art, including the specific embodiments enumerated below, embodiments formed in combination with other chemical synthesis methods, and those well known to those skilled in the art Equivalent to alternatives, preferred embodiments include, but are not limited to, the embodiments of the present invention.
- NMR nuclear magnetic resonance
- MS mass spectrometry
- the MS was measured using an ISQ EC mass spectrometer (manufacturer: Thermo, model: ISQ EC).
- HPLC High performance liquid chromatography
- CombiFlash rapid preparation instrument uses CombiFlash Rf+LUMEN (TELEDYNE ISCO).
- the thin layer chromatography silica gel plate uses Yantai Yinlong HSGF 254 or GF 254 silica gel plate, the size of the silica gel plate used for thin layer chromatography (TLC) is 0.17mm ⁇ 0.23mm, and the size of the TLC separation and purification products is 0.4mm ⁇ 0.5mm.
- Silica gel column chromatography generally uses Rushan Shangbang silica gel 100-200 mesh silica gel as the carrier.
- Reagents LDA-lithium diisopropylamide, THF-tetrahydrofuran, TEA-triethylamine, Dioxane-1,4-dioxane, BH3-borane, EDCl-1-ethyl-( 3 -dimethylamine) aminopropyl)carbodiimide hydrochloride, HOBT-1-hydroxybenzotriazole, DIPEA-N,N-diisopropylethylamine, DMF-N,N-dimethylformamide, K 2CO3 - potassium carbonate, DMSO-dimethylsulfoxide, EtOH -ethanol, NaH-sodium hydride, toluene-toluene, rt-room temperature, PdCl2 (dppf)-[1,1'-bis(diphenylphosphine) base)ferrocene]palladium dichloride, Pd(OAc)2-palladium acetate,
- abs refers to absolute configuration, absolute configuration.
- Step A Synthesis of tert-butyl 4-(6-((1-methyl-1H-indazol-6-yl)methoxy)pyridin-2-yl)piperidine-1-carboxylate
- tert-butyl 4-(6-chloropyridin-2-yl)piperidine-1-carboxylate (150.3 mg, 0.5 mmol), (1-methyl-1H-indazol-6-yl) Methanol (98.3 mg, 0.6 mmol), cesium carbonate (260.2 mg, 0.8 mmol) were dissolved in dry dioxane (10 mL) and protected by nitrogen replacement three times.
- Tridibenzylideneacetone dipalladium (22.4 mg, 25.1 micromoles) and 2-dicyclohexylphosphorus-2,4,6-triisopropylbiphenyl (12.2 mg, 25.3 micromoles) were then added and again flushed with nitrogen Replace three protections. The temperature was raised to 90 degrees Celsius and the reaction was refluxed overnight.
- reaction solution was filtered through celite, and the obtained filtrate was concentrated under reduced pressure.
- the mixture was diluted with water (50 mL), the aqueous layer was extracted with ethyl acetate (30 mL ⁇ L), washed with saturated brine (50 mL ⁇ L), dried over anhydrous sodium sulfate, and finally concentrated under reduced pressure.
- Step B Synthesis of 1-methyl-6-(((6-(piperidin-4-yl)pyridin-2-yl)oxy)methyl)-1H-indazole
- tert-butyl 4-(6-((1-methyl-1H-indazol-6-yl)methoxy)pyridin-2-yl)piperidine-1-carboxylate (120.4 mg, 284.1 Micromolar) was dissolved in 4 mol per liter of ethyl acetate solution of hydrochloric acid (10 ml), stirred for 1 hour, and gradually a white solid was precipitated.
- Step C Synthesis of (S)-2-((4-(6-((1-methyl-1H-indazol-6-yl)methoxy)pyridin-2-yl)piperidin-1-yl) Methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester
- reaction solution was diluted with water (80 mL), the aqueous layer was extracted with ethyl acetate (50 mL ⁇ L), washed with saturated brine (50 mL ⁇ L), and then dried over anhydrous sodium sulfate. , and finally concentrated under reduced pressure.
- Step D Synthesis of (S)-2-((4-(6-((1-methyl-1H-indazol-6-yl)methoxy)pyridin-2-yl)piperidin-1-yl) Methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid
- Step B (S)-Methyl 4-amino-3-((oxetan-2-ylmethyl)amino)benzoate
- Step C Synthesis of 1-((4-(methoxycarbonyl)-2-(((S)-oxetan-2-ylmethyl)amino)phenyl)carbamoyl)-6-azaspiro [2.5]octane-6-carboxylate tert-butyl ester
- reaction solution was diluted with ethyl acetate (150 mL), washed with water (30 mL ⁇ L), washed with saturated brine (30 mL ⁇ L), then dried with anhydrous sodium sulfate, and finally reduced pressure concentrate.
- Step D Synthesis of 2-(6-(tert-butoxycarbonyl)-6-azaspiro[2.5]octan-1-yl)-1-((S)-oxetan-2-ylmethyl) -1H-Benzo[d]imidazole-6-carboxylate methyl ester
- reaction solution was cooled to room temperature, diluted with water (100 mL), the aqueous layer was extracted with ethyl acetate (50 mL ⁇ L), the organic layers were combined, and then washed with saturated aqueous sodium carbonate (50 mL). ⁇ liters), washed with saturated brine (50 ml ⁇ liters), then dried over anhydrous sodium sulfate, and finally concentrated under reduced pressure.
- Step E Synthesis of 1-((S)-oxetan-2-ylmethyl)-2-(6-azaspiro[2.5]octan-1-yl)-1H-benzo[d]imidazole -6-Carboxylic acid methyl ester
- Step F Synthesis of 1-methyl-6-(((3,5,6-trifluoropyridin-2-yl)oxy)methyl)-1H-indazole
- Step G Synthesis of 2-(6-(3,5-Difluoro-6-((1-methyl-1H-indazol-6-yl)methoxy)pyridin-2-yl)-6-aza Spiro[2.5]octan-1-yl)-1-((S)-oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate methyl ester
- Step H Synthesis of 2-(6-(3,5-Difluoro-6-((1-methyl-1H-indazol-6-yl)methoxy)pyridin-2-yl)-6-aza Spiro[2.5]octan-1-yl)-1-((S)-oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid
- aqueous citric acid solution was added dropwise to the reaction solution until the pH of the solution reached 5.
- Water (50 mL) was added to dilute, the aqueous layer was extracted with ethyl acetate (25 mL ⁇ L), the organic layers were combined, washed with saturated brine (25 mL ⁇ L), then dried over anhydrous sodium sulfate, and finally reduced pressure concentrate.
- Methyl 2-methyl-2H-indazole-6-carboxylate (300.0 mg, 1.6 mmol) was dissolved in dry tetrahydrofuran (10 mL) solution under ice-bath conditions and nitrogen purged three times. Under nitrogen, lithium aluminum tetrahydride (121.6 mg, 3.2 mmol) was added in portions.
- reaction solution was continued to stir for 1 hour under ice bath conditions. After the reaction was completed, 1N aqueous sodium hydroxide solution was added dropwise to quench the reaction. After stirring for 15 minutes, it was filtered through celite. The obtained filtrate was diluted with ethyl acetate (150 mL), washed with water (30 mL ⁇ L), saturated brine (30 mL ⁇ L), and then washed with anhydrous It was dried over sodium sulfate and finally concentrated under reduced pressure.
- Step B Synthesis of 2-methyl-6-(((3,5,6-trifluoropyridin-2-yl)oxy)methyl-2H-indazole
- Step C Synthesis of 2-(6-(3,5-Difluoro-6-((2-methyl-2H-indazol-6-yl)methoxy)pyridin-2-yl)-6-aza Spiro[2.5]octan-1-yl)-1-((S)-oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate methyl ester
- Step D Synthesis of 2-(6-(3,5-Difluoro-6-((2-methyl-2H-indazol-6-yl)methoxy)pyridin-2-yl)-6-aza Spiro[2.5]octan-1-yl)-1-((S)-oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid
- aqueous citric acid solution was added dropwise to the reaction solution until the pH of the solution reached 5.
- Water (30 mL) was added to dilute, the aqueous layer was extracted with ethyl acetate (50 mL ⁇ L), the organic phases were combined and washed with saturated brine (25 mL ⁇ L), then dried over anhydrous sodium sulfate, and finally reduced pressure concentrate.
- Step A Synthesis of 1-methyl-5-(((3,5,6-trifluoropyridin-2-yl)oxy)methyl-1H-indazole
- Step B Synthesis of 2-(6-(3,5-Difluoro-6-((1-methyl-1H-indazol-5-yl)methoxy)pyridin-2-yl)-6-aza Spiro[2.5]octan-1-yl)-1-((S)-oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate methyl ester
- Step C Synthesis of 2-(6-(3,5-Difluoro-6-((1-methyl-1H-indazol-5-yl)methoxy)pyridin-2-yl)-6-aza Spiro[2.5]octan-1-yl)-1-((S)-oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid
- aqueous citric acid solution was added dropwise to the reaction solution until the pH of the solution reached 5.
- Water (50 mL) was added to dilute, the aqueous layer was extracted with ethyl acetate (25 mL ⁇ L), washed with saturated brine (25 mL ⁇ L), dried over anhydrous sodium sulfate, and finally concentrated under reduced pressure.
- Methyl 2-methyl-2H-indazole-5-carboxylic acid methyl ester (300.0 mg, 1.6 mmol) was dissolved in dry tetrahydrofuran (10 mL) solution under ice-bath conditions and nitrogen purged three times. Under nitrogen, lithium aluminum tetrahydride (121.6 mg, 3.2 mmol) was added in portions. The resulting reaction solution was further stirred for 1 hour under ice bath conditions.
- Step B Synthesis of 2-methyl-5-(((3,5,6-trifluoropyridin-2-yl)oxy)methyl-2H-indazole
- Step C Synthesis of 2-(6-(3,5-Difluoro-6-((2-methyl-2H-indazol-5-yl)methoxy)piperidin-2-yl)-6-nitrogen Heterospiro[2.5]octan-1-yl)-1-((S)-oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate methyl ester
- Step D Synthesis of 2-(6-(3,5-Difluoro-6-((2-methyl-2H-indazol-5-yl)methoxy)pyridin-2-yl)-6-aza Spiro[2.5]octan-1-yl)-1-((S)-oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid
- aqueous citric acid solution was added dropwise to the reaction solution until the pH of the solution reached 5.
- Water (50 mL) was added to dilute, the aqueous layer was extracted with ethyl acetate (25 mL ⁇ L), washed with saturated brine (25 mL ⁇ L), dried over anhydrous sodium sulfate, and finally concentrated under reduced pressure.
- Step B Synthesis of (S)-2-methyl-4-(2-(((1-methyl-1H-indazol-6-yl)methoxy)pyrimidin-4-yl)piperazine-1- tert-butyl formate
- Step C Synthesis of (S)-1-methyl-6-((((4-(3-methylpiperazin-1-yl)pyrimidin-2-yl)oxy)methyl)-1H-indazole
- Step D Synthesis of 2-(((S)-2-methyl-4-(2-((1-methyl-1H-indazol-6-yl)methoxy)pyrimidin-4-yl)piperazine -1-yl)methyl)-1-((((S)-oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate methyl ester
- Step E Synthesis of 2-(((S)-2-methyl-4-(2-((1-methyl-1H-indazol-6-yl)methoxy)pyrimidin-4-yl)piperazine -1-yl)methyl)-1-((((S)-oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid
- Step A Synthesis of 2-(6-(3,5-Difluoro-6-(imidazo[1,2-a]pyridine-6-methoxy)pyridin-2-yl)-6-azaspiro[ 2.5] Octan-1-yl)-1-((((S)-oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester
- Imidazo[1,2-a]pyridin-6-ylmethanol (23mg, 0.155mmol) was dissolved in 5ml of anhydrous N,N-dimethylformamide, and 60% sodium hydride (10mg, 0.25 mmol) was stirred for 10 minutes and then 1-((((S)-oxetan-2-yl)methyl)-2-(6-(6-(3,5,6-trifluoropyridine- 2-yl)-6-azaspiro[2.5]octan-1-yl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester (75 mg, 0.155 mmol) in 3 mL of N,N-dicarbonate The methylformamide solution was continued to react for 2 hours at zero degrees Celsius.
- Step B Synthesis of 2-(6-(3,5-Difluoro-6-(imidazo[1,2-a]pyridine-6-methoxy)pyridin-2-yl)-6-azaspiro[ 2.5]Oct-1-yl)-1-((S)-oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid
- the reaction was completed, diluted with water, then extracted with dichloromethane (20 mL ⁇ L), and the organic phases were combined. The organic phase was washed with saturated brine (20 mL ⁇ L), then dried with anhydrous sodium sulfate, and finally reduced.
- Step B Synthesis of 2-(-6-(5-fluoro-4-((1-methyl-1H-indazol-5-yl)methoxy)pyrimidin-2-yl)-6-azaspiro[ 2.5]Oct-1-yl)-1-((S)-oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate methyl ester
- Step C Synthesis of 2-(-6-(5-fluoro-4-((1-methyl-1H-indazol-5-yl)methoxy)pyrimidin-2-yl)-6-azaspiro[ 2.5]Oct-1-yl)-1-((S)-oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid
- Step B Synthesis of 4-(4-Fluoro-3-hydroxyphenyl)-3,6-dihydropiperidine-1(2H)-carboxylate tert-butyl ester
- Step C Synthesis of tert-butyl 4-(4-fluoro-3-hydroxyphenyl)piperidine-1-carboxylate
- Step D Synthesis of tert-butyl 4-(4-fluoro-3-((1-methyl-1H-indazol-6-yl)methoxy)phenyl)piperidine-1-carboxylate
- tert-butyl 4-(4-fluoro-3-hydroxyphenyl)piperidine-1-carboxylate (396.8 mg, 1.3 mmol) and 6-(bromomethyl)-1-methyl-1H -Indazole (438.7 mg, 1.9 mmol) was dissolved in N,N-dimethylformamide (4 mL) and anhydrous potassium carbonate (542.1 mg, 3.9 mmol) was added. The reaction solution was stirred at room temperature for 6 hours.
- Step E Synthesis of 6-((2-Fluoro-5-(piperidin-4-yl)phenoxy)methyl)-1-methyl-1H-indazole
- Step F Synthesis of (S)-2-((4-(4-Fluoro-3-((1-methyl-1H-indazol-6-yl)methoxy)phenyl)piperidin-1-yl ) methyl-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate methyl ester
- reaction solution was reacted at room temperature for 6 hours, diluted with ethyl acetate (150 mL), washed with water (30 mL ⁇ 2 times), saturated brine (30 mL ⁇ 1 time), and then washed with anhydrous sodium sulfate It was dried and finally concentrated under reduced pressure.
- Step G Synthesis of (S)-2-((4-(4-Fluoro-3-((1-methyl-1H-indazol-6-yl)methoxy)phenyl)piperidin-1-yl ) methyl-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid
- Step A Synthesis of tert-butyl 4-(6-(((2-methylquinolin-6-yl)methoxy)pyridin-2-yl)piperidine-1-carboxylate
- tert-butyl 4-(6-chloropyridin-2-yl)piperidine-1-carboxylate 150.0 mg, 0.50 mmol
- (2-methylquinolin-6-yl)methanol 130.0 mg , 0.75 mmol
- cesium carbonate 326.0 mg, 1.00 mmol
- dioxane 5.0 mL
- 2-dicyclohexylphosphorus-2,4,6-triisopropylbiphenyl 47.0 mg, 0.1 mmol
- tris(dibenzylideneacetone)dipalladium 46.0 mg, 0.05 mmol
- Step B Synthesis of 2-methyl-6-(((6-(piperidin-4-yl)pyridinyl-2-yl)oxy)methyl)quinoline
- tert-butyl 4-(6-(((2-methylquinolin-6-yl)methoxy)pyridin-2-yl)piperidine-1-carboxylate (67.0 mg, 0.15 mmol)
- Dioxane hydrochloric acid solution (1.00 mmol/mL, 5 mL) was added, and the reaction was carried out at room temperature for 1 hour under the protection of N 2 .
- Step C Synthesis of (S)-2-(((4-(6-((2-methylquinolin-6-yl)methoxy)pyridin-2-yl)piperidin-1-yl)methyl )-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate methyl ester
- Step D Synthesis of (S)-2-((4-(6-((2-methylquinolin-6-yl)methoxy)pyridin-2-yl)piperidin-1-yl)methyl) -1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid
- Step A Synthesis of (S)-2-((4-(6-(((1-methyl-1H-indazol-5-yl)methoxy)pyridin-2-yl)piperidin-1-yl )methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate tert-butyl ester
- reaction solution was filtered through a pad of celite, the filtrate was slowly added dropwise to a saturated aqueous ammonium chloride solution (20.0 mL), the mixture was extracted with ethyl acetate (20.0 mL ⁇ 3 times), the organic phases were combined, and the organic phase was washed with saturated common salt water (15.0 mL ⁇ 3 times), dried over anhydrous sodium sulfate, and concentrated under reduced pressure.
- Step B Synthesis of (S)-2-((4-(6-((1-methyl-1H-indazol-5-yl)methoxy)pyridin-2-yl)piperidin-1-yl) Methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid
- diisopropyl azodicarboxylate 130 mg, 0.65 mmol
- triphenylphosphine 1500 mg, 5.24 mmol
- 1-methyl-1H-indazol-5-yl 300 mg, 1.85 mmol
- 5-bromo-2-fluorophenol 386 mg, 2.04 mmol
- Step B Synthesis of 4-(4-fluoro-3-((1-methyl-1H-indazol-5-yl)oxy)phenyl)-3,6-dihydropyridine-1(2H)-carboxyl tert-butyl acid
- Step C Synthesis of 5-((2-Fluoro-5-(1,2,3,6-tetrahydropyridin-4-yl)phenoxy)methyl)-1-methyl-1H-indazole
- Step D Synthesis of (S)-2-((4-(4-Fluoro-3-((1-methyl-1Hindazol-5-ylmethoxy)phenyl)-3,6-dihydropyridine- 1(2H)-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate methyl ester
- Step E Synthesis of (S)-2-((4-(4-Fluoro-3-((1-methyl-1H-indazol-5-yl)methoxy)phenyl)-3,6-di Hydropyridin-1(2H)-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid
- reaction solution was diluted with 10 ml of ethyl acetate, poured into water, the pH of the aqueous phase was adjusted to neutrality with saturated ammonium chloride solution, the organic layer was separated, dried over anhydrous sodium sulfate, and evaporated to dryness to obtain a pale yellow solid .
- Step F Synthesis of (S)-2-((4-(4-Fluoro-3-((1-methyl-1H-indazol-5-yl)methoxy)phenyl)piperidin-1-yl )methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid
- Step A Synthesis of (S)-2-((4-(6-(imidazo[1,2-a]pyridin-7-ylmethoxy)pyridin-2-yl)piperidin-1-yl)methan yl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate tert-butyl ester
- Step B Synthesis of (S)-2-((4-(6-(imidazo[1,2-a]pyridin-7-ylmethoxy)pyridin-2-yl)piperidin-1-yl)methan yl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid
- the reaction was completed, quenched by adding water, adjusted to pH 8 with sodium bicarbonate solution (0.5 mol/L), the mixed solution was extracted with dichloromethane (30 mL ⁇ L), the organic phases were combined, and the organic phase was first used with an aqueous ammonium chloride solution.
- Step A Synthesis of tert-butyl 4-(6-(quinolin-6-ylmethoxy)pyridin-2-yl)piperidine-1-carboxylate
- Step B Synthesis of 6-((((6-(piperidin-4-yl)pyridinyl-2-yl)oxy)methyl)quinoline
- Step C Synthesis of (S)-1-(oxetan-2-ylmethyl)-2-(((4-(6-(quinoline-6-methoxy)pyridin-2-yl)piperidine Perid-1-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid tert-butyl ester
- Step D Synthesis of (S)-1-(oxetan-2-ylmethyl)-2-((4-(6-(quinolin-6-ylmethoxy)pyridin-2-yl)piperidine Perid-1-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid
- Step A Synthesis of methyl 2-methylbenzo[d]oxazole-6-carboxylate
- Methyl 2-methylbenzo[d]oxazole-6-carboxylate 120 mg, 0.67 mmol was dissolved in tetrahydrofuran (10.0 mL), and after stirring for 15 minutes at minus 20 degrees Celsius, lithium aluminum tetrahydrogen (38 mg, 1.0 mmol) was added to the reaction solution, stirred at minus 20 degrees Celsius for 30 minutes, and monitored by LC-MS until the reaction was complete.
- Step C Synthesis of (S)-2-((4-(6-((2-methylbenzo[d]oxazol-6-yl)methoxy)pyridin-2-yl)piperidine-1- yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate tert-butyl ester
- reaction solution was filtered through a pad of celite, the filtrate was slowly added dropwise to a saturated aqueous ammonium chloride solution (20.0 mL), the mixture was extracted with ethyl acetate (20.0 mL ⁇ 3 times), the organic phases were combined, and the organic phase was washed with saturated common salt water (15.0 mL ⁇ 3 times), dried over anhydrous sodium sulfate, and concentrated under reduced pressure.
- Step D Synthesis of (S)-2-((4-(6-((2-methylbenzo[d]oxazol-6-yl)methoxy)pyridin-2-yl)piperidine-1- yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid
- Dichloromethane (30.0 mL) was added to the reaction solution to dilute, saturated ammonium chloride solution (5.0 mL) was added, the layers were separated, the aqueous phase was extracted three times with dichloromethane (20.0 mL ⁇ 3 times), the organic phases were combined, Dry over sodium sulfate, filter, and concentrate under reduced pressure.
- Step A Synthesis of (S)-1-(oxetan-2-ylmethyl)-2-(((4-(6-(quinolin-4-ylmethoxy)pyridin-2-yl) Piperidin-1-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate tert-butyl ester
- Step B Synthesis of (S)-1-(oxetan-2-ylmethyl)-2-((4-(6-(quinolin-4-ylmethoxy)pyridin-2-yl)piperidine Perid-1-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid
- the reaction was completed, quenched by adding water, adjusted to pH 8 with sodium bicarbonate solution (0.5 mol/L), the mixed solution was extracted with dichloromethane (30 mL ⁇ L), the organic phases were combined, and the organic phase was first used with an aqueous ammonium chloride solution. (30 mL ⁇ L times) washed, then dried over anhydrous sodium sulfate, and the crude product was purified by preparative high performance liquid chromatography.
- the separation conditions were as follows, column: Agilent 5 Prep-C18 100mm ⁇ 30mm 5 ⁇ M; mobile phase: water (containing 0.1% trifluoroacetic acid) and acetonitrile; flow rate: 20 ml/min; gradient: wash with 8% acetonitrile at 5.10 minutes come out; detection wavelength: 254nm.
- Step A Synthesis of (S)-2-((4-(6-(((1H-indol-5-yl)methyl)amino)pyridin-2-yl)piperidin-1-yl)methyl) -1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate tert-butyl ester
- Step B Synthesis of (S)-2-((4-(6-(((1H-indol-5-yl)methyl)amino)pyridin-2-yl)piperidin-1-yl)methyl) -1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid
- Step A Synthesis of (S)-2-((4-(6-(imidazo[1,2-a]pyridin-6-ylmethoxy)pyridin-2-yl)piperidin-1-yl)methan yl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate tert-butyl ester
- the reaction solution was filtered through a pad of celite, the filtrate was slowly added dropwise to a saturated aqueous ammonium chloride solution (20.0 mL), the mixture was extracted with ethyl acetate (20.0 mL ⁇ 3 times), the organic phases were combined, and the organic phase was washed with saturated common salt water (15.0 mL ⁇ 3 times), dried over anhydrous sodium sulfate, and concentrated under reduced pressure.
- Step B Synthesis of (S)-2-((4-(6-(imidazo[1,2-a]pyridin-6-ylmethoxy)pyridin-2-yl)piperidin-1-yl)methan yl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid
- Step A Synthesis of (S)-2-((4-(6-((1-ethyl-1H-indazol-5-yl)methoxy)pyridin-2-yl)piperidin-1-yl) Methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate tert-butyl ester
- Step B Synthesis of (S)-2-((4-(6-((1-ethyl-1H-indazol-5-yl)methoxy)pyridin-2-yl)piperidin-1-yl) Methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid
- Step A Synthesis of a mixture of methyl 1-methyl-1H-benzo[d]imidazole-5-carboxylate and methyl 1-methyl-1H-benzo[d]imidazole-6-carboxylate
- methyl 1H-benzo[d]imidazole-5-carboxylate (0.95 g, 5.40 mmol) was dissolved in tetrahydrofuran (10 mL), and sodium hydride (0.3 g) was added in portions under nitrogen protection. , 7.60 mmol), stirred for 20 minutes, then slowly added iodomethane (1.53 g, 1.08 mmol) dropwise, heated to 25 degrees Celsius, and stirred for 1 hour.
- Methyl 1-methyl-1H-benzo[d]imidazole-5-carboxylate (0.77 g, 4.05 mmol) was dissolved in tetrahydrofuran (10 mL) at zero degrees Celsius, hydrogenated in portions under nitrogen Lithium aluminum (0.77 g, 20.25 mmol), stirred for 1 hour.
- Step C Synthesis of (S)-2-((4-(6-((1-methyl-1H-benzo[d]imidazol-5-yl)methoxy)pyridin-2-yl)piperidine- 1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate tert-butyl ester
- Step D Synthesis of (S)-2-((4-(6-((1-methyl-1H-benzo[d]imidazol-5-yl)methoxy)pyridin-2-yl)piperidine- 1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid
- Step C Synthesis of (S)-2-((4-(6-((1-ethyl-1H-indazol-6-yl)methoxy)pyridin-2-yl)piperidin-1-yl) Methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate tert-butyl ester
- Step D Synthesis of (S)-2-((4-(6-((1-ethyl-1H-indazol-6-yl)methoxy)pyridin-2-yl)piperidin-1-yl) Methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid
- Step A Synthesis of (S)-1-(oxetan-2-ylmethyl)-2-((4-(6-((quinolin-6-ylmethyl)amino)pyridin-2-yl )piperidin-1-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid
- Step C Synthesis of (S)-2-((4-(6-((2-ethyl-2H-indazol-6-yl)methoxy)pyridin-2-yl)piperidin-1-yl) Methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate tert-butyl ester
- Step D (S)-2-((4-(6-((2-ethyl-2H-indazol-6-yl)methoxy)pyridin-2-yl)piperidin-1-yl)methan yl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid
- Methyl 1-methyl-1H-indazole-6-carboxylate (110 mg, 0.56 mmol) was dissolved in tetrahydrofuran (10.0 mL), and after stirring at 0°C for 15 min, deuterated lithium aluminum hydride (42 mg, 1.0 mmol) was added to the reaction solution, stirred at zero degrees Celsius for 30 minutes, and monitored by LC-MS until the reaction was complete.
- Step B Synthesis of (S)-2-((4-(6-((1-methyl-1H-indazol-6-yl)methoxy-D2)pyridin-2-yl)piperidine-1- yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid
- reaction solution was filtered through a pad of celite, the filtrate was slowly added dropwise to a saturated aqueous ammonium chloride solution (20.0 mL), the mixture was extracted with ethyl acetate (20.0 mL ⁇ 3 times), the organic phases were combined, and the organic phase was washed with saturated common salt water (15.0 mL ⁇ 3 times), dried over anhydrous sodium sulfate, and concentrated under reduced pressure.
- Step A Synthesis of methyl 3-bromo-1-methyl-1H-indazole-6-carboxylate
- Methyl 3-bromo-1H-indazole-6-carboxylate (2.50 g, 10.0 mmol) was dissolved in N,N-dimethylformamide (30.0 mL) and potassium carbonate (2.76 g, 20.0 mmol) was added. mol), iodomethane (0.8 mL, 12.0 mmol) was added to the reaction solution, and after stirring at room temperature for 18 hours, TLC was monitored until the reaction was complete.
- Step B Synthesis of methyl 3-cyclopropyl-1-methyl-1H-indazole-6-carboxylate
- Methyl 3-bromo-1-methyl-1H-indazole-6-carboxylate 500 mg, 1.86 mmol was dissolved in 1,4-dioxane (20.0 mL) and water (5.0 mL) , followed by cyclopropylboronic acid (300 mg, 3.49 mmol), potassium carbonate (550 mg, 3.99 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloride palladium (150 mg, 0.20 mmol) was added to the reaction solution, and after nitrogen protection, stirred at 100 degrees Celsius for 16 hours, and monitored by LC-MS until the reaction was complete.
- Step D Synthesis of (S)-2-((4-(6-((3-cyclopropyl-1-methyl-1H-indazol-6-yl)methoxy)pyridin-2-yl)piperidine Perid-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid
- reaction solution was filtered through a pad of celite, the filtrate was slowly added dropwise to a saturated aqueous ammonium chloride solution (20.0 mL), the mixture was extracted with ethyl acetate (20.0 mL ⁇ 3 times), the organic phases were combined, and the organic phase was washed with saturated common salt water (15.0 mL ⁇ 3 times), dried over anhydrous sodium sulfate, and concentrated under reduced pressure.
- Step A Synthesis of methyl 5-fluoro-2-methyl-2H-indazole-6-carboxylate
- Methyl 5-fluoro-1H-indazole-6-carboxylate 150 mg, 0.77 mmol
- cesium carbonate 503 mg, 1.54 mmol
- iodomethane 0.5 mL
- Methyl 5-fluoro-2-methyl-2H-indazole-6-carboxylate (55 mg, 0.26 mmol) was dissolved in tetrahydrofuran (2 mL) at room temperature, cooled to zero degrees Celsius in an ice bath, Lithium aluminum tetrahydride (50 mg, 1.32 mmol) was added, and the mixture was stirred at room temperature for 0.5 hour.
- Step C (S)-2-((4-(6-((5-Fluoro-2-methyl-2H-indazol-6-yl)methoxy)pyridin-2-yl)piperidine-1 -yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid
- Step A Synthesis of methyl 5-fluoro-1H-indazole-6-carboxylate
- Step B Synthesis of methyl 5-fluoro-1-methyl-1H-indazole-6-carboxylate
- Methyl 5-fluoro-1H-indazole-6-carboxylate 150 mg, 0.77 mmol
- cesium carbonate 503 mg, 1.54 mmol
- iodomethane 0.5 mL
- Methyl 5-fluoro-1-methyl-1H-indazole-6-carboxylate (95 mg, 0.46 mmol) was dissolved in tetrahydrofuran (3 mL) at room temperature, cooled to zero degrees Celsius in an ice bath, Lithium aluminum tetrahydride (87 mg, 2.28 mmol) was added, and the mixture was stirred at room temperature for 0.5 hour.
- Step D (S)-2-((4-(6-((5-Fluoro-1-methyl-1H-indazol-6-yl)methoxy)pyridin-2-yl)piperidine-1 -yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid
- Step A Synthesis of methyl 1-acetyl-5-fluoro-1H-indazole-6-carboxylate
- Methyl 5-amino-2-fluoro-4-methylbenzoate (1.83 g, 10 mmol) was dissolved in chloroform (50 mL), cooled to zero degrees Celsius under an ice bath, and acetic anhydride (2.36 mL) was added dropwise , the reaction temperature was raised to room temperature and stirred for 1 hour, then potassium acetate (0.29 g) and isoamyl nitrite (2.69 mL) were added, and the reaction temperature was raised to 70 degrees Celsius and refluxed for 5 hours.
- Step B Synthesis of 1-(5-Fluoro-6-(hydroxymethyl)-1H-indazol-1-yl)ethan-1-one
- Methyl 1-acetyl-5-fluoro-1H-indazole-6-carboxylate 100 mg, 0.42 mmol was dissolved in tetrahydrofuran (2 mL) at room temperature, cooled to zero degrees Celsius in an ice bath, Lithium aluminum tetrahydride (80 mg, 2.1 mmol) was added, and the mixture was stirred at room temperature for half an hour.
- Step C Synthesis of (S)-2-((4-(6-((5-fluoro-1H-indazol-6-yl)methoxy)pyridin-2-yl)piperidin-1-yl)methan yl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid and (S)-2-((4-(6-(((5-fluoro) -2H-Indazol-6-yl)methoxy)pyridin-2-yl)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo [d]Imidazole-6-carboxylic acid
- Step A Synthesis of quinoline-5-methanol
- quinoline-5-carbaldehyde 100 mg, 0.64 mmol was dissolved in methanol (2 mL), and under nitrogen protection, sodium borohydride (49 mg, 1.28 mmol) was added, and the mixture was stirred for 1 hour.
- Step B Synthesis of (S)-1-(oxetan-2-ylmethyl)-2-(((4-(6-(quinolin-5-ylmethoxy)pyridin-2-yl) Piperidin-1-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate tert-butyl ester
- Step C Synthesis of (S)-1-(oxetan-2-ylmethyl)-2-(((4-(6-(quinolin-5-ylmethoxy)pyridin-2-yl) Piperidin-1-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid
- Step A Synthesis of methyl 2-(2-methoxyethyl)-2H-indazole-6-carboxylate
- Methyl 2-(2-methoxyethyl)-2H-indazole-6-carboxylate (220.0 mg, 0.9 mmol) was dissolved in tetrahydrofuran (8 mL) at room temperature, and tetrahydrofuran was added under ice bath conditions. Lithium aluminum hydride (71.4 mg, 1.9 mmol), reacted for 1.0 hour.
- Step C Synthesis of (S)-2-((4-(6-((2-(2-(2-(2-(2-methoxyethyl)-2H-indazol-6-yl)methoxy)pyridine-2 -yl)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate tert-butyl ester
- Step D Synthesis of (S)-2-((4-(6-((2-(2-(2-(2-(2-methoxyethyl)-2H-indazol-6-yl)methoxy)pyridine-2 -yl)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid
- the reaction was completed, quenched by adding water, adjusted to pH 8 with sodium bicarbonate solution (0.5 mol/L), the mixed solution was extracted with dichloromethane (20 mL ⁇ L), the organic phases were combined, and the organic phase was first used with an aqueous ammonium chloride solution. (30 mL ⁇ L times) washed, then dried over anhydrous sodium sulfate, and the crude product was purified by preparative high performance liquid chromatography.
- Step B Synthesis of tert-butyl 4-(6-((1-methyl-1H-indazol-6-yl)methoxy)pyridin-2-yl)piperazine-1-carboxylate
- Step C Synthesis of 1-methyl-6-(((6-(piperazin-1-yl)pyridin-2-yl)oxy)methyl)-1H-indazole
- tert-butyl 4-(6-((1-methyl-1H-indazol-6-yl)methoxy)pyridin-2-yl)piperazine-1-carboxylate (90 mg, 0.21 mmol) was dissolved in 10 ml of methanol solvent, 3 ml of 4M/L hydrochloric acid dioxane solution was added under ice bath, and the reaction was carried out at room temperature for 2 hours.
- Step D Synthesis of (S)-2-((4-(6-((1-methyl-1H-indazol-6-yl)methoxy)pyridin-2-yl)piperazin-1-yl) Methyl)-1-(oxetan-2-ylmethyl)-benzo[d]imidazole-6-carboxylate tert-butyl ester
- Step E Synthesis of (S)-2-((4-(6-((1-methyl-1H-indazol-6-yl)methoxy)pyridin-2-yl)piperazin-1-yl) Methyl)-1-(oxetan-2-ylmethyl)-benzo[d]imidazole-6-carboxylic acid
- Step A Synthesis of (S)-2-methyl-4-(6-((1-methyl-1H-indazol-6-yl)methoxy)pyridin-2-yl)piperazine-1-carboxylate tert-butyl acid
- Step C Synthesis of (S)-1-methyl-6-(((6-(3-methylpiperazin-1-yl)pyridin-2-yl)oxy)methyl)-1H-indazole
- Step D Synthesis of 2-(((S)-2-methyl-4-(6-((1-methyl-1H-indazol-6-yl)methoxy)pyridin-2-yl)piperazine -1-yl)methyl)-1(((S)-oxetan-2-ylmethyl)-benzo[d]imidazole-6-carboxylate tert-butyl ester
- Step E Synthesis of 2-(((S)-2-methyl-4-(6-((1-methyl-1H-indazol-6-yl)methoxy)pyridin-2-yl)piperazine -1-yl)methyl)-1-((S)-oxetan-2-ylmethyl)-benzo[d]imidazole-6-carboxylic acid
- Step A Synthesis of methyl 1-(2-methoxyethyl)-1H-indazole-6-carboxylate and methyl 2-(2-methoxyethyl)-2H-indazole-6-carboxylate ester
- Methyl 1-(2-methoxyethyl)-1H-indazole-6-carboxylate (300.0 mg, 1.3 mmol) was dissolved in tetrahydrofuran (8.0 mL) at room temperature, and tetrahydrofuran was added under ice bath conditions. Lithium aluminum hydride (97.2 mg, 2.6 mmol), reacted for 1.0 hour.
- Step C Synthesis of (S)-2-((4-(6-((1-(2-(methoxyethyl)-1H-indazol-6-yl)methoxy)pyridin-2-yl )piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid tert-butyl ester
- Step D Synthesis of (S)-2-((4-(6-((1-(2-(2-methoxyethyl)-1H-indazol-6-yl)methoxy)pyridine-2 -yl)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid
- the reaction was completed, quenched by adding water, adjusted to pH 8 with sodium bicarbonate solution (0.5 mol/L), the mixed solution was extracted with dichloromethane (30 mL ⁇ L), the organic phases were combined, and the organic phase was first used with an aqueous ammonium chloride solution. (30 mL ⁇ L times) washed, then dried over anhydrous sodium sulfate, and the crude product was purified by preparative high performance liquid chromatography.
- Step A Synthesis of methyl 1-isopropyl-1H-indazole-6-carboxylate
- Methyl 1H-indazole-6-carboxylate (1.0 g, 5.60 mmol) and cesium carbonate (3.6 g, 11.2 mmol) were dissolved in N,N-dimethylformamide (20 mL) at room temperature , and then iodoisopropane (1.0 g, 6.20 mmol) was added, and the mixture was stirred at room temperature for 0.5 h.
- methyl 1-isopropyl-1H-indazole-6-carboxylate 600 mg, 2.75 mmol was dissolved in tetrahydrofuran (15 mL), cooled to zero degrees Celsius in an ice bath, and tetrahydrofuran was added.
- Aluminum lithium 500 mg, 13.76 mmol was stirred at room temperature for 0.5 h.
- Step C (S)-2-((4-(6-((1-isopropyl-1H-indazol-6-yl)methoxy)pyridin-2-yl)piperidin-1-yl) Methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid
- isoquinoline-5-carbaldehyde 100 mg, 0.64 mmol was dissolved in methanol (2 mL), sodium borohydride (49 mg, 1.28 mmol) was added under nitrogen protection, and the mixture was stirred for 1 hour.
- Step B Synthesis of (S)-2-((4-(6-(isoquinolin-5-ylmethoxy)pyridin-2-yl)piperidin-1-yl)methyl)-1-(oxygen Hetidine-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate tert-butyl ester
- Step C Synthesis of (S)-2-((4-(6-(isoquinolin-5-ylmethoxy)pyridin-2-yl)piperidin-1-yl)methyl)-1-(oxygen Hetidine-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid
- Methyl 1H-indazole-6-carboxylate 200 mg, 1.14 mmol
- 2-iodopropane 388 mg, 2.28 mmol
- potassium carbonate 304 mg, 2.28 mmol
- Step C Synthesis of (S)-2-((4-(6-((2-isopropyl-2H-indazol-6-yl)methoxy)pyridin-2-yl)piperidin-1-yl )methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate tert-butyl ester
- Step D Synthesis of (S)-2-((4-(6-((2-isopropyl-2H-indazol-6-yl)methoxy)pyridin-2-yl)piperidin-1-yl )methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid
- Step A Synthesis of methyl 1-(difluoromethyl)-1H-indazole-6-carboxylate
- methyl 1H-indazole-6-carboxylate 500.0 mg, 2.82 mmol was added to acetonitrile (28.0 mL), followed by ethyl 2-bromo-2,2-difluoroacetate (690.2 mg). , 3.42 mmol), potassium hydroxide (314.6 mg, 5.63 mmol), under the protection of N 2 , at 60 degrees Celsius for 16.0 hours.
- Step C Synthesis of (S)-2-((4-(6-((1-(difluoromethyl)-1H-indazol-6-yl)methoxy)pyridin-2-yl)piperidine- 1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate tert-butyl ester
- Step D Synthesis of (S)-2-((4-(6-((1-(difluoromethyl)-1H-indazol-6-yl)methoxy)pyridin-2-yl)piperidine- 1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid
- Step A Synthesis of 1-(oxetan-3-yl)-1H-indazole-6-carboxylate methyl ester
- Step C Synthesis of (S)-1-(oxetan-2-ylmethyl)-2-((4-(6-((1-(oxetan-3-yl)-1H-indone azol-6-yl)methoxy)pyridin-2-yl)piperidin-1-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate tert-butyl ester
- Step D Synthesis of (S)-1-(oxetan-2-ylmethyl)-2-((4-(6-((1-(oxetan-3-yl)-1H-indone azol-6-yl)methoxy)pyridin-2-yl)piperidin-1-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid
- Step A Synthesis of methyl 1,3-dimethyl-1H-indazole-6-carboxylate
- Methyl 3-bromo-1-methyl-1H-indazole-6-carboxylate 500 mg, 1.86 mmol was dissolved in 1,4-dioxane (20.0 mL) and water (5.0 mL) , followed by 2,4,6-trimethyl-1,3,5,2,4,6-trioxaborolane (440 mg, 3.49 mmol), potassium carbonate (550 mg, 3.99 mmol) , [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (150 mg, 0.20 mmol) was added to the reaction solution, followed by nitrogen protection, stirred at 100 degrees Celsius for 16 hours, and monitored by LC-MS until the reaction is complete.
- Methyl 1,3-dimethyl-1H-indazole-6-carboxylate 200 mg, 0.98 mmol was dissolved in tetrahydrofuran (10.0 mL), and after stirring for 15 minutes at zero degrees Celsius, lithium aluminum hydride ( 38 mg, 1.0 mmol) was added to the reaction solution, and after stirring at zero degrees Celsius for 30 minutes, LC-MS was monitored until the reaction was complete.
- Step C Synthesis of (S)-2-((4-(6-((1,3-Dimethyl-1H-indazol-6-yl)methoxy)pyridin-2-yl)piperidine-1 -yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid
- reaction solution was filtered through a pad of celite, the filtrate was slowly added dropwise to a saturated aqueous ammonium chloride solution (20.0 mL), the mixture was extracted with ethyl acetate (20.0 mL ⁇ 3 times), the organic phases were combined, and the organic phase was washed with saturated common salt water (15.0 mL ⁇ 3 times), dried over anhydrous sodium sulfate, and concentrated under reduced pressure.
- Step A Synthesis of (S)-2-((4-(6-((2-methylbenzo[d]thiazol-6-yl)methoxy)pyridin-2-yl)piperidin-1-yl )methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate tert-butyl ester
- Step B Synthesis of (S)-2-((4-(6-((2-methylbenzo[d]thiazol-6-yl)methoxy)pyridin-2-yl)piperidin-1-yl )methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid
- Step A Synthesis of methyl 1-((3-methyloxetan-3-yl)methyl)-1H-indazole-6-carboxylate
- Methyl 1H-indazole-6-carboxylate 200 mg, 1.14 mmol
- 3-(bromomethyl)-3-methyloxetane 225 mg, 1.36 mmol
- potassium carbonate 304 mg, 2.28 mmol
- Step B Synthesis of 1-((3-Methyloxetan-3-yl)methyl)-1H-indazole-6-methanol
- Step C Synthesis of (S)-2-((4-(6-((1-((3-methyloxetan-3-yl)methyl)-1H-indazol-6-yl)methan oxy)pyridin-2-yl)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid tert-butyl ester
- Butyl ester (80 mg, 0.16 mmol) was dissolved in 1,4-dioxane (1 mL), followed by the addition of 1,1'-binaphthyl-2,2'-bisdiphenylphosphine (20 mg, 0.03 mmol), tris(dibenzylideneindenoneacetone)dipalladium (15 mg, 0.016 mmol), sodium tert-butoxide (31 mg, 0.32 mmol), after the addition was completed, under nitrogen protection, the temperature was increased to 100 degrees Celsius , stir for 1 hour.
- Step D Synthesis of (S)-2-((4-(6-((1-((3-methyloxetan-3-yl)methyl)-1H-indazol-6-yl)methan Oxy)pyridin-2-yl)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid
- 2,5-Difluoro-4-nitrobenzoic acid (1.2 g, 6.0 mmol) was dissolved in 4.0 M potassium hydroxide solution (20.0 mL), stirred at room temperature for 16 hours, and monitored by LC-MS until the reaction was complete.
- Step B Synthesis of methyl 2-fluoro-5-hydroxy-4-nitrobenzoate
- Step C Synthesis of methyl 4-amino-2-fluoro-5-hydroxybenzoate
- Methyl 2-fluoro-5-hydroxy-4-nitrobenzoate (340 mg, 1.60 mmol) was dissolved in methanol (10.0 mL), saturated ammonium chloride solution (4.0 mL) and reducing iron powder ( 560 mg, 10.0 mmol) was added to the reaction solution, stirred at room temperature for 16 hours, and monitored by LC-MS until the reaction was complete.
- Step D Synthesis of methyl 5-fluoro-2-methylbenzo[d]oxazole-6-carboxylate
- Methyl 4-amino-2-fluoro-5-hydroxybenzoate (200 mg, 1.1 mmol) was dissolved in triethyl orthoacetate (3.0 mL), stirred at 100 degrees Celsius for 3 hours, and the reaction was monitored by LC-MS completely.
- Methyl 5-fluoro-2-methylbenzo[d]oxazole-6-carboxylate 210 mg, 1.0 mmol was dissolved in tetrahydrofuran (10.0 mL), and after stirring at 0°C for 15 minutes, the hydrogenated Lithium aluminum (76 mg, 2.0 mmol) was added to the reaction solution, and after stirring at zero degrees Celsius for 30 minutes, LC-MS was monitored until the reaction was complete.
- Step F Synthesis of (S)-2-((4-(6-((5-Fluoro-2-methylbenzo[d]oxazol-6-yl]methoxy)pyridin-2-yl)piperidine Perid-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate tert-butyl ester
- reaction solution was filtered through a pad of celite, the filtrate was slowly added dropwise to a saturated aqueous ammonium chloride solution (20.0 mL), the mixture was extracted with ethyl acetate (20.0 mL ⁇ 3 times), the organic phases were combined, and the organic phase was washed with saturated common salt water (15.0 mL ⁇ 3 times), dried over anhydrous sodium sulfate, and concentrated under reduced pressure.
- Step G Synthesis of (S)-2-((4-(6-((5-Fluoro-2-methylbenzo[d]oxazol-6-yl]methoxy)pyridin-2-yl)piperidine Perid-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid
- Step A Synthesis of (S)-1-(oxetan-2-ylmethyl)-2-((4-(6-(quinoxalin-6-ylmethoxy)pyridin-2-yl) Piperidin-1-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid
- Step A Synthesis of methyl 1-(2-hydroxy-2-methylpropyl)-1H-indazole-6-carboxylate
- Step B Synthesis of 1-(6-(hydroxymethyl)-1H-indazol-1-yl)-2-methylpropan-2-ol
- Step C Synthesis of (S)-2-((4-(6-((1-(2-(2-hydroxy-2-methylpropyl)-1H-indazol-6-yl)methoxy) Pyridin-2-yl)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate tert-butyl ester
- Step D Synthesis of (S)-2-((4-(6-((1-(2-(2-hydroxy-2-methylpropyl)-1H-indazol-6-yl)methoxy) Pyridin-2-yl)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
L'invention concerne un composé représenté par la formule (I), son procédé de préparation et son utilisation en médecine. En particulier, l'invention concerne un composé représenté par la formule (I) ou un stéréoisomère, un tautomère et un sel pharmaceutiquement acceptable de celui-ci. Les composés sont des agonistes de récepteurs du peptide 1 apparenté au glucagon (GLP-1R). La présente invention concerne également une composition pharmaceutique comprenant les composés et l'utilisation des composés dans des médicaments pour le traitement de maladies telles que le diabète.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202180030750.1A CN115515956B (zh) | 2020-09-29 | 2021-09-27 | 一种苯并咪唑类衍生物及其制备方法和医药用途 |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011050944 | 2020-09-29 | ||
CN202011050944.1 | 2020-09-29 | ||
CN202011311263.6 | 2020-11-20 | ||
CN202011311263 | 2020-11-20 | ||
CN202011491886 | 2020-12-17 | ||
CN202011491886.6 | 2020-12-17 | ||
CN202110634855 | 2021-06-08 | ||
CN202110634855.X | 2021-06-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022068772A1 true WO2022068772A1 (fr) | 2022-04-07 |
Family
ID=80949690
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2021/120978 WO2022068772A1 (fr) | 2020-09-29 | 2021-09-27 | Dérivé de benzimidazole, son procédé de préparation et son utilisation médicale |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN115515956B (fr) |
WO (1) | WO2022068772A1 (fr) |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022192430A1 (fr) * | 2021-03-11 | 2022-09-15 | Gilead Sciences, Inc. | Composés modulateurs de glp-1r |
WO2022192428A1 (fr) * | 2021-03-11 | 2022-09-15 | Gilead Sciences, Inc. | Composés modulateurs de glp-1r |
WO2022246019A1 (fr) | 2021-05-20 | 2022-11-24 | Eli Lilly And Company | Agonistes macrocycliques du récepteur du peptide 1 de type glucagon |
WO2023057427A1 (fr) | 2021-10-05 | 2023-04-13 | Astrazeneca Ab | Certains 2,5-diazabicyclo[4.2.0]octanes utilisés en tant que modulateurs du récepteur glp-1 |
WO2023057429A1 (fr) | 2021-10-05 | 2023-04-13 | Astrazeneca Ab | Certains 2,5-diazabicyclo[4.2.0]octanes et octahydrofuro[3,4-b]pyrazines utilisés en tant que modulateurs du récepteur glp-1 |
WO2023057414A1 (fr) | 2021-10-05 | 2023-04-13 | Astrazeneca Ab | Certaines octahydrofuro 3,4-b]pyrazines utilisées en tant que modulateurs du récepteur glp-1 |
WO2023090859A1 (fr) * | 2021-11-17 | 2023-05-25 | 일동제약(주) | Procédé de préparation d'un dérivé d'isoxazole et nouvel intermédiaire associé |
WO2023111144A1 (fr) | 2021-12-16 | 2023-06-22 | Astrazeneca Ab | 3-azabicyclo [3.1.0] hexanes en tant que modulateurs du récepteur glp-1 |
WO2023111145A1 (fr) | 2021-12-16 | 2023-06-22 | Astrazeneca Ab | Certains 3-azabicyclo[3.1.0] hexanes utilisés en tant que modulateurs du récepteur de glp-1 |
US11702404B2 (en) | 2019-10-25 | 2023-07-18 | Gilead Sciences, Inc. | GLP-1R modulating compounds |
US11851419B2 (en) | 2020-11-20 | 2023-12-26 | Gilead Sciences, Inc. | GLP-1R modulating compounds |
US11858918B2 (en) | 2021-04-21 | 2024-01-02 | Gilead Sciences, Inc. | GLP-1R modulating compounds |
US11897851B2 (en) | 2020-08-06 | 2024-02-13 | Gasherbrum Bio, Inc. | Heterocyclic GLP-1 agonists |
US11926626B2 (en) | 2020-08-28 | 2024-03-12 | Gasherbrum Bio, Inc. | Heterocyclic GLP-1 agonists |
WO2024102625A1 (fr) | 2022-11-11 | 2024-05-16 | Eli Lilly And Company | Agonistes de récepteur du peptide 1 de type glucagon |
WO2024107781A1 (fr) | 2022-11-16 | 2024-05-23 | Eli Lilly And Company | Agonistes du récepteur du glucagon-like peptide 1 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3200245A1 (fr) * | 2020-11-27 | 2022-06-02 | Junjun Wu | Derive de benzimidazole, son procede de preparation et son utilisation medicale |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110325530A (zh) * | 2016-12-16 | 2019-10-11 | 辉瑞大药厂 | Glp-1受体激动剂及其用途 |
WO2019239319A1 (fr) * | 2018-06-13 | 2019-12-19 | Pfizer Inc. | Agonistes du récepteur glp-1 et leurs utilisations |
WO2019239371A1 (fr) * | 2018-06-15 | 2019-12-19 | Pfizer Inc. | Agonistes du récepteur glp-1 et leurs utilisations |
WO2020103815A1 (fr) * | 2018-11-22 | 2020-05-28 | Qilu Regor Therapeutics Inc. | Agonistes de glp-1r et leurs utilisations |
WO2020207474A1 (fr) * | 2019-04-12 | 2020-10-15 | Qilu Regor Therapeutics Inc. | Agonistes de glp-1r et leurs utilisations |
CN113480534A (zh) * | 2021-07-23 | 2021-10-08 | 广州必贝特医药技术有限公司 | 苯并咪唑或氮杂苯并咪唑-6-羧酸类化合物及其应用 |
-
2021
- 2021-09-27 CN CN202180030750.1A patent/CN115515956B/zh active Active
- 2021-09-27 WO PCT/CN2021/120978 patent/WO2022068772A1/fr active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110325530A (zh) * | 2016-12-16 | 2019-10-11 | 辉瑞大药厂 | Glp-1受体激动剂及其用途 |
WO2019239319A1 (fr) * | 2018-06-13 | 2019-12-19 | Pfizer Inc. | Agonistes du récepteur glp-1 et leurs utilisations |
WO2019239371A1 (fr) * | 2018-06-15 | 2019-12-19 | Pfizer Inc. | Agonistes du récepteur glp-1 et leurs utilisations |
WO2020103815A1 (fr) * | 2018-11-22 | 2020-05-28 | Qilu Regor Therapeutics Inc. | Agonistes de glp-1r et leurs utilisations |
WO2020207474A1 (fr) * | 2019-04-12 | 2020-10-15 | Qilu Regor Therapeutics Inc. | Agonistes de glp-1r et leurs utilisations |
CN113480534A (zh) * | 2021-07-23 | 2021-10-08 | 广州必贝特医药技术有限公司 | 苯并咪唑或氮杂苯并咪唑-6-羧酸类化合物及其应用 |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11702404B2 (en) | 2019-10-25 | 2023-07-18 | Gilead Sciences, Inc. | GLP-1R modulating compounds |
US11897851B2 (en) | 2020-08-06 | 2024-02-13 | Gasherbrum Bio, Inc. | Heterocyclic GLP-1 agonists |
US11926626B2 (en) | 2020-08-28 | 2024-03-12 | Gasherbrum Bio, Inc. | Heterocyclic GLP-1 agonists |
US11851419B2 (en) | 2020-11-20 | 2023-12-26 | Gilead Sciences, Inc. | GLP-1R modulating compounds |
WO2022192428A1 (fr) * | 2021-03-11 | 2022-09-15 | Gilead Sciences, Inc. | Composés modulateurs de glp-1r |
WO2022192430A1 (fr) * | 2021-03-11 | 2022-09-15 | Gilead Sciences, Inc. | Composés modulateurs de glp-1r |
US11858918B2 (en) | 2021-04-21 | 2024-01-02 | Gilead Sciences, Inc. | GLP-1R modulating compounds |
WO2022246019A1 (fr) | 2021-05-20 | 2022-11-24 | Eli Lilly And Company | Agonistes macrocycliques du récepteur du peptide 1 de type glucagon |
WO2023057429A1 (fr) | 2021-10-05 | 2023-04-13 | Astrazeneca Ab | Certains 2,5-diazabicyclo[4.2.0]octanes et octahydrofuro[3,4-b]pyrazines utilisés en tant que modulateurs du récepteur glp-1 |
WO2023057414A1 (fr) | 2021-10-05 | 2023-04-13 | Astrazeneca Ab | Certaines octahydrofuro 3,4-b]pyrazines utilisées en tant que modulateurs du récepteur glp-1 |
WO2023057427A1 (fr) | 2021-10-05 | 2023-04-13 | Astrazeneca Ab | Certains 2,5-diazabicyclo[4.2.0]octanes utilisés en tant que modulateurs du récepteur glp-1 |
WO2023090859A1 (fr) * | 2021-11-17 | 2023-05-25 | 일동제약(주) | Procédé de préparation d'un dérivé d'isoxazole et nouvel intermédiaire associé |
WO2023111145A1 (fr) | 2021-12-16 | 2023-06-22 | Astrazeneca Ab | Certains 3-azabicyclo[3.1.0] hexanes utilisés en tant que modulateurs du récepteur de glp-1 |
WO2023111144A1 (fr) | 2021-12-16 | 2023-06-22 | Astrazeneca Ab | 3-azabicyclo [3.1.0] hexanes en tant que modulateurs du récepteur glp-1 |
WO2024102625A1 (fr) | 2022-11-11 | 2024-05-16 | Eli Lilly And Company | Agonistes de récepteur du peptide 1 de type glucagon |
WO2024107781A1 (fr) | 2022-11-16 | 2024-05-23 | Eli Lilly And Company | Agonistes du récepteur du glucagon-like peptide 1 |
Also Published As
Publication number | Publication date |
---|---|
CN115515956A (zh) | 2022-12-23 |
CN115515956B (zh) | 2024-06-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2022068772A1 (fr) | Dérivé de benzimidazole, son procédé de préparation et son utilisation médicale | |
WO2022111624A1 (fr) | Dérivé de benzimidazole, son procédé de préparation et son utilisation médicale | |
US11242334B2 (en) | Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof | |
CN107108534B (zh) | 用于成像亨廷顿蛋白的探针 | |
US10023557B2 (en) | Therapeutic inhibitory compounds | |
KR102209667B1 (ko) | 돌연변이-아이소시트레이트 탈수소효소 저해제로서의 피리딘-2(1h)-온 퀴놀린 유도체 | |
US20230113598A1 (en) | Heterocyclic compounds useful as pdk1 inhibitors | |
US20210188868A1 (en) | Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof | |
EP2970260B1 (fr) | Dérivés d'imidazo[4,5-c]pyridine et de pyrrolo[2,3-c]pyridine en tant qu'inhibiteurs ssao | |
KR20190076976A (ko) | Ret 키나제 억제제로서의 치환된 피라졸로[1,5-a]피리딘 화합물 | |
US9181272B2 (en) | Aldosterone synthase inhibitors | |
CN110036005A (zh) | 酰胺衍生物及其在药物中的应用 | |
EP2136810A1 (fr) | Nouveaux composés de type 1,8-naphthyridine | |
CA2784393A1 (fr) | Composes et methodes pour la modulation des kinases, et leurs indications | |
TW201625619A (zh) | 抑制瞬態電位受器a1離子通道 | |
US11667624B2 (en) | Indole compounds as androgen receptor modulators | |
WO2012167606A1 (fr) | Inhibiteurs doubles de pi3k/mtor de pyridonaphtyridine et préparation et utilisation de ceux-ci | |
WO2023016535A1 (fr) | Composé de terpyridine dicétone ou son sel, son procédé de préparation et son utilisation | |
CA3219925A1 (fr) | Inhibiteurs chromenone allosteriques de la phosphoinositide 3-kinase (pi3k) pour le traitement du cancer | |
CN115594669A (zh) | 一种并环类衍生物及其制备方法和医药用途 | |
CN114853730A (zh) | 用作hpk1激酶抑制剂的化合物及其制备方法和应用 | |
CN114644627B (zh) | AhR抑制剂及其用途 | |
US10183949B2 (en) | Pyrimidinone derivative having autotaxin-inhibitory activity | |
CN115703792A (zh) | 一种并三环类衍生物及其制备方法和医药用途 | |
WO2024022481A1 (fr) | Composés de dihydronaphtyridine à substitution phényle, leur préparation et leur utilisation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21874432 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 09/06/2023) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21874432 Country of ref document: EP Kind code of ref document: A1 |